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Fibrosis is scarring of tissues characterised by excessive accumulation of collagen proteins, 
in which transforming growth factor (TGF)-β1 plays a central role. Fibrosis affects virtually 
all organs and is a common pathology behind chronic organ failure and mortality. Few anti-
fibrotic drugs are available to prevent or reverse fibrosis, thus, it represents a significant 
unmet medical need to better understand fibrosis and to develop novel antifibrotics. 
Botanicals could be both cause and cure of fibrosis. Aconiti Radix (AR) and Aconiti 
Lateralis Radix (ALR) were suggested pro-fibrotic and potentially nephrotoxic, while 
Scutellariae Radix (SR) and SR flavonoids were reportedly anti-fibrotic. I hypothesised that 
AR/ALR and SR might affect fibrogenesis as a function of AR/ALR alkaloids and SR 
flavonoids, respectively. This project aimed to (i) further scrutinise effects of AR, ALR, 
AR/ALR alkaloids, SR and SR flavonoids in a TGF-β1-induced in-vitro model of fibrosis; 
and (ii) develop a proteomic view of the in-vitro model of fibrosis and the differential 
mechanisms of action of selected antifibrotics. 
In NRK-49F renal fibroblasts with and without treatment by TGF-β1 and antifibrotics, 
fibrogenesis was quantified by total collagen assays and examination of fibrogenic molecular 
markers. Cell lysates and conditioned media were harvested for proteomic analysis. Proteins 
of interest were validated by enzyme-linked immunosorbent assay (ELISA). 
Results showed that aqueous and ethanolic extracts of unprocessed and processed AR did 
not affect fibrogenesis. Seven of nine AR alkaloids showed anti-fibrotic effects. These 
disapproved my hypothesis on AR/ALR and their alkaloids. Supporting SR flavonoids as the 
main anti-fibrotic compounds in SR, however, methanolic extract of SR (SRM), which 
contained 8-fold higher flavonoids than SR aqueous (SRA) extract, is more potently anti-
fibrotic than SRA. Five tested SR flavonoids were more or less anti-fibrotic, with baicalein 
being the most anti-fibrotic and least toxic. Hence, in further proteomic studies, I focused on 
mechanisms of TGF-β1-induced in-vitro model of fibrosis and the anti-fibrotic mechanisms 
of SRM and baicalein, in comparison with IN1130, an inhibitor of TGF-β type I receptor. In 
cell lysates of TGF-β1-stimulated NRK-49F cells, there was an apparent mismatch between 
increased ribosomal proteins and reduced proteins involved in multiple metabolism 
pathways, in between which there was increased Impdh2, a druggable target. Secretomic 
analysis indicated that TGF-β1-induced fibrosis was mediated by dysregulation of key 
regulators of matrix degradation (PAI-1and Mmp3), signalling mediators (Ccn1, Ccn2, Ccn3 
and Tsku) and a collagen crosslinker (Plod2), and was coupled with increased chemokines 
Ccl2 and Ccl7. SRM, baicalein and IN1130 all significantly regulated the ribosome pathway; 
SRM and baicalein, but not IN1130, regulated the lysosome pathway, while they 
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differentially regulated metabolism pathways. They all reversed TGF-β1-induced PAI-1, 
Plod2, Ccn2, Ccl2 and Ccl7. Baicalein and IN1130, but not SRM, reversed TGF-β1-induced 
Ccn1 and Tsku. Only baicalein reversed TGF-β1 repression of Mmp3. Only IN1130 reversed 
TGF-β1 induction of Impdh2 and repression of Aldh3a1 and Ccn3. Among all proteins in 
cell lysates, Enpp1 was most dramatically induced by TGF-β1 and it was also among the 
most dramatically repressed by SRM, baicalein and IN1130.  
In conclusion, TGF-β1-induced fibrogenesis in renal fibroblasts involves dysregulation of 
multiple secreted proteins involved in regulation of collagen synthesis, crosslinking and 
degradation, and is characterised by dysregulation of intracellular metabolism. It is 
inherently coupled with increased secretion of chemokines, suggestive of a pro-
inflammatory role for TGF-β1 and myofibroblasts. Comparative proteomic analysis has 
uncovered overlapping mechanisms of the three antifibrotics. Besides known anti-fibrotic 
targets e.g. PAI-1 and Ccn2, it deserves further investigation to determine whether ribosome, 
lysosome, metabolism pathways and individual proteins e.g. Aldh3a1, Ccn1, Ccn3, Enpp1, 
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Chapter 1 Introduction 
 
1.1. Chronic kidney disease (CKD) 
The definition and classification of CKD have evolved over time, but current international 
guidelines define this condition as decreased kidney function shown by glomerular filtration 
rate (GFR) of less than 60 mL/min per 1.73 m
2
, or markers of kidney damage, or both, of at 
least 3 months duration, regardless of the underlying cause (1). The most common causes of 
CKD are hypertension and diabetes, both aggravated by aging. Other diseases and conditions 
that may also induce CKD, such as glomerulonephritis (i.e. the inflammation of the 
glomeruli), polycystic kidney disease (i.e. gradual growth of masses of cysts in both kidneys), 
interstitial nephritis (i.e. the inflammation of the kidney's tubules and surrounding structures), 
pyelonephritis (i.e. recurrent kidney infections), failure of normal kidney development 
during pregnancy and the long-term consumption of some medicaments (e.g. non-steroidal 
anti-inflammatory drugs like aspirin and ibuprofen)(2, 3).  
 
CKD affects around 10% of the worldwide population with high mortality, partly due to 
limited available and affordable treatment (4, 5). There is no direct cure for CKD actually 
and treatment usually depends on the stages of CKD. In the early stages (1-3), the treatment 
mainly consists in having a healthy and balanced diet, moderating the alcohol consumption, 
stopping smoking, getting regular physical exercise, losing weight in case of 
overweight/obesity and taking medication to control the blood pressure and lower the blood 
cholesterol levels. On the advanced stages (4-5), additional medications can be prescribed to 
control or prevent the symptoms of CKD. Finally, in case of end-stage kidney disease, it is 
fatal without renal-replacement therapy like dialysis or kidney transplantation (6, 7). 
 
Currently new strategies for the treatment of CKD include more comprehensive blockade of 
the renin-angiotensin-aldosterone system (RAAS) with direct renin inhibitors (4, 8), 
endothelin receptor antagonists (9), drugs that target TGF-β system (10) and connective 
tissue growth factor (Ctgf) inhibitors, etc (11). Many clinical trials have been undertaken 
aiming at blocking and/or reversing CKD progression (Table 1.1), with some of the trials 
directly or indirectly targeting renal fibrosis, including glomerulosclerosis (i.e. scarring of 
glomeruli) and tubulointerstitial fibrosis (TIF, i.e. scarring of the tubulointerstitial 
compartment). Despite the primary aetiology of CKD, tubulointerstitial injury and TIF 
appear to be the common pathway to end-stage kidney disease 
(https://www.ncbi.nlm.nih.gov/pubmed/14964574). Thus, the following discussions will 
focus on TIF, including its mechanisms, prevention and treatment.
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Table 1.1. Some recent clinical trials on treatments of CKD. 
Group Drug Target Kidney disease (Stage) Outcome  Reference 
TGF-β blockers 
 
LY2382770 TGF-β DN (Phase 2) Terminated prematurely due to a lack of efficacy (12), NCT01113801 
Pirfenidone TGF-β DN ((Phase 1) Slowed the rate of eGFR decline (13)  
Pirfenidone TGF-β CKD (Phase 2) 
Ongoing 
NCT02408744 
Pirfenidone TGF-β DN (Phase 3) NCT02689778 
 Ctgf blockers 
 
FG-3019 Ctgf DN (Phase 1) Reduced microalbuminuria  (14)  
FG-3019 Ctgf DN (Phase 2) Prematurely stopped for suboptimal study design NCT00913393 
Endothelin receptor antagonists 
 
Atrasentan ET-1 DN (Phase 3) Terminated (strategic considerations) NCT01858532 
Avosentan ET-1 DN (Phase 1) Stopped because of fluid retention (15) 
Atrasentan ET-1 DN (Phase 2) Reduced albuminuria (16, 17) 
Atrasentan ET-1 CKD (Phase 2) Ongoing NCT01424319 
Avosentan ET-1 DN (Phase 1) Reduced urinary albumin (18) 




MLN1202 CCR2 DN (Phase 2) Prematurely stopped for unknown reasons NCT02410499 
BMS-813160 CCR2/5 DN (Phase 2) Discontinuation of clinical development of the drug NCT01752985 
PF-04634817 CCR2/5 DN (Phase 2) Reduced urinary albumin NCT01712061 
NOX-E36 CCR2 DN (Phase 2) Reduced albuminuria (20) 
CCX140-B CCR2 DN (Phase 2) Reduced albuminuria (21), NCT01447147 
PPAR antagonists 
Fenofibrate PPAR-α DN (Phase 1) Reduced albuminuria, slowed the rate of GFR decrease (22) 
Elafibranor  PPAR-α & -δ type 2 diabetes mellitus Ongoing NCT01261494 
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Group Drug Target Kidney disease (Stage) Outcome  Reference 
(Phase 2) 
Rosiglitazone PPAR-γ type 2 diabetes mellitus (Phase 3) Reduced albuminuria and proteinuria 
(23, 24) 
NCT00279045 
BMP-7 agonists THR-184 BMP CKD (Phase 2) No effects on GFR decline, reduced incidence of AKI NCT01830920 
Nrf2 activator 
Bardoxolone Nrf2 CKD (Phase 1) Slowed the rate of GFR decrease, increased albuminuria (25, 26) 
Bardoxolone Nrf2 DN, CKD (Phase 2) Ongoing NCT02316821 
Bardoxolone Nrf2 DN, CKD (Phase 3) Terminated (safety concerns) (27), NCT01351675 
NFκB blockers  
ACTH MCP-1 DN (Phase 4) Slowed the rate of GFR decrease, reduced proteinuria (28), NCT01028287 
Bindarit MCP-1 DN (Phase 2) Reduced albuminuria NCT01109212 
JAK-STAT inhibitors Baricitinib JAK DN (Phase 2) Reduced albuminuria, no changes in kidney function (29), NCT01683409 
Galectin-3 antagonists  
GCS-100 galectin-3 DN (Phase 2) 
Discontinuation of clinical development of the drug because the 
Company was required to conduct additional chemical 
characterization 
(30), Poster 
GCS-100 galectin-3 CKD (Phase 2) Slowed the rate of GFR decrease NCT01843790 
GPR40&GPR84 antagonists PBI-4050 GPR40&GPR84 type 2 diabetes mellitus (Phase 2) 
Terminated (Failure to meet recruitment target during the 
recruitment period) NCT03081598 
Thromboxane receptor 
antagonists and thromboxane 
synthase inhibitors 





Note: AKI, acute kidney injury; ACTH, adrenocorticotropic hormone; CKD, chronic kidney disease; CTGF, connective tissue growth factor; CCR2/5, 
chemokine receptor 2/5; DN, diabetic nephropathy; ET-1, endothelin-1; GFR, glomerular filtration rate; JAK, Janus kinase; MCP-1, monocyte chemotactic 




TIF is characterised by excessive extracellular matrix (ECM) accumulation in the 
tubulointerstitial compartment and is considered as a common final feature of almost all 
progressive CKD (31, 32). The tubulointerstitium consists of multiple cell components 
including tubular epithelial, endothelial, mesenchymal (fibroblasts and pericytes) and 
inflammatory cells, all of which involve and participate in some way in the pathogenesis of 
TIF, illustrating the immense complexity of this process. 
 
Tubular epithelia are targeted by acute and chronic injuries. The injured epithelia 
differentiate and proliferate resulting in repair after acute kidney injury (33). When epithelial 
injury occurs repetitively or persists over time, tubular apoptosis may occur and lead to 
progressive TIF (34). These dying epithelial cells may produce growth factors and cytokines 
such as TGF-β and PDGF. These growth factors may initially promote regeneration of the 
injured epithelia but, in persistent injury, may have some effects on surrounding cells such as 
fibroblasts causing them to transform into myofibroblasts. It was also known that the injured 
epithelia undergo epithelial to mesenchymal transition (EMT) and contribute to ECM 
production and ultimately fibrosis. Similarly, myofibroblasts might derive from capillary 
endothelium by endothelial-mesenchymal transition (EndoMT). EndoMT is considered to be 
a unique form of EMT, as endothelial cells are a specialized type of epithelia (35). Although 
epithelial cells can clearly respond to fibrotic stimuli resulting in loss of epithelial features 
and acquisition of mesenchymal markers, its role as a potential source of myofibroblasts in 
TIF has been questioned (36, 37). Nonetheless, emerging evidence supports a role for 
epithelial cells as efficient producers of stable extracellular matrix and thus contributing to 
renal tubule thickening and TIF (36, 37).  
 
Fibroblasts are quiescent cells found within the interstitial space, important for maintaining 
the structural integrity of kidneys by producing basal level of extracellular matrix. During 
the normal tissue repair process after damage, these cells can be activated by cytokines 
including TGF-β (38) and tumour necrosis factor alpha (TNFα) (39) as well as stress stimuli 
including hypoxia (40) to proliferate and produce collagens to make new connective tissue. 
Activated fibroblasts have increased stress fibres, proliferate, and produce ECM components 
like collagens leading to progressive TIF. It is commonly regarded that fibroblast activation 
and the expression of α smooth muscle actin (α-SMA) is indicative of its transformation into 
myofibroblasts, which are the main contributors to TIF (41). However, the expression of α-
SMA is not exclusive to myofibroblasts, being also expressed on vascular smooth cells. In 
addition, vimentin and CD73 expressed by fibroblasts and myofibroblasts are also expressed 
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by immune cells (42). Thus, it is difficult to conclude on what exact percentage of 
myofibroblasts are derived from fibroblasts, due to the lack of specific cellular markers for 
both fibroblasts and myofibroblasts. 
 
Fibrocytes are circulating bone marrow-derived cells that are positive for the leukocyte 
marker CD45 and are capable of producing type I collagen (43). Fibrocytes also express 
certain chemokine receptors, such as CCR7. The differentiation of fibrocytes is critically 
dependent on other inflammatory cells, such as CD4(+) T cells, through secreted cytokines 
(44). The relative importance of fibrocytes in renal fibrosis is unclear, at least in part because 
of the lacking of specific markers for these cells, making it a great challenge to clearly 
differentiate fibrocytes from monocytes, macrophages, fibroblasts and myofibroblasts.  
 
Inflammatory cells, specifically macrophages and dendritic cells (DC), are also important 
modulators of CKD. Macrophages/DCs populate the uninjured renal interstitium and act as 
antigen-presenting cells and macrophages also have an important phagocytic function (45). 
After renal injury, these inflammatory cells expand both through local proliferation and 
infiltration of circulating monocytes and subsequent differentiation. The classic view on the 
connection between inflammation and fibrosis is that they are mediated in a paracrine 
manner, whereby inflammatory cells secrete profibrotic cytokines that act on resident 
fibroblasts and tubular cells to promote fibrogenesis (46). 
 
In the pathogenesis of TIF, infiltrated inflammatory cells become activated after a sustained 
kidney injury, which sets up the fibrogenic stage and triggers the activation and expansion of 
ECM-producing cells from multiple sources through various mechanisms, mainly including 
activation of interstitial fibroblasts and pericytes, phenotypic conversion of tubular epithelial 
and endothelial cells and recruitment of circulating fibrocytes. These ECM-producing cells 
integrate input from various fibrogenic signals to drive the production of matrix components 
and their extracellular assembly (42). Myofibroblasts are the principal ECM-producing cells 
and have been identified as key cellular mediators of TIF, thus to understand the cellular and 
molecular mechanisms responsible for the creation of myofibroblasts and their activities is 
central to the development of therapies.  
 
Myofibroblasts are characterised by expression of the intermediate filaments desmin, 
vimentin and the contractile protein α-SMA (47). Myofibroblasts can be derived from 
several sources, as shown in Fig. 1.1, including proliferation and activation of quiescent 
tissue-resident fibroblasts into a myofibroblastic phenotype, recruitment and activation of 
fibrocytes from bone marrow, and trans-differentiation of epithelial or endothelial into a 
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mesenchymal phenotype (31, 32, 48). In view that resident fibroblasts are believed to be the 
most important sources of myofibroblasts (47), this project will mainly use renal fibroblasts 





Fig. 1.1. Origin of matrix-producing myofibroblasts that directly mediate TIF (48). 
Schematic illustration shows the possible mechanisms via myofibroblasts can originate 
during kidney fibrosis with their proposed proportions on the total number of interstitial 
myofibroblasts. Recent studies estimate that approximately 35% of fibroblasts arise from 
bone marrow, 10% and 5% via local EndoMT or EMT, respectively, and 50% of 
myofibroblasts result from proliferation and activation of resident fibroblasts. 
 
 
TGF-β is considered one of the strongest pro-fibrotic growth factors due to its ability to 
activate fibroblasts into myofibroblasts and stimulate matrix production. TGF-β belongs to 
the TGF-β superfamily of cytokines, playing important roles in embryogenesis and adult 
tissue homeostasis by regulating cell proliferation, differentiation and migration. TGF-β is 
made up of three isoforms, TGF-β 1, 2 and 3 (49). TGF-β1 is the most broadly studied of the 
TGF-β isoforms and it promotes progressive renal fibrosis by stimulating ECM synthesis, 
preventing its degradation, activating fibroblasts and mediating EMT or EndoMT (48, 50). 
In addition, TGF-β1 induces the expression of a variety of ECM molecules including 
collagens type I, III and IV, fibronectin and plasminogen activator inhibitor (PAI)-1, all of 
which are increased in TIF (49). 
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Active TGF-β1 is released via proteolytic cleavage and binds to the TGF-β type II receptor 
and initiates Smad-dependent and -independent signalling pathways. In the canonical TGF-
β1/Smad pathway, phosphorylated Smad2/3 complexes together with Smad4 translocate into 
the nucleus to modulate transcription of a number of target genes. Increasing evidence has 
demonstrated that TGF-β-induced activation of downstream Smad signalling is a major 
driver for renal fibrosis (51). The expression of TGF-β and its receptor is increased in human 
and experimental models of CKD (52), overexpression of active TGF-β in mice promotes the 
development of glomerulosclerosis and TIF (53) and inhibition of TGF-β activity attenuates 
renal disease in experimental models of renal fibrosis (54). In addition, TGF-β released from 
injured tubular cells or inflammatory cells promotes TIF by increasing ECM gene 
transcription, tubular cell apoptosis, myofibroblast differentiation and EMT depending on 
the cellular context of TGF-β action (55). In addition to the Smad pathway, multiple Smad-
independent signalling pathways are also involved in renal fibrosis (51), such as Wnt/β-
catenin (56), JNK/STAT3 (57), and MAPKs (56, 57). 
Despite the aforementioned mechanisms, our knowledge on the exact intracellular and 
extracellular mechanisms in myofibroblasts remains very limited. Further understanding 
such intracellular and extracellular mechanisms promises to discover novel therapeutic 
targets and to guide developing effective strategies to prevent or even reverse TIF and CKD. 
 
1.3. Anti-fibrotic and pro-fibrotic activities of botanicals 
Despite the commonly accepted role for TIF in CKD progression, there are currently few 
approved treatments in conventional medicine that directly target the mechanisms of fibrosis 
[33-36]. A range of biological activities offered by natural products and herbal medicines 
have aroused increasing interests thanks to their potentials for treating fibrotic diseases (58-
62). For example, GQ5, a small molecular phenolic compound isolated from the dried resin 
of Toxicodendron vernicifluum, hindered renal fibrosis in obstructive nephropathy by 
selectively inhibiting TGF-β1-induced Smad3 phosphorylation (63). On the other hand, 
some botanicals also cause fibrosis. For example, aristolochic acid, a natural compound 
present in plants of the Aristolochia, Bragantia and Asarum genera, has been known to 
induce a fibrotic nephropathy, designated aristolochic acid nephropathy, as well as urothelial 
cancer (64).  
To discover and compare inflammation-independent anti-fibrotic and pro-fibrotic activities, 
a high-throughput cellular model of fibrosis was established in my supervisor’s laboratory, 
based on TGF-β1 induced total collagen accumulation, a gold standard for clinical diagnosis 
of fibrosis (65, 66). On this in-vitro platform, five herbal compounds, eleven individual 
herbal extracts and sixteen herbal formulae showed anti-fibrotic activities and three ethanolic 
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extract had potent in-vitro pro-fibrotic activities (66, 67). For instance, anti-fibrotic activities 
are identified in Scutellariae Radix and two flavonoids derived from this herb; unprocessed 
Aconiti Radix (AR), which have alkaloids-mediated acute poisonous effects, showed potent 
in-vitro pro-fibrotic activities. Nevertheless, the anti-fibrotic and pro-fibrotic chemical 
principles in SR and AR and exact mechanisms remain poorly understood. Therefore, the 
present study set out to study the chemical principles and molecular mechanisms of SR and 
AR, with particular focuses on SR flavonoids and AR alkaloids, in TGF-β1-induced in-vitro 
models of fibrosis. 
 
1.4. Aconitum carmichaeli Debx. and its alkaloid compounds 
The Aconitum genus are widely used in traditional Chinese medicine (TCM) and have been 
used in TCM clinics for 2000 years. Aconitum carmchaeli Debx. is one of the almost 80 
aconite species used for medical purposes (68). Two herbal drugs recorded in the 2015 
edition of the Chinese Pharmacopoeia are mainly derived from this species - Aconiti Radix 
(AR), the main roots, and Aconiti Lateralis Radix (ALR), the lateral roots (Fig. 1.2).  
 
AR and ALR are mostly producted in Sichuan Province, the south-western of China. Local 
people normally use it as a vegetable to make soup, by cutting the roots into slices and 
boiling with different vegetables and meat. Since the local climate in these areas is very 
humid and according to TCM theory, pungent and bitter tasting herbs can counteract the 
influence of a damp environment on the human body. Therefore, Aconitum is believed to 
help to treat cold-damp type of illness. However, the improper use of Aconitum in China and 
other Asian countries still poses a high risk of poisoning as it can cause severe 
cardiotoxicity and neurotoxicity. The typical symptoms of poisoning include palpitation, 
vomiting, nausea, arrhythmia, shock, dizziness, hypotension, coma, even lead to death if the 
rescue is not timely (68).  
 
Both AR and ALR are known to be highly poisonous because they contain abundant toxic 
components-aconite alkaloids.  Currently, chemical studies have shown that three major 
groups of aconite alkaloids have been extensively studied: (i) diester-diterpenoid alkaloids 
(DDAs), mainly comprise aconitine, mesaconitine and hypaconitine; (ii) monoester-
diterpenoid alkaloids (MDAs), such as benzoylaconine, benzoylmesaconine and 
benzoylhypaconine; and (iii) unesterified-diterpene alkaloids (UDAs), mainly containing 
aconine, mesaconine and hypaconine. In particular, the DDAs have the highest toxicity to 
the cardiovascular and nervous system. DDAs are not stable, which are easily hydrolysed 
into MDAs in the presence of water and/or heat. As shown in Fig. 1.3, MDAs can be further 
 25 
converted into UDAs through a second hydrolysis (68, 69). Hydrolysis of the 
DDAsmarkedly decreases their toxicities by over 100-fold (70). The three lethal dose 50% 
(LD50) values of the rat oral administration were 1.0-1.8 mg/kg, 1.9 mg/kg, and 5.8 mg/kg 
respectively (68). Therefore, aconitum toxicity can be reduced by adding water and heat 
processing, this is mainly due to the promotion of hydrolysis of DDAs into the low toxicity 





Fig. 1.2. Photographs of Aconitum carmchaeli Debx. and its derived herbal drugs. (A) 
The morphology of Aconitum carmchaeli Debx. (69); (B) AR, the principal root: 
Irregularly conical, slightly curved. Externally brown or greyish-brown, shrunken, 
with tuberculate rootlets and scars of daughter roots. Texture compact, fracture 
whitish or greyish-yellow, cambium ring polygonal. Odour, slight; taste, pungent and 
numb. (C) ALR, the lateral root: Irregularly spherical, matte. Texture compact. 
Externally slate grey or greyish-brow, fracture oyster whitish. Odour, slight fishy; 
















Fig. 1.3. Schematic representation of two step hydrolysis of alkaloids. 
 
 
This detoxicating procedure, known as Paozhi in TCM, is the traditional processing method 
of TCM, playing an important role in detoxifying toxic herbs. Aconitum processing methods 
can be broadly divided into three categories: water processing (soaking, moistening or 
rinsing in water, wine, vinegar or other liquid adjuvants, etc.), fire processing (baking, 
roasting, stir-frying, etc.) and fire and water processing (steaming, decocting with or without 
adjuvants) (71). Only processed AR and ALR are allowed to be clinically used in TCM 
practice (72). In the 2015 edition of the Chinese Pharmacopoeia, five decoction pieces of AR 
and ALR were recorded, as shown in Fig. 1.4: Zhichuanwu, Heishunpian, Baifupian, 
Danfupian, and Paofupian. In addition, the clinical dosage and decoction time of AR and 
ALR decoction pieces are exactly described: AR, 1.5-3 g and ALR, 3-15 g, a day. It should 
be decocted first and for a long period of time. Moreover, doctors should remind users to pay 




















Fig. 1.4. The form of traditional processing of AR/ALR in the Chinese Pharmacopoeia.  
 
Aconite alkaloids also served as quality markers for the chemical evaluation of AR and ALR. 
Due to the high toxicity of AR/ALR and the DDAs, accurate qualitative and quantitative 
determination of DDAs is of great importance. Intoxications could probably be prevented if 
a standardized method for quality control could be established. Some publications show that 
high-performance liquid chromatography (HPLC) is an appropriate method of quality 
control for aconite preparations (73). According to the Chinese Pharmacopeia 2015, HPLC 
method is accepted for the quantitative analysis of alkaloids in AR and ALR. The legal 
ranges of DDAs in AR and ALR, calculated taking aconitine, mesaconitine and hypaconitine 
into consideration, are 0.050%0.17% and < 0.20%, respectively.  
 
The processed AR and ALR are known to have important pharmaceutical properties, e.g. the 
effects on the cardiovascular system, oedema, abdominal colic and irregular menstruation, 
antinociceptive, analgesic and anti-epileptic activities, and around 600 formulae containing 
processed AR and ALR are on the Chinese market alone (68, 69, 74). Despite the well-
established acute toxicities of the genus Aconitum, the chronic adverse effects of AR, ALR 
and other products containing Aconitum species are largely unknown. In an ealier screening 
expriemnt, my supervisor’s laboratory found that the ethanolic extracts of unprocessed AR 

























the first report linking AR to potent pro-fibrotic activities as far as we know. This in-vitro 
finding also has important clinical implications as consumption of an ethanolic extract of 
Aconitum species is known to cause acute kidney injury (76) and consumption of an ALR-
containing product was recently linked to end-stage renal failure (77). Thus, it is important to 
determine the reliability of the screeing findings by repeating experiments and to establish if 
the potent pro-fibrotic effect of this toxic herb could be reduced or even eliminated through 
traditional “Paozhi” and if this newly identified adverse effect is attributable to any aconite 
alkaloids.  
 
1.5. Scutellaria baicalensis Georgi and its flavonoid compounds  
Scutellaria baicalensis Georgi is one of the most commonly used medical plant in China, 
Korean, Japan, Mongolia and Russian Federation (Fig. 1.5). Scutellariae Radix, the dry roots 
of the plants, is officially recorded in the Chinese (78), European (79), and American Herbal 
Pharmacopoeias (80). SR is used as a local medicine to clear away the “heat-evil” and expel 
“superficial evils”, eliminate stasis and activate blood circulation, induce diuresis and reduce 
edema. In TCM clinics, extracts of SR are widely applied to treat pneumonia, hypertension, 
jaundice, dysentery and intestinal catarrh, pyogenic infection, etc (81). Apart from the above 
properties, SR alone, or used as a key ingredient in combination with other herbs, has been 
shown to have wide therapeutic effects on cancer (82, 83), liver disease (84, 85) and kidney 
diseases (86, 87).  
SR is especially rich in flavonoids (88). Flavonoids, from the Latin word flavus meaning 
yellow, their color in nature, are a class of plant secondary metabolites. Epidemiological 
studies have shown that dietary intake of flavonoids is significantly associated with a 
reduced risk of cancer, inflammation and heart disease (89, 90). Indeed, the flavonoids 
isolated from SR have been shown to exert antioxidant (91), anti-viral (92), anti-





Fig. 1.5. Photographs of Scutellaria baicalensis Georgi and its derived herbal drug. (A) 
The morphology of Scutellaria baicalensis Georgi (96). (B) SR: Irregularly cylindrical. 
Externally medium brown beige. Texture hard and fragile. Odour, woody and beany; taste, 
strong bitter. 
 
SR contains five major flavonoid compounds which have similar structures (Fig. 1.6): 
baicalin (7-glucuronic acid, 5, 6-dihydroxy-flavone), baicalein (5, 6, 7-trihydroxyfavone), 
wogonin (5, 7-dihydroxy-8-methoxyflavone), wogonoside (wogonin-7-glucuronic acid) and 
oroxylin-A (Oroxylin A 7-O-beta-D-glucuronide). One or more flavonoids are usually 
adopted for qualitative and quantitative analysis of SR. For example, baicalin, the main 
flavonoid with the highest content, is employed to control the quality of SR-containing 
medicinal materials and related products. In Chinese Pharmacopeia 2015, the content of 
baicalin should be at least 9% in dried SR (78).  
 
 
Fig. 1.6. Structures of five SR flavonoids. 
Scutellariae Radix (SR)
BA
Scutellaria baicalensis Georgi 
-A
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SR and its flavonoids, have been reported as potential anti-fibrotic agents (97-100). Table 2 
summarises the effects and mechanisms of SR extracts and five aforementioned flavonoids 
on fibrosis in various experimental fibrotic disease models. SR ethanolic extracts attenuated 
liver fibrosis in rat models induced by dimethylnitrosamine (101) and lipopolysaccharide 
(84). SR methanol extract is effective in preventing liver (102) and colonic fibrosis (103).  
Baicalin can inhibit hepatic stellate cells activation (104) and progression of liver fibrosis in 
carbon tetrachloride-induced rat model (105, 106). In addition, baicalin attenuated the 
accumulation of inflammatory cells and fibrotic changes in lung tissues (107) and also 
alleviated renal interstitial fibrosis in vivo (108). Baicalein was used as a potential 
antioxidant against hepatic (109, 110), pulmonary fibrosis (111) and protective potential for 
myocardial fibrosis (112-115). Baicalein treatment can inhibit stellate cell activation and 
proliferation (116, 117) and attenuate tubulointerstitial fibrosis by inducing myofibroblast 
apoptosis (118) and inhibiting inflammation (98). Wogonoside was reported to prevent liver 
fibrosis (119) and wogonin can suppressed collagen deposition in cardiac fibroblasts (115) 
and mitigated cardiac fibrosis through inhibiting inflammation and oxidative stress (120). In 
addation, my supervisor’s laboratory has reported that methanolic extract of the SR has 
potent in-vitro anti-fibrotic activities, and so do baicalin and baicalein (65, 66). 
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Table 1.2. SR and its flavonoids showed anti-fibrotic activities in fibrotic disease models. 
Herbal agents Type In-vivo In-vitro Signalling Reference 
SR aqueous extracts N/A N/A N/A N/A N/A 




DMN-induced rat model  HSC-T6 ERK-p53-p21 
ERK-p53-bax-caspase-3/9 
(121) 
LPS- induced rat model primary rat liver 
endothelial cells and 
HSCs 
attenuates LPS-induced liver endothelial cell activation and inhibits 
HSC migration (MCP-1/Ccl2 ¯) 
(84) 
DMN-induced rat model  N/A attenuate oxidative stress (SOD­ GPx ­Catalase­) (101) 
SR methanol 
extracts  
Liver  BDL- and CCl4-induced rat 
models  
N/A reduced levels of connective tissue (α-SMA, hydroxyproline) and lipid 
peroxidation MDA 
(102) 
Colon  TNBS-induced rat model N/A TGF-β1/smad3 pathway (103) 
Kidney  N/A NRK-49F Total collagen (PSR staining) ¯; -SMA¯ ; Collagen I ¯ (66) 
Baicalin Liver N/A primary HSCs  interaction between PPARγ (­) and Wnt pathway (¯) (104) 
CCl4-induced rat model N/A interaction between PPARγ (­) and TGF-β1 pathway (¯)  (105) 
Colchicine-induced rat model  HSCs inhibit proliferation and promote apoptosis; MDA ¯; SOD­ 
reduce ECM (TIMP-1/MMP-1¯); Collagen I&III ¯; TGF-β1 ¯ 
(122) 
CCl4-induced rat model  N/A TGF-β1¯; TNF-α ¯; IL-6 ¯; IL-10 ­ (106) 
Lung silica-induced mice model N/A inhibit Th17 cells differentiation; inhibit inflammatory (IL-6 ¯; IL23 ¯) (107) 




Liver CCl4-induced rat model N/A inhibits the activation and proliferation of HSCs (PDGF-β receptor ¯) (116) 
N/A primary HSCs inhibit proliferation (117) 
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Baicalein Lung bleomycin-induced rat model N/A improve antioxidant activity; attenuate inflammation; repress miR-21 
inhibit TGF-β1/smad3 
(111) 
Heart abdominal aorta constriction 
rat model  
H9c2 prevent apoptosis; 
reduce ECM (Mmp2¯; Mmp9 ¯) 
(112) 
Aortic banding mice model H9c2 MEK-ERK1/2 pathway (113) 
spontaneously hypertensive rat 
model 
N/A pro-collagen I & III¯; 12-lipoxygenase ¯ 
p-ERK/PEK ¯; MMP-9 ¯ 
(114) 
N/A primary cardiac 
fibroblasts from neonatal 
normotensive and 
hypertensive rats  
12-lipoxygenase ¯ 
p-ERK/PEK ¯; MMP-9 ¯ 
(115) 
Kidney  UUO mice model  NRK-49F PI3k/Akt pathway; induce myofibroblast apoptosis (118) 
UUO mice model N/A NF-κB ¯; MAPK signal pathway (98) 
Wogonoside Liver  CCl4-induced rat model  HSCs PI3K/Akt/mTOR pathway (119) 
Wogonin Heart N/A primary cardiac 
fibroblasts from neonatal 
normotensive and 
hypertensive rats  
12-lipoxygenase ¯ 
p-ERK/PEK ¯; MMP-9 ¯ 
(115) 
Streptozotocin-induced 
diabetic mice model  
N/A anti-inflammatory (IL-1β ¯; IL-6 ¯; TNF-α¯; PAI-1¯; NF-κB ¯) 
anti-oxidative (SOD1/2 ­; Catalase ­) 
(120) 
Oroxylin-A N/A N/A  N/A N/A N/A 
 
Note: DMN: dimethylnitrosamine; GPx: glutathione peroxidase; SOD: superoxide dismutase; BDL: bile duct ligation and scission; CCl4: carbon tetrachloride; MDA: malondialdehyde;  





1.6. Hypothesis and aims 
My hypothesis is that the pro-fibrotic effect of AR and anti-fibrotic activity of SR can be 
attributed to AR alkaloids and SR flavonoids, respectively. This project is designed to test 
the above hypothesis and to explore underlying molecular mechanisms by a proteomic 
approach.  
 
Specifically, the objectives of this project are: 
• To examine effects of unprocessed and processed AR/ALR extracts in a TGF-β1-
induced in-vitro model of fibrosis; 
• To examine whether the pro-fibrotic activities of unprocessed and processed AR are 
attributable to alkaloids or non-alkaloids in the herb; 
• To compare the SR methanolic and aqueous extracts in a TGF-β1-induced in-vitro 
model of fibrosis; 
• To compare the anti-fibrotic activities of five SR flavonoids; 
• To establish a proteomic view of an in-vitro model of TGF-β1-induced fibrogenesis; 
• To explore mechanisms underlying the anti-fibrotic activities of the most promising SR 














Chapter 2 Materials and Methods 
 
This chapter describes the materials and methods used for all laboratory work, including 
procurement and quality control of herbal materials, processing, extraction and chemical 
profiling of herbs, authentication and quality control of cell lines, establishing in-vitro 
models of fibrosis, testing anti- and pro-fibrotic activities of the herbal materials, 
mechanistic investigations by proteomic approach and further validation.  
 
2.1. Herbs and herbal compounds  
Aconiti Radix (AR), Aconiti Lateralis Radix (ALR) and Scutellariae Radix (SR), as shown 
in Fig. 1.2 and Fig. 1.5, were supplied and authenticated through stringent quality control by 
PuraPharm International Ltd. (Hong Kong) as detailed in Supplementary Fig. 1-3. The 
voucher samples have been deposited at Royal Botanic Gardens Kew, UK (Economic 
Botany Collection number: 84041, 84042, 84040 for AR, ALR and SR, respectively). Fig. 
1.3 and 1.6 illustrate the structure of herbal compounds, which were supplied as HPLC-
grade compounds of >98% purity and their molecular weights have been confirmed at 
King’s by high-resolution mass spectrometry (HRMS), as to be shown in 2.4. 
Authentication of herbal compounds. All herbs and herbal compounds used in this project 
are listed in Table 2.1.  
 
2.2. Reagents, buffers and solutions  
All buffers, solutions and reagents were prepared following the recipes and protocols 
demonstrated below. Ultrapure water dispensed from a Maxima USF Alsa machine was used 
for dilution and dissolution of reagents. A Metler teledo AB204-S weighting balance was 
used for weighting chemical reagents; a Stutart CB161 magenetic stirrer (with Fisher Brand 
magnetic stir bar) and a Grant Bio PV-1vortex mixer were used for mixing purpose; and a 




Table 2.1. List of herbal materials. 
Herbs and herbal compounds Manufacturers 
Aconiti Radix (AR) 
PuraPharm International 
Ltd., Hong Kong, China. Aconiti Lateralis Radix (ALR) 
Scutellariae Radix (SR) 
Aconitine (CAS: 302-27-2, C34H47NO11) 
Santa Cruz Biotechnology, 
Inc., Heidelberg, Germany. 
Mesaconitine (CAS: 2752-64-9, C33H45NO11) 
Chengdu Must Bio-
Technology Co. Ltd., 
Chengdu, China. 
Hypaconitine (CAS: 6900-87-4, C33H45NO10) 
Benzoylaconine (CAS: 466-24-0, C32H45NO10) 
Benzoylmesaconine (CAS: 63238-67-5, C31H43NO10) 
Benzoylhypaconine (CAS: 63238-66-4, C31H43NO9) 
Aconine (CAS: 509-20-6, C25H41NO9) 
Mesaconine (CAS: 6792-09-2, C24H39NO9) Chengdu Chroma-
Biotechnology Co. Ltd., 
Chengdu, China. Hypaconine (CAS: 63238-68-6, C24H39NO8) 
Baicalin (CAS: 21967-41-9, C21H18O11) 
Chengdu Must Bio-
Technology Co. Ltd. 
(Chengdu, China) 
Baicalein (CAS: 491-67-8, C15H10O5) 
Wogonin (CAS: 632-85-9, C16H12O5) 
Wogonoside (CAS: 51059-44-0, C22H20O11) 
Oroxylin A 7-O-beta-D-glucuronide (Oroxylin-A; CAS: 36948-76-2, 
C22H20O11) 
 
2.2.1. In-vitro model of fibrosis 
TGF-β1: Human platelet TGF-β1 (R&D Systems, Abingdon, UK) was reconstituted in 
sterile 4 mM hydrochloric acid (HCl; VWR International Ltd, Lutterworth, UK) and 0.1% 
bovine serum albumin (BSA; PAA Laboratories GmbH) that had been filter-sterilised 
through polyethersulfone membrane with 0.2 μm pore size. A stock solution of 10 ng/μL 
TGF-β1 was stored at -80 °C until use.   
IN1130: A selective inhibitor of TGF-β type I receptor (Alk5), is a kind gift from Dr. Dae-
Kee Kim (Ewha Woman’s University, Korea).  A stock of 2 mM IN1130 in normal saline 
was stored at -80 °C until use.   
Herbal stock solutions: Stock solutions of herbal extracts and compounds were prepared by 















Herbal extracts - 16 1000.0 16 mg/mL 
Aconitine 645.74 10 774.3 20 mM 
Mesaconitine  631.71 10 791.5 20 mM 
Hypaconitine  615.71 10 812.1 20 mM 
Benzoylaconine 603.7 10 828.2 20 mM 
Benzoylmesaconine 589.67 10 847.9 20 mM 
Benzoylhypaconine 573.67 10 871.6 20 mM 
Aconine  499.59 10 1000.8 20 mM 
Mesaconine 485.57 10 1029.7 20 mM 
Hypaconine  469.57 10 1064.8 20 mM 
Baicalin   446.36 10 1120.2 20 mM 
Wogonoside  460.39 10 1086.0 20 mM 
Baicalein 270.24 10 925.1 40 mM 
Wogonin 284.26 10 879.5 40 mM 
Oxylin-A  460.39 10 1086.0 20 mM 
 
All stock solutions were stored at -80 °C until use. The protocols and procedures of herbal 
extraction are described in 2.3 Preparation of herbal extracts section. 
 
Picro-Sirius red (PSR) stain (0.1%): 1.5 g of picric acid (Sigma-Aldrich, UK) was added 
to 100 mL H2O to make saturated picric acid. Then add 0.1 g of Sirius Red 80 (Sigma-
Aldrich, UK) to make 0.1% PSR.  
Acetic acid solution (0.1%): 5 mL of acetic acid (VWR International Ltd) was added to 500 
mL of H2O to make 1% stock solution. Stock solution was further diluted 10× to make 0.1% 
acetic acid solution. 
Sodium hydroxide (NaOH) solution (0.1M): 20 g of NaOH (Sigma-Aldrich, UK) was 
added to 500 mL H2O to make 1 M stock solution. Stock solution was then diluted 10× to 




Phosphate buffered saline (PBS): To make 1 L of 10× PBS, 80 g NaCl (Sigma-Aldrich, 
UK), 2 g KCl (Sigma-Aldrich, UK), 14.4 g Na2PO4 (Sigma-Aldrich, UK) and 2.4 g KH2PO4 
(Sigma-Aldrich, UK) were dissolved in H2O to a volume of 1 L and adjusted to pH 7.4 using 
1 M NaOH (Sigma-Aldrich, UK). For use in experiments 1× PBS was made by adding 100 
mL 10× PBS to 900 mL H2O. 
 
2.2.2. Immunocytochemistry 
Antibodies: Antibodies used in this project and their sources are listed in Table 2.3. All 
antibodies were stored according to recommendations form the suppliers. 
Paraformaldehyde solution (3.7%): 2 mL of 37% formaldehyde solution (Sigma-Aldrich) 
was added to 18 mL PBS. 
Triton X solution (0.1%): 10 μL Triton X-100 (Sigma-Aldrich) was added to 10 mL PBS. 
BSA blocking reagent (1%):  0.1 g BSA was added to 10 mL PBS.  
 
Table 2.3.  List of antibodies.  
Antibodies Suppliers 
Non-immune mouse IgG (sc-2025) 
Santa Cruz Biotechnology, Inc. 
(Heidelberg, Germany) 
Non-immune goat IgG (sc-2028) 
Anti-factor VIII goat polyclonal IgG (E-16, sc-27649) 
Anti-fibronectin rabbit polyclonal IgG (H-300, sc-9068) 
Anti-vimentin mouse monoclonal IgG1 (V6389) Sigma-Aldrich (Gillingham, UK) 
Anti-cytokeratin mouse monoclonal IgG1 (ab49779) 
Abcam (Cambridge, UK) 
Anti-collagen I rabbit polyclonal IgG (ab292) 
Anti-collagen III rabbit polyclonal IgG (ab778) 
Alexa Fluor 488 goat anti-mouse IgG (H&L) (ab150113) 
Alexa Fluor 555 donkey anti-goat IgG (H&L) (A21432) Invitrogen (Paisley, UK) 







2.2.3. Protein preparation  
RIPA lysis and extraction buffers: To make 10× stock solution of RIPA lysis and 
extraction buffer, add a vial of protease and phosphatase inhibitors (MS-SAFE, Sigma-
Aldrich) into 2 mL of RIPA lysis and extraction buffer (R0278, Sigma-Aldrich) and stored at 
-20 °C. Stock solution was then diluted 10× into 1× RIPA lysis and extraction buffer 
working solution.  
2.2.4. Enzyme-linked immunosorbent assay (ELISA) 
The ELISA kits used in this study and their sources are listed in Table 2.4 and stored 
according to recommendations from the suppliers.  
Table 2.4.  List of ELISA kits. 
ELISA kits Suppliers 
Protein Nov (Ccn3), ab205570 
Abcam (Cambridge, UK) 
Plasminogen activator inhibitor 1 (PAI-1/Serpine1), ab201283 
Connective Tissue Growth Factor (Ctgf), MBS261004 
MyBiosource (San Diego, USA) 
Matrix Metalloproteinase 3 (Mmp3), MBS762109 
Procollagen Lysine-2-Oxoglutarate-5-Dioxygenase 2 (Plod2), 
MBS9391878 
C-C motif chemokine 2 (Ccl2), MBS824584 
C-C motif chemokine 7 (Ccl7), MBS8244676 
Protein Cyr61, MBS9425693 
Inosine-5'-monophosphate dehydrogenase 2 (Impdh2), XPER1807 Express biotech International (Frederick, USA) 
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 
(Enpp1), ER0419 Fine Biotech (Wuhan, China) 
Transferrin receptor (Tfrc), ER1375 
Aldehyde dehydrogenase, dimeric NADP-preferring (Aldh3a1), 
E02A1034 
BlueGene Biotech (Shanghai, China) Coiled-coil domain-containing protein 80 (Ccdc80), E02C1111 
Tsukushin (Tsku), E02T0739 




2.3. Preparation of herbal extracts  
Herbal extracts were produced and analysed by Ms. Jun Yuan and Zhitao Liang in Professor 
Zhongzhen Zhao’s Laboratory (Hong Kong Baptist University, Hong Kong) and the specific 
protocols and procedures for each herb were described below.  
 
2.3.1. Processing and extraction of AR and ALR  
Fig.2.1 illustrates the workflow of processing and extraction of AR and ALR. To make 
processed AR, AR was graded according to size and macerated in Milli-Q water until there 
was no dry core. Taken out and boiled in water until there was no white core. AR was then 
cut into slices and dried at 50 °C for 24 h. 
 
 
Fig. 2.1. The procedure flow of AR and ALR extraction and downstream assays. 
 
Three types of processed ALR are recorded in the Chinese pharmacopoeia 2015 edition. The 
most commonly used, known as Heishunpian (HSP), was chosen for this study. Besides, 
another type of processed ALR, known as Zhengfuzi (ZFZ), which is recommended by the 
Japanese Pharmacopoeia 17th edition was also chosen for study.  
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To make HSP, ALR was graded according to size and macerated in saturated Danba solution 
(86.42 % CaCl2, Penglai Salt Chemical Co. Ltd., Chengdu, China) until there was no dry 
core. After washing with distilled water, slices were cut and autoclaved at 121 °C (0.1 Mpa) 
for 2 h. The slices were then dried at 50 °C for 24 h.  
To make ZFZ, ALR was graded and macerated in Milli-Q water for 2 days, cut halfway, and 
then macerated in Milli-Q water until there was no dry core. Autoclaved at 121 °C (0.1 Mpa) 
for 2 h, followed by moisture overnight, the herb was autoclaved for another 2 h at 121 °C 
(0.1 Mpa) and then dried at 50 °C for 24 h.  
For ultra-high-performance liquid chromatography-quadrupole time-of-flight mass 
spectrometry (UPLC/Q-TOF-MS)-based chemical analysis and quality control, 0.5 g fine 
powders were dissolved in 5 mL 50% methanol and then diluted 4 times by 50% methanol.  
For testing activities of unprocessed and processed AR and ALR in in-vitro models of 
fibrosis, 85 g fine powders were mixed in 600 mL Milli-Q water or 80% ethanol, simmered 
for 2 h under reflux on electric heating-jacket, cooled, filtered, dried under vacuum freeze 
and the extracts were stored at -20 °C until use. 
 
2.3.2. Extraction of SR  
The procedure flow of SR extraction is illustrated in Fig.2.2. 
SR aqueous and methanolic (SRA and SRM) extracts: 85 g SR powder (through 40 
meshes) was simmered in 600 mL Milli-Q water or 70% methanol for 2 h under reflux on 
electric heating-jacket, cool and filter. Extracts were dried under vacuum freeze and stored at 
-20 °C until use.  
Sample preparation for MS analysis: Lyophilised powder of aqueous/methanolic extracts 
were accurately weighed and dissolved in 100% methanol to obtain 1 mg/mL solutions prior 
to UPLC/Q-TOF-MS analysis. 
Mass spectrometry: UPLC was carried out using an Agilent 6540 accurate-mass Q-TOF 
LC/MS (Agilent Technologies, U.S.A.). Liquid chromatographic separation was performed 




100 mm I.D., 1.7 μm, ACQUITY UPLC®BEH, Waters, U.S.A.), attached with a C18 pre-
column (2.1 mm × 5 mm I.D., 1.7 μm, VanGuardTM BEH, Waters, U.S.A.). MS analyses 
were performed under the following operation parameters: dry gas temperature 300 °C, dry 
gas (N2) flow rate 8 L/min, nebulizer pressure 45 psi, Vcap 4500 V, nozzle voltage 500 V 
and fragment voltage 150 V. Mass spectra were acquired in the positive ion mode by 
scanning from 50 to 1700 in the mass-to- charge ratio (m/z). The mobile phase composition 
used for UHPLC-QTOF MS comprised of a mixture of H2O (A) and CH3CN (B), both 
containing 0.1% HCOOH, with an optimized linear gradient elution as follows: 0-10 min, 5-
25% B; 10-25 min, 25-75% B; 25-28 min, 75-100% B; 28-31 min, 100-100% B; 31-31.1 
min, 100-5% B with 3.9 min of equilibrium time. The injection volume was 2 μL. The flow 
rate was set at 0.4 mL/min.  
 
 
Fig. 2.2. The procedure of SR extraction and downstream analysis.  
Note: F5: five SR flavonoids, including baicalin, baicalein, wogonoside, wogonin, oroxylin-A. 
 
F5 depletion: To address whether major SR flavonoids (F5: baicalin, baicalein, wogonoside, 
wogonin and oroxylin-A) are the main contributors to the anti-fibrotic activities in NRK-49 
cells, F5 compounds were isolated from SRA and SRM extracts and pooled as the F5 
fractions and the rest as F5-depleted fractions. Freeze-dried powder of SRA (110.6 mg) and 
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0.22 μm membrane. Preparative liquid chromatography was carried out using Waters 2489 
UV/visible detector, Waters 2545 binary gradient module, an Empower workstation (Waters, 
USA) and a reversed phase C18 column (40×300 mm, 12 μm, Symmetry Prep TM). The 
mobile phase composition used for depletion comprising of a mixture of H2O (A) and 
methanol (B), with an optimised linear gradient elution as follows: 0-60 min, 35% B; 60-70 
min, 35-100% B; 70-90 min, 100% B; 90-100 min, 35% B; 100-110 min, 35% B. The flow 
rate was set at 10 mL/min. 
 
2.4. Authentication of herbal compounds  
To examine if aconite alkaloids have pro-fibrotic effects in vitro and could account for the 
reported pro-fibrotic effect of AR, nine aconite alkaloids were procured and their molecular 
weights were validated, with the mass errors lower than 2.5961 ppm (Table 2.5).  
To examine if SR flavonoids have anti-fibrotic effects and could account for the previously 
reported anti-fibrotic activities of the herb, five SR flavonoids (baicalin, wogonoside, 
baicalein, wogonin, oroxylin-A) were purchased and examined to validate their molecular 
weights, as listed in Table 2.6. The five flavonoids were found to have the expected 
molecular weights with the mass errors lower than 3.3823 ppm.  
 
2.5. Cell culture and quality control  
Normal rat kidney fibroblasts (NRK-49F; LGC Standards, Teddington, UK) were an 
established cell line derived from an adult non-inbred Osborne-Mendel rat kidney and 
developed as a fibroblastic clone. This cell type has been widely used in TGF-β1-induced 
fibrogenesis studies and the culture conditions to maximise the fibrogenesis and minimise 
proliferation in response to TGF-β1 have already been developed. Likewise, in our previous 
research, a TGF-β1-induced in-vitro model of fibrosis has been established in NRK-49F 
cells for screening the anti-fibrotic activities of herbs and herbal compounds. Therefore, 





Table 2.5. Validation of molecular weights of AR/ALR alkaloids by HRMS. 
Note: ESI: Electrospray ionization. 
 
Table 2.6. Validation of molecular weights of SR flavonoids by HRMS. 
 
NRK-49F cells were maintained in Dulbecco's Modified Eagle Medium (DMEM, Thermo 
Fisher Scientific Inc.) supplemented with 5% fetal calf serum (FCS, Sigma-Aldrich, UK), 
penicillin 100 IU/mL, streptomycin 100 μg/mL (PAA Laboratories, GmbH) and 
amphotericin B 2.5 μg/mL (Invitrogen, Paisley, UK) at 37 °C and 5% CO2. For passaging or 
use in experiments, adherent cells were first washed with sterile PBS (PAA Laboratories 
GmbH) then incubated in 1 mL trypsin (0.5 mg/mL)-ethylenediaminetetraacetic acid (EDTA, 










A1 C34H47NO11 646.3219 [M+H]+ 646.3227 [M+H]+ -1.2378 ESI+ 
A2 C33H45NO11 632.3061 [M+H]+ 632.3071 [M+H]+ -1.5815 ESI+ 
A3 C33H45NO10 616.3106 [M+H]+ 616.3122 [M+H]+ -2.5961 ESI+ 
A4 C32H45NO10 604.3107 [M+H]+ 604.3122 [M+H]+ -2.4822 ESI+ 
A5 C31H43NO10 590.2953 [M+H]+ 590.2965 [M+H]+ -2.0329 ESI+ 
A6 C31H43NO9 574.3004 [M+H]+ 574.3016 [M+H]+ -2.0895 ESI+ 
A7 C25H41NO9 500.2852 [M+H]+ 500.2860 [M+H]+ -1.5991 ESI+ 
A8 C24H39NO9 486.2963 [M+H]+ 486.2703[M+H]+ -2.0565 ESI+ 
A9 C24H39NO8 470.2743 [M+H]+ 470.2754 [M+H]+ -2.3391 ESI+ 
Compound Molecular 
formula 





Baicalin C21H18O11 445.0782 [M-H]- 445.0771 [M-H]- 2.5164 ESI- 
Wogonoside C22H20O11 459.0937 [M-H]- 459.0927 [M-H]- 2.1129 ESI- 
Baicalein C15H10O5 269.0459 [M-H]- 269.0449 [M-H]- 3.3823 ESI- 
Wogonin C16H12O5 283.0612 [M-H]- 283.0606 [M-H]- 1.9784 ESI- 




by examining the cells under microscope. Fresh culture medium was added, then aspirated 
and dispensed into new culture flasks. A sub-cultivation ratio of 1:3 to 1:4 was used as 
recommended by supplier.  
 
2.5.1. Cell species identification 
Misidentification and cross-contamination of cell lines are common problems of cell cultures 
that can make scientific results and their reproducibility unreliable. Simple and quick 
polymerase chain reaction (PCR)-based method was used to identify the species of cultured 
cells and to detect inter-species cross contamination. DNA was extracted from the tested 
cells and PCR was conducted by using oligonucleotide primer pairs for cytochrome oxidase 
subunit (Cox I) sequences for Homo sapiens, Rattus norvegicus and Mus musculus. The cell 
lines and primary cell cultures used for species identification was listed in Table 2.7.  
 
DNA extraction: Total DNA was extracted using PureLink Genomic DNA Mini Kit (K1820, 
Life technologies) according to the manufacturer’s guidelines. Briefly, cell culture medium 
was removed and cells were harvested by trypsinisation, then the cells were resuspended in 
200 μL PBS. 20 μL Proteinase K, 20 μL RNase and 200 μL Lysis/Binding Buffer were 
added and mixed well to obtain a homogenous solution. After incubation at 55 °C for 10 min, 
200 μL 100% ethanol was added to the lysates and samples were transferred to a Spin 
Column, centrifuged at 10,000 × g for 1 min, washed once with 500 μL Wash Buffer 1 then 
centrifuged at 10,000 × g for 1 min. Further washing was performed using 500 μL Wash 
Buffer 2 then centrifuged at maximum speed. Finally, DNA was eluted into 1.5 collection 
tubes by adding 100 μL Elution Buffer directly to the spin column followed by 
centrifugation for 1 min at full speed. The purity of the eluted total DNA was confirmed 
using a NanoDrop 8000 Spectrophotometer (Thermo Fisher Scientific) and stored at -20 °C 






Table 2.7. List of cell lines and primary cell cultures. 
Name Expected species Expected cell type Supplier 
HUVEC Human Endothelial Dr. Lingfang Zeng, King’s College London, London, UK 
HEK Human Embryonic LGC Standards, Teddington, UK 
HKC-8 Human Epithelial Dr. Lorraine Racusen, Johns Hopkins University, Baltimore, USA 
“TK173” Human Fibroblastic Prof. Gerhard Müller, University of Göttingen, Goettingen, Germany 
“TK188” Human Fibroblastic Prof. Gerhard Müller, University of Göttingen, Goettingen, Germany 
NRK-49F Rat Fibroblastic LGC Standards, Teddington, UK 
SM43 Rat Mesangial Dr. Masanori Kitamura, UCL, London, UK 
mPTECs Mouse Epithelial Dr. Mark Dockrell, South West Thames Institute for Renal Research, London, UK 
mIMCD-3 Mouse Epithelial LGC Standards, Teddington, UK 
 
Primers: Oligonucleotide primer pairs, GenBank information and amplification product 
sizes were listed in Table 2.8. Oligonucleotides were supplied by Sigma-Aldrich and Cox I 
sequences for Homo sapiens, Rattus norvegicus, Mus musculus were employed to select 
highly specific application primers (123). 
PCR amplification: Amplification was carried out in a Thermal Cycler (Applied 
Biosystems). Genomic DNA from each cell line was used as the template and amplified by 
PCR using DreamTaq PCR Master Mix (K1071, Life technologies). Gradient PCR was 
performed to determine the optimal annealing temperature for each pair of primers. The 
reaction composition and cycling protocol that were used for amplification are shown in 
Table 2.9 and Table 2.10. The amplification product (10 μL) was run on 2% agarose gel 
Sigma-Aldrich (Gillingham, UK), stained with ethidium bromide (Invitrogen), visualised 








Table 2.8. Species-specific primers.  
Species 
Gene/GenBank 
Accession No. Position Direction Sequence Size (bp) 































Table 2.9. The reaction composition for species-specific amplification.  
Reagent Concentration Volume  
Dream Taq PCR Master Mix 2´ 10.0 μL 
Forward primer 100 μM 0.2 μL 
Reverse primer 100 μM 0.2 μL 
Template DNA 100 ng/μL 5.0 μL 
Water (nuclease-free) - 4.6 μL 
Total - 20.0 μL 
 
Table 2.10. Cycling protocol for species-specific amplification. 
Stage Temperature (°C) Time Number of Cycles 
Initial denaturation 95 3 min 1 






Extension 72 1 min 
Final Extension 72 5 min 1 





NRK-49F cells were set for authentication in present study, alongside with “TK173” and 
“TK188”, which were expected to be human kidney fibroblast cell lines originated from 
healthy and fibrotic kidneys, respectively, in comparison with a range of other cells as 
species and phenotype controls. “TK173” and “TK188”, if authenticated as human kidney 
fibroblasts, were candidate cells for developing human cell-based in-vitro models for 
validating the human relevance of findings from NRK-49F cells.  
 
 
Fig. 2.3. PCR amplification with species-specific human, mouse and rat primer pairs. 
Amplified fragments were detected by ethidium bromide staining after 2% agarose gel 
electrophoresis. On each gel, the amplified products were loaded in the same order. L: DNA 
ladder (100 bp, New England Biolabs); lane 1: HUVEC (human); lane 2: HEK (human); 
lane 3: HKC-8 (human); lane 4: “TK173” (expected to be human); lane 5: “TK188” 
(expected to be human); lane 6: NRK-49F (rat); lane 7: SM43 (rat); lane 8: mPTECs 
(mouse); lane 9: mIMCD-3 (mouse) and lane 10: Human control DNA (Qiagen).  
 
As shown in Fig. 2.3, most cells were confirmed of their expected species, with the 
exception of “TK173” and “TK188” cells, which were expected as human cells. However, 
DNAs extracted from these cells were unexpectedly amplified by mouse specific primers, 
but not human. To further confirm the species of “TK173” and “TK188” cells, fresh DNAs 
of each cell line were extracted and subjected to PCR amplification using human and mouse 
specific primers. As illustrated in Fig. 2.4, “TK173” and “TK188”, once again were 
characterised as of murine origin rather than human. 
In conclusion, the above studies confirmed that NRK-49F cells were of rat origin as 
expected, however, “TK173” and “TK188” were not human renal fibroblasts and were of 






Fig. 2.4. PCR amplification with human and mouse primer pairs. Amplified fragments 
were detected by ethidium bromide staining after 2% agarose gel electrophoresis. L: 100 bp 
DNA ladder; lane 1: HUVEC (human); lane 2: HKC-8 (human); lane 3: “TK173”; lane 4: 
“TK188”; lane 5: NRK-49F (rat); lane 6: SM43 (rat); lane 7: mPTECs (mouse); lane 8: 
mIMCD-3 (mouse). 
 
2.5.2. Cellular morphology and immunocytochemical characterisation 
Cell morphology was observed under Nikon Eclipse TE2000-S microscope (Nikon 
Instruments Europe BV, Amstelveen, the Netherlands) regularly to confirm the healthy 
status of the cells. The phase contrast images (Fig. 2.5) show the morphology of healthy 
NRK-49F cells in adherent at 60% confluence. The cells were always passaged before they 
reach confluence to avoid transformation. 
 
 
Fig. 2.5. NRK-49F cells in culture. The figure shows NRK-49F cells cultured for 48 h with 





A basic cell characterisation was performed to confirm identify of NRK-49F cells. 
Expression of vimentin, cytokeratin and factor viii, the markers of fibroblasts, epithelial cells 
and endothelial cells, respectively, were examined by indirect immunocytofluorescence. 
Cells were seeded at 5×103 cells/well into 96 well plates in DMEM with 10% FCS (NRK-
49F, “TK177”, “TK188”); DMEM/F12 (1:1) with 5% FCS (HKC-8); Medium199 with 10% 
FCS (HUVEC). After an overnight incubation, cells were fixed with ice-cold 100% 
methanol at -20 °C for 10 min, followed by washing with three changes of PBS, 5 min each. 
Cells were then permeabilised with 0.1% Triton X-100 for 5 min, washed with PBS three 
times and blocked with 1% BSA for 1 h at room temperature. Cells were then stained for 1 h 
at room temperature with anti-vimentin mouse monoclonal IgG1, anti-cytokeratin mouse 
monoclonal IgG1 and anti-factor VIII goat polyclonal IgG, as well as negative control non-
immune mouse IgG and goat IgG, respectively. Table 2.3 lists the antibodies used in 
experiments and their sources. After three PBS washing, cells were incubated for 1 h with 
Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 555 donkey anti-goat IgG, 
respectively, followed by washing, counterstain with 4’6-diamidino-2-phenylindole (DAPI) 
and visualisation under a Nikon Eclipse TE2000-S fluorescence microscope.  
 
 




As shown in Fig. 2.6, NRK-49F stained positive for the fibroblast maker vimentin and 
negative for the epithelial maker cytokeratin and the endothelial maker factor viii as 
expected. HKC-8 cells stained positive for cytokeratin and negative for vimentin and factor 
viii; and HUVEC stained positive not only for factor viii but also vimentin, and negative for 
cytokeratin. 
 
2.5.3. Mycoplasma contamination detection 
Conditioned media were harvested for PCR with a LookOut Mycoplasma PCR Detection Kit 
(MP 0035, Sigma-Aldrich). The reaction composition and cycling protocol that were used 
for amplification are shown in Table 2.11 and Table 2.12. 20 μL amplification product was 
run on 1.2% agarose gel with ethidium bromide and photographed under UV light.  
NRK-49F and mIMCD-3 cells were examined for mycoplasma detection. As shown in Fig. 
2.7, the negative control and positive control samples showed distinct a 481 bp band and a 
260 bp band, respectively. Both NRK-49F cells and mIMCD-3 cells were confirmed free of 
mycoplasma contamination. 
Table 2.11. The reaction composition for mycoplasma amplification.  







Reagent  Sample  Positive Negative 
Rehydration buffer/DNA Polymerase* 23 μL 25 μL 23 μL 
Sample volume 2 μL - - 
DNA-free water - - 2 μL 




Table 2.12. Cycling protocol for mycoplasma amplification. 
Stage Temperature (°C) Time Number of Cycles 
Initial denaturation 94 2 min 1 
Denaturation 94 30 sec 
40 Annealing 55 30 sec 
Extension 72 40 sec 




          
 
Fig. 2.7. PCR amplification for mycoplasma detection. Amplified fragments were 
detected by ethidium bromide staining after 1.2% agarose gel electrophoresis. L: 100 
bp DNA ladder; P: Positive control; S1: NRK-49F cells; S2: mIMCD-3 cells; N: 
Negative control. 
 
In summary, NRK-49F cells were confirmed as rat cells that showed typical morphology of 
fibroblasts, positive for mesenchymal cell marker and negative for epithelial and endothelial 
markers, and the cells were free of mycoplasma contamination. 
The initial plan was to use “TK173” and “TK188” cells to validate findings in NRK-49F 
cells to establish human relevance of findings. Unexpectedly, these cells were proven to be 









2.6. In-vitro model of fibrosis 
The in-vitro model of TGF-β1-induced fibrosis was used to determine the effect of herbal 
extracts and compounds on fibrogenesis in NRK-49F cells. This model is qualitatively 
stained by strong anionic dye PSR for the total collagen and quantified by spectrophometric 
analysis of the eluted stain. PSR contains the small anionic picric acid and the large 
hydrophobic Sirius Red, which can bind to collagens via the interaction of its acid sulfonic 
groups with the basic groups of collagen molecules. Since collagens are abundant in basic 
amino acids, PSR can strongly react with these collagens.  
	
NRK-49F cells were seeded at a density of 1×104 cells/well in 96-well collagen type I-coated 
tissue culture plates in DMEM supplemented with 2.5% FCS and 2.5% Nu-Serum 
(Collaborative Biomedical, Bedford, MA, USA) for 3 days then change to DMEM 
supplemented with 1´ insulin-transferrin-sodium selenite Liquid Media Supplement (ITS; 
Sigma) for 4 days. Cells were treated with herbal compounds and/or TGF-β1 in 1% ITS 
DMEM for further 48 h. Control groups were treated by equivalent concentrations of 
vehicles only. Changes in cell morphology were observed and captured by photomicroscopy 
using a Nikon Eclipse TE2000-S epifluorescence microscope (Nikon Instruments Europe 
BV, Amstelveen, the Netherlands) and a DXM 1200F Nikon digital camera (Nikon UK 
Limited, Kingston upon Thames, UK). 
 
Cell detachment index in each well was recorded under microscope and categorised using 
the following scoring criteria: a score of 0 represents no cell detachment and 4 represents a 
complete disruption of the cell monolayer. Scores 0.5, 1, 1.5, 2, 2.5, 3, 3.5 stand for 
detachment of 5%, 10%, 20%, 30%, 40%, 60, and 80% cells, respectively. The cells were 
then fixed with 100% ice-cold methanol overnight at -20 °C, rinsed twice for 5 min with 
PBS before staining with 200 μL 0.1% PSR for 6 h on a rocking platform at room 
temperature. PSR solution was removed and washed twice with 0.1% acetic acid. The plate 




by photomicroscopy. The PSR eluted with 200 μL 0.1 M NaOH for 1 h on a rocking 
platform at room temperature. Following elution, PSR staining was quantified by 
spectrophotometric analysis at 540 nm using a spectrophotometer (Dynex Technologies, 
Worthing, UK). Experiments were repeated independently at least three times. 
 
2.7. Lactate dehydrogenase (LDH) release assays 
LDH assay was used to assess in-vitro cytotoxic effects, using Promega’s CytoTox 96® Non-
Radioactive Cytotoxicity Assay kits (Promega, Southampton, UK). LDH is a cytosolic 
enzyme that can release into cell culture media when cells are damaged. The amount of LDH 
in the media can be measured by a coupled enzymatic reaction in which LDH catalyses the 
conversion of lactate to pyruvate via NAD+ reduction to NADH. Diaphorase then uses 
NADH to reduce a tetrazolium salt to a red formazan product that can be measured by 
spectrophotometry. The level of formazan formation is directly proportional to the amount of 
LDH released into the medium, which is indicative of cytotoxicity.  
NRK-49F cells were seeded in quadruplicate into 96 well collagen type I-coated plates and 
treated as per protocol for the in-vitro model. A medium control without cells, a cell 
spontaneous LDH release control and a control to determine maximum LDH release from 
cells were included in the plates. To measure the maximum LDH release from cells, 20 μL 
lysis solution was added to the medium control and cell control for complete lysis and the 
plates were incubated at 37 °C and 5% CO2 for 45 min.  50 μL conditioned media from 
control and experimental wells were transferred to 96 well flat bottom enzymatic assay 
plates (Nunc, Roskilde, Denmark) and an equal volume of substrate mix was added. Plates 
were incubated at room temperature for 30 min protected from light then 50 μL of stop 
solution was added to stop the reaction and the absorbance recorded at 490 nm using a 
spectrophotometer. 
Percentage cytotoxicity for the test conditions was calculated as follows: 
Maximum LDH release= (cells + lysis solution) - (medium + lysis solution) 




Test LDH release= (cells in test conditions) - (medium alone) 
% cytotoxicity= (test LDH release) - (baseline LDH release) × 100 
                                            Maximum LDH release 
% cytotoxicity was presented as an average of quadruplicates. 
 
2.8. Immunocytofluorescence assay 
1×104 cells/well NRK-49F cells were seeded in quadruplicate into 96 well collagen type I- 
coated plates and treated as per protocol for the in-vitro model. Cells were fixed with 3.7% 
paraformaldehyde on ice for 10 min, followed by washing with three times of PBS. Cells 
were then permeabilized with 0.1% Triton X-100 for 5 min, washed with PBS three times 
and blocked with 1% BSA for 1 h at room temperature, then incubated with anti-collagen I, 
anti-collagen III, anti-α-SMA and anti-fibronectin primary antibodies, as well as negative 
control non-immune IgG overnight at -4°C, respectively. After three times PBS washing, 
cells were incubated for 1 h with Alexa Fluor 488 or 555 conjugated secondary antibodies 
respectively, followed by washing with PBS and counterstaining with DAPI. Fluorescence 
intensity was then measured using a Cytation 5 Multi-Mode reader (Bio Tek) and expressed 
in a relative fluorescence unit (RFU)/well.  
 
2.9. Protein extraction 
2.0×106 NRK-49F cells were grown in 75 mm2 flask in DMEM with 2.5% FCS and 2.5% 
Nu-serum replacement for 3 days, then changed the medium to 15 mL 1% ITS-DMEM for 
another 4 days. Cells were washed with serum free, phenol red-free DMEM (Thermo Fisher 
Scientific, 31053028) and added fresh one then incubated at 37 °C for 30 min. Repeat this 
step once. The medium was removed and the cells were treated with 40, 80 μg/mL SRM, 40 
μM, 80 μM baicalein and 1 μM IN1130 with 5 ng/mL TGF-β1 in serum-free, phenol red-free 





The conditioned media were collected and added protease and phosphatase inhibitors (MS-
SAFE, Sigma), then centrifuged at 500 g for 5 min at 4 °C to pellet detached cells and large 
debris. The supernatant was collected and then centrifuged at 2,500 g for 5 min at 4 °C to 
pellet smaller debris. The final supernatant was saved and kept at -80 °C until use.  
 
For extraction of total cell lysates, cell culture flasks were placed on ice and washed thrice 
with cold PBS. 1.0 mL/flask RIPA buffer (R0278, Sigma) with protease and phosphatase 
inhibitors were added to cover cell monolayer. Cell lysates were harvested by scraper and 
centrifuged at a full speed for 10 min to pellet debris. The bicinchoninic acid (BCA) protein 
assay (Pierce Protein Research products, Thermo Scientific, Rockford, USA) was used to 
measure the protein concentration of the samples. The BCA protein assay combines the 
reduction of Cu2+ to Cu1+ by protein in an alkaline medium with the highly sensitive and 
selective colorimetric detection of the cuprous cation (Cu1+) by BCA. The resulting intense 
purple-coloured product can be measured by spectrophotometric analysis at 540 nm. Total 
cell lysate was stored at -80°C until use. 
 
2.10. QuickZyme total collagen assay 
The total collagen content was measured indirectly through measurement of hydroxyproline 
using the QuickZyme total Collagen Assay (QZBtotcol, QuickZyme, Leiden, Netherlands). 
Hydroxyproline is a non-proteinogenic amino acid, which in mammals occurs in elastin and 
collagen. It is formed post-translationally form specific proline residues by action of the 
enzyme prolyhydroxylase. This assay measures the total amount of hydroxyproline present 
in the sample, which represents all the types of collagens including pro-collagen, mature 
collagen and collagen degradation products. The measurement of collagen is started by 
complete hydrolysis of the sample in 6 M HCl at 95 °C. The hydrolysate hydroxyproline 
residues are quantified using a modification of the method described by Prockop and 
Udenfriend (124). Cell lysate and standards were mixed with 12 mol/L HCl and hydrolysis 




hydrolysis procedure, the tubes were cooled to room temperature and then centrifuged for 
10 min at 13,000 g. The supernatants were collected and diluted the samples with demi H2O 
(200 μL hydrolysate + 100 μL H2O). The samples are now in 4 M HCl. 35 μL diluted 
hydrolyzed samples and prepared collagen standards were added into 96-well plates, 75 μL 
assay buffer was added to each well. The plate was covered with an enclosed adhesive plate 
seal and incubated 20 min at room temperature, while shaking the plate. 75 μL mixed 
detection reagents A and B (2:3) were added into each well and incubated for 60 min at 
60 °C. The absorbance was recorded at 540 nm. 
 
2.11. Sicrol soluble collagen assay 
The Sircol assay is a dye-binding method designed for the analysis of acid and pepsin-
soluble collagens. The amount of soluble collagen in conditioned media was colorimetrically 
detected by the Sicrol soluble collagen assay (Biocolor Ltd., Northern Ireland, UK) 
according to the manufacturer’s protocol. In brief, 1.0 mL culture supernatant was harvested 
and concentrated by 200 μL collagen isolation and concentration reagent overnight at 4 °C. 
The supernatant was gently removed followed by centrifugation at 13,000 g for 10 min (The 
pellet of hydrated transparent collagen is invisible). 1.0 mL of the dye (Sirius-Red) in picric 
acid was added and shaked for 30 min, the pellet was carefully collected and washed with 
750 μL washing solution. The pellet bound dye was dissolved in 250 μL alkaline solution, 
and measured the absorbance of the pellet solution at 540 nm. 
 
2.12. Proteomic analysis 
2.12.1. Sample preparation 
Sample preparation is a critical step in proteomics workflow, because the quality and 
reproducibility of sample extraction and preparation could significantly affect the results 





The protein preparation procedure is illustrated in Fig. 2.8. Medium samples were first 
concentrated by Amicon Ultra-0.5® 3kD centrifugal filtration device (Millipore, Billerica, 
MA). Then cell lysate and medium samples were denatured by adding 6 M urea/2 M 
thiourea and reduced with 10 mM dithiothreitol (DTT) for 1 h at 37 °C in the dark. 50 mM 
iodoacetamide were added for alkylation and the samples were briefly spinned down and 




Fig. 2.8. Protein sample preparation for proteomic analysis. Sample preparation 
procedure mainly includes denaturation, reduction, alkylation, precipitation, digestion and 
clean-up steps. 
 
Protein content was extracted by pre-chilled (-20 °C) acetone precipitation (8× volume) 
overnight at -20 °C. Samples were centrifuged at 14,000 g for 25 min at 4 °C and the 
supernatant subsequently discarded. The residue was dried in a Speed Vac vacuum 
centrifuge and re-suspended in 0.1 M triethylammonium bicarbonate (TEAB, pH=8.2) and 
followed by digestion with trypsin (1:50, enzyme: substrate) overnight at 37 °C. The 
digestion was stopped by acidification of samples with 1% trifluoroacetic acid (TFA) then 
the samples were loaded onto 96-well MACROSpin C18 plates (Harvard Apparatus) for 
clean-up and peptide concentrations were measured according to manufacturer’s instructions. 
The plate was firstly activated using 200 μL methanol and centrifuged at 1,000 g for 1 











three equilibration steps using 200 µL of 1% acetonitrile, 0.1% TFA in H2O with 
centrifugation (1,000 g for 1 min) after each step. Samples were loaded into the plate and 
centrifuged at 1,500 g for 1 min; the flow through was reloaded onto the plate a second time 
and centrifugation repeated. The plate was then washed three times with 200 µL 1% 
acetonitrile, 0.1% TFA in H2O, then centrifuged at 1,500 g for 1 min. Finally, the samples 
were eluted with 170 µL of 50% acetonitrile, 0.1% TFA in H2O and centrifuged at 1,500 g 
for 1 min; this step was repeated and the eluates were combined. The eluted peptides were 
dried in a Speed Vac vacuum centrifuge and re-suspended in 2% acetonitrile containing 0.05% 
TFA. Isobaric labelling of the digested peptides was performed using 10-plex Tandem mass 
tags (TMT) reagents (Thermo Fisher, Loughborough, Leics., UK).  
 
2.12.2. HPLC-MS/MS analysis 
Samples were injected onto a nano-trap column (Acclaim® PepMap100 C18 Trap, 5 mm × 
300 μm, 5 μm, 100 Å), at a flow rate of 25 μL/min for 3 min, using mobile phase (A) 0.1% 
formic acid in H2O and (B) 2% ACN. The following nano-LC gradient was then used to 
separate the peptides at 0.3 μL/min: 0-10 min, 2-10% B; 10-200 min, 10-30% B; 200-210 
min, 30-40% B; 210-220 min, 99% B; 220-250 min, 2% B. The nano column (Acclaim® 
PepMap100 C18, 50 cm × 75 μm, 3 μm, 100 Å) was set at 40 °C and coupled to a nano 
spray source (Picoview, New Objective, US). The MS spectra are collected from Orbitrap 
mass analyzer (LTQ-Orbitrap XL, Thermo Fisher Scientific) with full ion scan mode over 
the mass-to-change (m/z) range 350-1550 m/z. MS/MS were performed on the Top Speed 
method to fit as many MS2 scan in 3 sec cycle time, and use SPS-MS3 method to acquire the 
TMT reporter ion signal. Raw files were analyzed using Proteome Discoverer 2.1 and 
Mascot 2.3.01 (Matrix science). The mass tolerance was set at 10 ppm for precursor ions. 








Volcano plot (GraphPad Prism software 6.0) was used to illustrate the distribution of 
quantified proteins according to p-value and fold change. DAVID (Database for Annotation, 
Visualisation, and Integrate Discovery, https://david.ncifcrf.gov/) was used to investigate the 
biological pathways in which the differentially expressed proteins may participate. The 
STRING database (https://string-db.org) was then used to build protein-protein interaction 
networks to further explore their functions.  
 
2.14. ELISA validation 
Based on the TMT-labelling MS-based proteomic findings, the proteins most robustly 
changed or particularly relevant to fibrosis were chosen for further validation by ELISA. 
Nine proteins in conditioned media (PAI-1, Ctgf, Plod2, Ccl2, Ccl7, Cyr61, Tsku, Nov and 
Mmp3) and six in cell lysates (Enpp1, Aldh3a1, Tfrc, Ccdc80, Sqstm1 and Impdh2) were 
selected and subjected to ELISA according to the manufactures’ instructions (Table 2.4). 














Chapter 3 Effects of AR and aconite alkaloids on fibrogenesis  
 
3.1. Quality control of AR/ALR extracts 
Nine alkaloids in raw AR and ALR, as well as processed AR and ALRs (HSP and ZFZ) 
were analysed. Percent contents of alkaloids in raw and processed ARs and ALRs are 
presented in Table 3.1 and their base peak chromatograms (BPCs) and extracted ion 
chromatograms (EICs) are shown in Fig. 3.1-3.3, respectively.  
In the BPCs (Fig. 3.1 A), most of the tested standards achieved the baseline separation, 
except A1 and A3, peaks of which were partially overlapping. The overlapping of A1 and 
A3 was also observed in the sample analysis of raw AR and ALR (Fig. 3.1B and Fig. 3.2A), 
as well as processed AR (Fig. 3.1C) and ALRs (HSP and ZFZ, Fig. 3.2B&C), which 
seemed difficult to quantify. Luckily, by using the Q/TOF-MS detector, specific target 
analyte with unique accurate molecular weight can be extracted as peaks without other 
interference for quantitative analysis (Fig. 3.3).  
As shown in Table 3.1, the total content (0.070%) of A4, A5 and A6 in processed AR met 
the legal range required by the Chinese pharmacopoeia (0.070%-0.150%). The content of A5 
was 0.041%, meeting the Hong Kong Chinese Materia Medica Standards, i.e. >0.035%. The 
total content of A1, A2 and A3 in processed AR was 0.0040%, which was in line with the 
requirements of the Chinese pharmacopoeia (≤ 0.040%) and Hong Kong Chinese Materia 
























Processed ALR  
type A (HSP) 
Processed ALR  
type B (ZFZ) 
A1 0.012249  0.000132  0.015511  0.000044  0.000037  
A2 0.044884  0.000430  0.040740  0.000066  0.000042  
A3 0.038604  0.003462  0.056877  0.000367  0.000049  
A4 0.012043  0.012014  0.021293  0.023439  0.019488  
A5 0.050283  0.041275  0.054304  0.040225  0.038998  
A6 0.010309  0.013210  0.014327  0.027763  0.026331  
A7 0.005383  0.002255  0.002577  0.003831  0.008461  
A8 0.038566  0.020804  0.017257  0.018136  0.041255  
A9 0.011134  0.004883  0.002207  0.004469  0.009835  
Note: (A1) aconitine, (A2) mesaconitine, (A3) hypaconitine, (A4) benzoylaconine, (A5) 
benzoylmesaconine, (A6) benzoylhypaconine, (A7) aconine, (A8) mesaconine and (A9) 
hypaconine. 
 
Two types of processed ALRs, HSP and ZFZ were produced. In HSP, the total content of A4, 
A5 and A6 was 0.091% and that of A1, A2 and A3 was 0.0038%, both meeting the standards 
of the Chinese pharmacopoeia (≥0.010% and ≤0.020%, respectively). In ZFZ, the contents 
of A1, A2 and A3 were 0.000037%, 0.000042% and 0.000049%, fulfilling the requirements 
of Japanese pharmacopoeia (≤ 0.006%, 0.014% and 0.028%, respectively).  
A4, A5, and A6 were the most abundant among the nine tested alkaloids, both in HSP and 
ZFZ. The content of A1, A2 and A3 in ZFZ (0.000128%) was 3 times lower than in HSP 
(0.000450%). The total content of A7, A8 and A9 in HSP (0.029670%) was >2-fold lower 




         
 
Fig. 3.1. BPCs of unprocessed and processed AR. (A) mix standards, (B) unprocessed AR 
and (C) processed AR. Alkaloid peaks: (A1) aconitine, (A2) mesaconitine, (A3) 
hypaconitine, (A4) benzoylaconine, (A5) benzoylmesaconine, (A6) benzoylhypaconine, (A7) 


































Fig. 3.2. BPCs of unprocessed and processed ALR. (A) Unprocessed ALR and two types 
of processed ALR: (B) HSP and (C) ZFZ. Alkaloid peaks: (A1) aconitine, (A2) mesaconitine, 
(A3) hypaconitine, (A4) benzoylaconine, (A5) benzoylmesaconine, (A6) benzoylhypaconine, 
































Fig. 3.3. EICs of nine alkaloids in unprocessed and processed AR and ALR.  EICs were generated using exact masse of targeted compounds from 
positive mode of LC-MS for the quantitation of nine alkaloids (A1-A9) in unprocessed and processed AR and ALR, togarther with the retention 
time (RT), peak height and area, concentration of each alkaloid.  








3.2. Effects of unprocessed and processed AR extracts on fibrogenesis 
An ethanolic extract of unprocessed AR was previously suggested to have in-vitro pro-
fibrotic activities at the concentrations of 20-80 μg/mL in the presence of TGF-β1 (66, 67). 
This in-vitro finding had important clinical implications as consumption of an ethanolic 
extract of Aconitum species has been reported to cause acute kidney injury (76). In addition, 
three cases of severe side effects of Aconitum-containing products has been reported, two 
cases suffered from acute poisonous effects and the third case developed chronic kidney 
failure and required dialysis (77). Before solid conclusions can be drawn, the potential pro-
fibrotic effect of unprocessed AR must be reproducible in new batches of quality-assured 
herbal extracts. Furthermore, effect of unprocessed AR in the absence of TGF-β1 remains 
unknown. To answer these questions, aqueous and ethanolic extracts of unprocessed AR 
were examined in NRK-49F cells in the absence and presence of TGF-β1.  As shown in Fig. 
3.4, the aqueous and ethanolic extracts of unprocessed AR, with or without TGF-β1, did not 
affect fibrogenesis at the concentrations of 10-80 μg/mL, without inducing significant cell 
detachment.  
 
Since AR has well known toxic effects, such as cardiotoxicity and neurotoxicity (125-127), 
unprocessed AR is never used as a medicinal material. According to the Chinese 
Pharmacopeia, only processed AR is allowed to be use legally, with great caution, as 
decoction pieces. It is important to examine whether detoxicating process procedure, known 
as Paozhi (68), could change its effects in in-vitro models of  fibrosis. As shown in Fig. 3.5 
the aqueous and ethanolic extracts of processed AR did not affect fibrogenesis in the range 
of 10-80 μg/mL, with little cytotoxicity.   
 
3.3. Effects of aconite alkaloids on fibrogenesis 
To test the hypotheses that the previously reported potential pro-fibrotic activity of AR may 
be attributed to aconite alkaloids. Nine aconite alkaloids, i.e. (A1) aconitine, (A2) 
mesaconitine, (A3) hypaconitine, (A4) benzoylaconine, (A5) benzoylmesaconine, (A6) 
benzoylhypaconine, (A7) aconine, (A8) mesaconine, (A9) hypaconine, were tested in an in-
vitro model of fibrosis. As shown in Fig. 3.6, all the nine alkaloids did not show any pro-
fibrotic activities. On the contrary, seven of them, i.e. A1, A2, A5 A6, A7, A8 and A9, 






Fig. 3.4. Unprocessed AR aqueous (AR-A) and ethanolic (AR-E) extracts did not affect 
fibrogenesis. NRK-49F cells were treated with 10-80 μg/mL extracts of unprocessed AR 
with or without 5 ng/ml TGF-β1 for 48 h. Effects on fibrogenesis were illustrated by 
representative PSR staining images (A, D), which visualised total collagen deposition in red 
colour; eluted PSR was quantified by spectrophotometric analysis (B, E) and cytotoxicity 
was approximated by recording a mean cell detachment index (C, F). Experiments were 
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Fig. 3.5. Processed AR aqueous (AR-A) and ethanolic (AR-E) extracts did not affect 
fibrogenesis. NRK-49F cells were treated with 10-80 μg/mL extracts of processed AR with 
or without 5 ng/ml TGF-β1 for 48 h. Effects on fibrogenesis were illustrated by 
representative PSR staining images (A, D), which visualised total collagen deposition in red 
colour; eluted PSR was quantified by spectrophotometric analysis (B, E) and cytotoxicity 
was approximated by recording a mean cell detachment index (C, F). Experiments were 
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Fig. 3.6a. Alkaloids A1 and A2, but not A3, showed dose-dependent anti-fibrotic activities. NRK-49F cells were treated with 20-100 μM alkaloids 
(A1-A3) with or without 5 ng/ml TGF-β1 for 48 h. Effects on fibrogenesis were illustrated by representative PSR staining images (A-C), which 
visualised total collagen deposition in red colour; eluted PSR was quantified by spectrophotometric analysis (Ai-Ci) and cytotoxicity was 
approximated by recording a mean cell detachment index (Aii-Cii). Experiments were performed in quadruplicate and shown are representative results 
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Fig. 3.6b. A5 and A6, but not A4, showed dose-dependent anti-fibrotic activities. NRK-49F cells were treated with 20-100 μM alkaloids (A4-A6) 
with or without 5 ng/ml TGF-β1 for 48h. Effects on fibrogenesis were illustrated by representative PSR staining images (D-F), which visualised 
total collagen deposition in red colour; eluted PSR was quantified by spectrophotometric analysis (Di-Fi) and cytotoxicity was approximated by 
recording a mean cell detachment index (Dii-Fii). Experiments were performed in quadruplicate and shown are representative results of two independent 
experiments with similar results. ψψψ p < 0.001 vs control group, * p < 0.05, ** p < 0.01, *** p < 0.001 vs TGF-β1 treated group. 
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Fig. 3.6c. Alkaloids A7, A8 and A9 showed dose-dependent anti-fibrotic activities. NRK-49F cells were treated with 20-100 μM alkaloids (A7-A9) 
with or without 5 ng/ml TGF-β1 for 48 h. Effects on fibrogenesis were illustrated by representative PSR staining images (G-I), which visualised 
total collagen deposition in red colour; eluted PSR was quantified by spectrophotometric analysis (Gi-Ii) and cytotoxicity was approximated by 
recording a mean cell detachment index (Gii-Iii). Experiments were performed in quadruplicate and shown are representative results of two independent 
experiments with similar results. ψψψ p < 0.001 vs control group, * p < 0.05, ** p < 0.01, *** p < 0.001 vs TGF-β1 treated group. 
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3.4. Discussion and Conclusions 
In a previous screening study, my supervisor’s lab found an ethanolic extract of unprocessed 
AR was pro-fibrotic in NRK-49F cells in the presence of TGF-β1 (66, 67). In contrast, my 
data indicated that, in the same in-vitro model, aqueous and ethanolic extracts of 
unprocessed and processed AR, did not affect fibrogenesis, either in presence or absence of 
TGF-β1. It is in disagreement with the initial expectation that AR is pro-fibrotic. The most 
likely reason lies in the difference in the two batches of herbs tested, given that the in-vitro 
model of fibrosis used was the same.  The quality control of herb AR used before was 
suboptimal, describing only based on herbal morphology thus less reliable. While the herb 
AR used in this project has been well authenticated and stringently quality-assured, as 
described in Supplementary Fig. 1. The further validations of these findings are still needed 
by testing additional well-authenticated batches of the same species and by alternative assays 
for total collagens and molecular markers of fibrogenesis.  
In addition, I found that all these nine aconite alkaloids did not show any pro-fibrotic 
activities. On the contrary, seven of them, A1, A2, A5, A6, A7, A8 and A9 suppressed TGF-
β1 induced fibrogenesis, as shown in Fig. 3.6.  
Since the main poisonous and bioactive compounds of AR were believed to be aconite 
alkaloids, which mainly include diester-diterpene alkaloids (DDAs), monoester-diterpene 
alkaloids (MDAs) and unesterified-diterpene alkaloids (UDAs). Aconite alkaloids are also 
used as biomarkers to guide toxicological and pharmacological studies, and in quality 
control (68).  The DDAs mainly include A1, A2, and A3, which are the most effective in 
treating diseases such as rheumatoid arthritis, cardiovascular diseases, tumors, skin wounds 
and diarrhea (69). However, DDAs also have the highest toxicity to the cardiovascular and 
nervous system, which limits the safe usage of AR and ALR in clinical therapeutics. DDAs 
can be firstly transformed into MDAs and then into UDAs through a second hydrolysis 
during processing as illustrated in Fig. 1.3, along with the toxicity is markedly decreased 
(69). The MDAs mainly comprise A4, A5 and A6, whereas the UDAs mainly include A7, 
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A8 and A9. In the present study, processing decreased the content of highly toxic A1, A2 
and A3 by 92.8, 104.4 and 11.2 times compared to that in unprocessed AR.  
 
Compared to unprocessed ALR, the contents of A1, A2 and A3 decreased 352.5, 617.2 and 
155.0 times, 419.2, 970.0 and 1160.8 times, respectively, in two types of processed ALR, 
HSP and ZFZ. However, the activities of unprocessed and processed ALR extracts have not 
been tested in in-vitro model of fibrosis in the present study yet, because of the results so far 
do not support my initial hypothesis that the pro-fibrotic activity of AR/ALR could be 
attributed to aconite alkaloids.  There is no report on anti-fibrotic effects of aconite alkaloids, 
but a school of traditional Chinese medicine (TCM), named “Huoshen Pai”, are popular for 
its extensive but deliberated exploitation of processed ALR to treat deficiency of kidney 
Yang, coldness of the waist and the knees, dropsical limbs, difficulty in micturition, or 
phlegm and retained fluid (69). This may be explained by TCM theory that ALR has the 
properties to “warm up” and “resolve” clots and lumps, which are often classified into 
fibrosis diseases.  
Nevertheless, there is ongoing controversy because of the severe toxicity of ALR once used 
at inappropriate dosages. The poisoning related to the culinary use of AR and ALR also have 
been reviewed (128). Severe or even fatal aconite alkaloid poisoning can occur after 
consumption of herbal soups and foods prepared from AR or ALR. Even prolonged boiling 
time may not be protective if raw preparations and large quantities of AR or ALR are used. It 
indicated that the public should be warned of the risk of severe poisoning related to the 
culinary and traditional medicinal uses of AR and ALR.  
 
In conclusion, the present results disagreed with my initial hypothesis that AR is pro-fibrotic 
as a function of its alkaloids: 
• Aqueous and ethanolic extracts of unprocessed and processed AR did not affect 
fibrogenesis (Fig. 3.4 and Fig. 3.5).  
• Seven of nine aconite alkaloids showed anti-fibrotic effects (Fig. 3.6). 
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• Further validation of these results will be needed. 
In view that expected pro-fibrotic effects of AR was not reproduced and considering the 

























Chapter 4 In-vitro anti-fibrotic activities of SR and SR flavonoids 
 
4.1. Quality control of SR extracts 
Contents of the five interested flavonoids (F5), i.e. baicalin, baicalein, wogonoside, wogonin 
and oroxylin-A, in aqueous and methanolic extracts of SR were evaluated by UPLC/Q-TOF-
MS and the BPCs and EICs are presented in Fig. 4.1 and Fig. 4.2. It can be found that on the 
BPCs the mixed standards of the F5 were already well separated with short analysis time 
(Fig. 4.1). For analysis of SRA and SRM, the F5 also reached the baseline separation with 
high resolution. In addition, due to the high selectivity of UPLC/Q-TOF-MS, the peak areas 
of F5 can be integrated much simpler and more accurate on the EICs (Fig. 4.2).  
 
As a result, the total content of F5 in SRM (22.71%) is 8 times higher than SRA (2.77%). 
The content of each calculated flavonoid was much more abundant in the SRM than SRA, 
especially baicalin, which was about 12 times more abundant in SRM. Nevertheless, in both 
SRA and SRM, baicalin was the most abundant among the F5, followed by wogonoside 
(Table 4.1).  
 
Table 4.1. Percent contents of F5 in SRA and SRM. 
Contents (%)  SRA  SRM  SRA-F5  SRA-F5D  SRM-F5  SRM-F5D 
Baicalin 1.1283 14.0509 2.7761 0.0330 5.9003 0.0992 
Oroxylin-A 0.1400 2.7523 1.0942 0.0781 4.7061 0.0517 
Wogonoside 0.8230 3.3455 6.5471 0.1187 3.1387 0.0320 
Baicalein 0.5470 2.0571 0.1222 0.0072 0.0294 0.0032 
Wogonin 0.1353 0.5007 0.0093 0.0008 0.0078 0.0368 
Total (%) 2.7736 22.7065 10.5489 0.2378 13.7823 0.2229 
Note: SRA-F5: “F5 fraction” of SRA; SRA-F5D: “F5-depleted fraction” of SRA; SRM-F5: “F5 fraction” of SRM; 







Fig. 4.1. BPCs of SRA and SRM. (A) mixed F5 standards, (B) SRA and (C) SRM. 85 g SR 
powder was simmered in 600 mL Milli-Q water (for extracting SRA) or 70% methanol (for 
extracting SRM) for 2 h under reflux on electric heating-jacket, cool and filter. Extracts were 
dried under vacuum freeze and stored at -20 °C until use. Extracts were dissolved in 100% 
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Fig. 4.2. EICs of F5 in SRA and SRM.  EICs were generated using exact masse of targeted 
compounds from positive mode of LC-MS for the quantitation of F5 in SRA and SRM. 
 
Contents of F5 in the “F5 fraction” and the “F5-depleted fraction” from SRA and SRM were 
evaluated by UPLC-Q/TOF-MS and BPCs are presented in Fig. 4.3 and Fig 4.4. The percent 
contents of the F5 in the “F5 fraction” and the “F5-depleted fraction” of SRA and SRM are 
listed in Table 4.1. The F5 were separated from both SR extracts and were detected in “F5 
fractions” along with several unknown peaks, as shown in Fig. 4.3 C and Fig. 4.4 C, 
indicating that the “F5 fractions” separation were not pure. Double isolation and separation 
of “F5 fractions” were unsuccessful due to current technical difficulties. Thus, the “F5 
fractions” and “F5-depleted fractions” will not be used for further tests as they are unable to 
address the hypothesis whether F5 are the main contributors to the anti-fibrotic activities of 












Fig. 4.3. BPCs of the “F5 fraction” (SRA-F5) and “F5-depleted fraction” (SRA-F5D) of 
SRA. Freeze-dried powder of SRA (110.6 mg) were dissolved in 5 mL methanol and 
separated by preparative liquid chromatography. Fractions were dried under vacuum freeze 
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Fig. 4.4. BPCs of the “F5 fraction” (SRM-F5) and the “F5-depleted fraction” (SRM-
F5D) of SRM. Freeze-dried powder of SRM (142.4 mg) were dissolved in 5 mL methanol 
and separated by preparative liquid chromatography. Fractions were dried under vacuum 
freeze and dissolved in methanol to 1 mg/mL prior to UPLC-Q/TOF-MS analysis.  
 
4.2. Anti-fibrotic activities of SR extracts in an in-vitro model of fibrosis 
SRA and SRM at concentrations of 20-80 μg/mL were tested in an in-vitro model of fibrosis. 
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Fig. 4.5, 80 μg/mL SRA and 40, 60 and 80 μg/mL SRM significantly reduced TGF-β1-
induced total collagen deposition as quantified by PSR staining, without significantly 
increasing cell detachment index (Fig. 4.5 E, F).  
 
In view that PSR stain of collagens might not be 100% specific, further validation was put in 
place by QuickZyme total collagen assays. This is the most common method for evaluating 
collagen deposition or tissue fibrosis by hydroxyproline quantification. NRK-49F cells were 
treated with 80 μg/mL SR extracts with 5 ng/ml TGF-β1 for 48 h and the total collagen were 
indirectly measured through hydroxyproline content from cell lysates. As shown in Fig. 4.6, 
at 80 μg/mL SRM, but not SMA, significantly reduced TGF-β1-induced total collagen 
accumulation in cell lysates.  
 
To further confirm the anti-fibrotic actives of SR extracts at the molecular level, the effects 
of 80 μg/mL SRA or SRM on TGF-β1-induced collagen type I, collagen type III, α-SMA 
and fibronectin was investigated. As expected, immunostaining and high-content imaging 
analysis revealed that TGF-β1 significantly increased collagen I, collagen III, α-SMA and 
fibronectin, SRM was more potent in suppressing those molecular markers of fibrogenesis 











Fig. 4.5. SRA and SRM extracts inhibited fibrogenesis in an in-vitro model of fibrosis 
induced by TGF-β1. NRK-49F cells were treated with 20-80 μg/mL SR extracts or 1 μM 
IN1130 (IN) with or without 5 ng/ml TGF-β1 for 48 h. Effects on fibrogenesis were 
quantified using eluted PSR by spectrophotometric analysis (A, B) and illustrated by 
representative PSR staining images (C, D), which visualised total collagen deposition in red 
colour; and cytotoxicity was approximated by recording a mean cell detachment index (E, F). 
Experiments were performed in quadruplicate and repeated for three times with similar 
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Fig. 4.6. At 80 μg/mL, SRM, but not SRA, significantly inhibited TGF-β1-induced total 
collagen accumulation in NRK-49F cells. The total collagen in cell lysates was quantified 
indirectly through hydroxyproline content in NRK-49F cells, which were treated with 80 
μg/mL extracts and/or 5 ng/ml TGF-β1 for 48 h. Experiments were performed in 





Fig. 4.7. 80 μg/mL SRM, but not SRA, significantly down-regulated TGF-β1-induced 
collagen type I, collagen type III, α-SMA and fibronectin in NRK-49F cells. 
Immunocytofluorescence analysis was used to visualise (A) and quantify (B-E) fibrotic 
makers in cells treated with 80 μg/ml SR extracts in the presence of 5 ng/ml TGF-β1 for 48 h. 
Fluorescence intensity was measured on a Cytation 5 Multi-mode Reader (BioTek) and 
expressed in relative fluorescence units (RFU)/well. Experiments were performed in 
triplicate (three wells of cells per group) and repeated twice with similar results. Shown are 
representative results of an independent biological study. ψψψ p <0.001 vs control; * p <0.05, 
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4.3. Anti-fibrotic activities of SR flavonoids in an in-vitro model of fibrosis 
As shown in Fig. 4.8, baicalin and baicalein showed in-vitro anti-fibrotic activities, this 
confirmed earlier reports from my supervisor’s laboratory (66). Also, anti-fibrotic activities 
of three additional main flavonoids rich in SR, wogonoside, wogonin, and oroxylin-A, were 
tested but only 80 μM wogonin showed in-vitro anti-fibrotic activities, suppressing total 
collagen deposition (Fig. 4.8 I). While 80 μM baicalin and wogonin showed good anti-
fibrotic effects, these concentrations were cytotoxic (Fig. 4.8 K and N and Fig. 4.9 B).  
 
Baicalein appeared to present the best dose-dependent manner as shown in Fig. 4.8, showing 
the best anti-fibrotic activity. Thus, hydroxyproline quantification was further used as a 
complementary method to measure the total collagen content. NRK-49F cells were treated 
with 60 μM flavonoids in presence of 5 ng/ml TGF-β1 for 48 h. Cell lysates were harvested 
for measurement of hydroxyproline content and LDH release, respectively. Baicalein most 
significantly inhibited total collagen accumulation (Fig. 4.9 A), with little cytotoxicity (Fig. 
4.9 B). However, baicalin and wogonin showed relatively strong LDH release at the 
concentration of 60 μM, which was consistent with the results of cell detachment index (Fig. 
4.8 K and N), suggesting baicalin and wogonin had relatively higher cytotoxicity. 
 
To measure the anti-fibrotic activity of SR flavonoids at the molecular level, further 
validation was done by image analysis of immunofluorescence staining to quantify 
molecular makers of fibrogenesis. As shown in Fig. 4.10, at the concentration of 60 μM, five 
SR flavonoids down-regulated TGF-β1-induced collagen type I, collagen type III, α-SMA 
and fibronectin expression in NRK-49F cells. Among the five flavonoids, baicalein was 
among the most potent in supressing collagen type I, collagen type III and α-SMA 
accumulation (Fig. 4.10A-D). Interestingly the five flavonoids seemed to have similar 






Fig. 4.8. Among F5, baicalin and baicalein were the most potent in inhibiting 
fibrogenesis in the presence of TGF-β1. NRK-49F cells were treated with 20-80 μM 
flavonoids or 1μM IN1130 (IN) with or without 5ng/ml TGF-β1 for 48 h. Effects on 
fibrogenesis were illustrated by representative PSR staining images (A-E), which visualised 
total collagen deposition in red colour; eluted PSR was quantified by spectrophotometric 
analysis (F-J) and cytotoxicity was approximated by recording a mean cell detachment index 
(K-O). Experiments were performed in quadruplicate and repeated three times independently. 
ψψψ p < 0.001 vs control group; * p < 0.05, ** p < 0.01, *** p < 0.001 vs TGF-β1 treated 
group. 
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Fig. 4.9. Among 60 μM F5, baicalein showed the best anti-fibrotic activity and little 
cytotoxicity. NRK-49F cells were treated with 60 μM flavonoids in presence or absence of 5 
ng/ml TGF-β1 for 48 h. (A) Total collagen accumulation was quantified indirectly through 
hydroxyproline content; (B) cytotoxicity was measured by LDH release from cells. 
Experiments were performed in quadruplicate and repeated for three times with similar 
results. ψψψ p <0.001 vs control group; * p < 0.05, *** p < 0.001 vs TGF-β1 treated group, 



























































































Fig. 4.10. 60 μM F5 down-regulated TGF-β1-induced collagen type I, collagen type III, 
α-SMA and fibronectin in NRK-49F cells. Immunocytofluorescence analysis was used to 
visualise (A) and quantify (B-E) fibrotic makers in cells treated with 60 μM flavonoids in the 
presence of 5 ng/ml TGF-β1 for 48 h. Fluorescence intensity was measured on a Cytation-5 
Multi-mode Reader (BioTek) and expressed in relative fluorescence units (RFU)/well. 
Experiments were performed in triplicate (three wells of cells per group) and repeated twice 
with similar results. Shown are representative results of an independent biological study. 
ψψψ p < 0.001 vs control, * p < 0.05, ** p < 0.01, *** p < 0.001 vs TGF-β1 treated group, Φ 
p <0.05, ΦΦΦ p <0.001 vs baicalein treated group). 
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4.4. Discussions and Conclusions  
The reported findings of my supervisor’s group that SRM, baicalin and baicalein had in-vitro 
anti-fibrotic activities have been successfully reproduced in the present study. The activities 
have also been confirmed by others both in vitro and in vivo (98, 114, 118). I further 
demonstrated that SRA was less anti-fibrotic than SRM, and the other three members of the 
F5 (wogonoside, wogonin and oroxylin-A) were less anti-fibrotic than baicalin and baicalein. 
Although the effects of SRA and oroxylin-A on fibrosis have not been reported previously, 
some recent reports did show anti-fibrotic effects of wogonoside in a liver fibrosis animal 
model (119). In addition, wogonin showed anti-fibrotic effects in renal tubular epithelial cell 
(129).  
 
According to chemical profiling analysis, the total content of F5 in SRM (22.71%) is more 
than 8 times higher than in SRA (2.77%, Table 4.1), and SRM is more potently anti-fibrotic 
than SRA (Fig. 4.6 and 4.7). These results support my hypothesis that flavonoids may 
mainly contribute to the anti-fibrotic effects of SR. In collaboration with Professor 
Zhongzhen Zhao’s laboratory at Hong Kong Baptist University, we tried to deplete F5 from 
the SRA and SRM and then determine whether flavonoids-depleted fractions have 
significantly reduced anti-fibrotic activity. Unfortunately, separation of F5 lacked specificity 
and efficiency (Fig 4.3 and Fig. 4.4), thus I cannot be certain that non-flavonoids in SRA 
and SRM do not contribute to their anti-fibrotic activities.  
 
Please note that, this study aimed to identify the most promising SR extract and SR-derived 
flavonoid for further proteomic studies, taking into consideration of both antifibrotic 
activities and cytotoxicity at the same concentrations. My data were sufficient to conclude 
that SRM was better than SRA, while baicalein was the best choice among the F5.  I 
acknowledge that, my current data were not sufficient to reliably quantify the IC50 for SRA, 
SRM and F5, which will need to test more concentrations for each extract and compound in 
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non-cytotoxic concentrations. This can be done in the future, but is beyond the scope of this 
project. 
 
In conclusion, SRM and baicalein have been selected for further proteomics-guided 






















Chapter 5 Proteomics of TGF-β1-induced in-vitro model of fibrosis 
 
In previous studies, a TGF-β1-induced in-vitro model of fibrosis has been established in 
NRK-49F normal rat kidney fibroblasts in my supervisor’s lab (65, 66, 130). The model was 
characterised by total collagen accumulation and expression of fibrogenic molecular markers. 
In order to develop an unbiased, holistic view on the mechanism of this TGF-β1-induced in-
vitro model of fibrosis, quantitative proteomic analysis of this model has been conducted and 
will be reported in this chapter.  
 
5.1. TGF-β1-induced in-vitro model of fibrosis 
To establish TGF-β1-induced in-vitro model of fibrosis, NRK-49F cells were cultured as 
described in Materials and Methods (Section 2.5) with or without 5 ng/mL TGF-β1. Cell 
lysates and conditioned media were harvested after 48h. To confirm successful biological 
experiments, collagen contents in cell lysates and conditioned media were measured by 
hydroxyproline assay and soluble collagen assay, respectively, as described in Materials and 
Methods (Sections 2.10 and 2.11). As shown in Fig. 5.1, TGF-β1 significantly induced total 
collagen and soluble collagen in cell lysates and conditioned media.  
 
5.2. Proteomic profiling analysis of cell lysates 
The cell lysates and conditioned media were trypinised, labelled with TMT reagents and 
subjected to LC-MS/MS as detailed in Materials and Methods (Section 2.12). The MS data 
were searched using the Proteome Discoverer software and identified proteins were analysed 
by bioinformatic platforms, including Venn diagram, KEGG pathway and Volcano plot 




Fig. 5.1. TGF-β1 induced accumulation of total collagen in cell lysates and soluble 
collagen in conditioned media. NRK-49F cells were cultured in absence and presence of 5 
ng/mL TGF-β1 for 48h. Cell lysates and conditioned media were harvested for 
hydroxyproline assay (A) and soluble collagen assay (B) to quantify total and soluble 
collagens, respectively. Data represent mean ± SEM of 4 independent cell culture studies. 
*** p<0.001 vs control group. 
 
To determine the proteins differentially expressed in NRK-49F cells with and without TGF-
β1, four independent pairs of cell lysates from control and TGF-β1-treated groups were 
subjected to in-solution trypsin-digestion and LC-MS/MS analysis. Peptides were searched 
against the Proteome Discoverer database and 1438 proteins were identified, with at least 2 
unique peptides detected and a 1% false discovery rate (FDR). In particular, 628 proteins 
were significantly regulated by TGF-β1 (Supplementary Table 1).  
 
Gene Ontology (GO) function enrichment analysis of the 628 proteins significantly changed 
in TGF-β1 group was performed on the Database for Annotation, Visualization and 
Integrated Discovery (DAVID; https://david.ncifcrf.gov/). Three ontologies were constructed, 
including cellular components, biological processes and molecular functions. As shown in 
Fig. 5.2, the enriched cellular component GO terms were grouped into 44 clusters (p<0.05), 
showing that the significantly changed proteins were more enriched in the cytoplasm, 




















































enriched biological processes (Fig. 5.3) included 24 clusters of proteins and the top five 
biggest protein clusters were involved in translation, oxidation-reduction process, response 
to drug, cell-cell adhesion and fatty acid beta-oxidation. As shown in Fig. 5.4, 27 enriched 
molecular function clusters were identified, mainly related to poly(A)RNA binding, protein 





Fig. 5.2. GO cellular component enrichment analysis of the proteins significantly regulated by TGF-β1 in cell lysates. The numbers of involved proteins 


















































































































































































































































































































































































































Fig. 5.3. GO biological process enrichment analysis of the proteins significantly regulated by TGF-β1 in cell lysates. The numbers of involved proteins 

























































































































































































































































































Fig. 5.4. GO molecular function enrichment analysis of the proteins significantly regulated by TGF-β1 in cell lysates. The numbers of involved proteins 





















































































































































































































































































































































Biological mechanisms and pathways regulated by TGF-β1 were analysed by the KEGG 
(https://david.ncifcrf.gov/) and the connections and interactions between these significantly 
changed proteins were evaluated by STRING analysis (https://string-db.org/). 42 pathways 
were enriched by KEGG analysis (Fig. 5.5A) and the proteins involved in each pathway are 
listed in Table 5.1. Multiple proteins involved in 14 pathways were repressed by TGF-β1, 
including Citrate cycle (TCA cycle), Pyruvate metabolism, Glyoxylate and dicarboxylate 
metabolism, Tryptophan metabolism, beta-Alanine metabolism, Propanoate metabolism, 
Histidine metabolism, Parkinson's disease, Butanoate metabolism, Oxidative 
phosphorylation, Alzheimer's disease, Fatty acid elongation, Phenylalanine metabolism and 
Tyrosine metabolism. Other 28 pathways were dysregulated, with some proteins repressed 
and some others induced by TGF-β1.  
The ribosome pathway dysregulated by TGF-β1 was the most significant and involved 68 
induced and one repressed proteins (Table 5.1). Ribosome is the cellular translational 
machinery primarily responsible for protein synthesis from messenger RNAs (131). 
Eukaryotic ribosomes, known as 80S ribosomes, include two unequal subunits, i.e. the small 
subunit (40S) and the large subunit (60S), according to their sedimentation coefficients (132, 
133). The small ribosomal subunit is responsible for decoding the information encoded in 
messenger RNA, whereas peptide bond synthesis occurs at the large ribosomal subunit (134). 
Altogether, eukaryotic ribosomes have 79 ribosomal proteins (135).  In the present study, 
TGF-β1 significantly induced 28 ribosomal proteins of the small subunits (Rps2, Rps3, 
Rps3a, Rps4X, Rps6, Rps8, Rps9, Rps10, Rps11, Rps13, Rps14, Rps15, Rps15a, Rps16, 
Rps17, Rps18, Rps19, Rps20, Rps21, Rps23, Rps24, Rps26, Rps27, Rps27l, Rps28, Rps29, 
Rps30/Fau and Rpsa) and 40 ribosomal proteins of the large subunits (Rpl4, Rpl5, Rpl6, 
Rpl7, Rpl7a, Rpl8, Rpl9, Rpl10, Rpl10a, Rpl12, Rpl13, Rpl13a, Rpl14, Rpl15, Rpl17, Rpl18, 
Rpl18A, Rpl19, Rpl21, Rpl22, Rpl23, Rpl23a, Rpl24, Rpl26, Rpl27, Rpl27a, Rpl28, Rpl29, 
Rpl3, Rpl30, Rpl32, Rpl34, Rpl35, Rpl35a, Rpl36, Rpl36a, Rpl37, Rpl38, Rplp0 and Rplp2). 
Only one mitochondrial (39S) ribosomal protein L3 (Mrpl3) was suppressed by TGF-β1.  
 95 
The highest number of proteins significantly regulated by TGF-β1, altogether 121 was 
involved in multiple metabolic pathways, including 17 proteins up-regulated and 104 down-
regulated by TGF-β1 (Table 5.1). 
STRING analysis illustrated predicted direct (physical) and indirect (functional) associations 
among proteins significantly regulated by TGF-β1, creating dense interaction networks 




Fig. 5.5. KEGG pathway and STRING network analyses of 628 proteins in cell lysates 
significantly regulated by TGF-β1. (A) KEGG analysis shows 42 pathways significantly 
regulated by TGF-β1, among which the most significantly regulated pathway was the 
ribosome pathway.  Y-axis represents significantly enriched KEGG pathway terms and X-
axis indicates -Log10 p-value. (B) STRING analysis illustrates predicted direct (physical) and 
indirect (functional) associations among proteins significantly regulated by TGF-β1, 
showing a huge, dense and irregular cluster of proteins.  














































§ 14 pathways in which TGF-β1 repressed multiple proteins 
§ 28 pathways in which TGF-β1 induced some and repressed some other proteins  
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Table 5.1. Cell-lysate proteins significantly regulated by TGF-β1 are involved in 42 KEGG pathways. Proteins are listed in order of fold-change (TGF-β1 
vs control) and red fonts indicated the pathways in which proteins were suppressed by TGF-β1. 
KEGG pathways Proteins significantly regulated by TGF-β1 (TGF-β1 vs control) 
Ribosome  
(most significant) 
Rps30 (2.07), Rpl36a (1.95), Rps23 (1.89), Rpl35a (1.71), Rps24 (1.6), Rpl37 (1.56), Rpl23a (1.56), Rpl27a (1.54), Rps3 (1.52),  Rplp0 (1.5), 
Rps10 (1.5), Rpl35 (1.5), Rps11 (1.47), Rps14 (1.46), Rpl17 (1.45), Rpl27 (1.45), Rpl32 (1.42), Rpsa (1.42), Rpl18A (1.42), Rps16 (1.41), Rps17 
(1.41), Rpl22 (1.37), Rps13 (1.36), Rpl18 (1.35), Rps29 (1.34), Rpl26 (1.34), Rps2 (1.33), Rps18 (1.33), Rpl36 (1.33), Rpl6 (1.33), Rps6 (1.33), 
Rpl13a (1.33), Rps19 (1.32), Rps8 (1.32), Rpl23 (1.32), Rpl13 (1.31), Rps15 (1.31), Rpl38 (1.31), Rpl5 (1.31), Rplp2 (1.3), Rpl10 (1.3), Rpl7 
(1.3), Rpl29 (1.3), Rpl15 (1.29), Rps27l (1.29), Rpl12 (1.29), Rps4X (1.28), Rps26 (1.28), Rpl30 (1.27), Rpl3 (1.27), Rpl7a (1.27), Rpl10a (1.27), 
Rpl21 (1.27), Rps3a (1.26), Rpl34 (1.26), Rpl8 (1.26), Rps20 (1.26), Rpl24 (1.26), Rpl4 (1.25), Rpl9 (1.23), Rps9 (1.23), Rps15a (1.22), Rpl28 
(1.22), Rpl19 (1.19), Rpl14 (1.18), Rps27 (1.18), Rps21 (1.17), Rps28 (1.14), Mrpl3 (0.84) 
Biosynthesis of antibiotics 
Bcat1 (1.94), Psph (1.67), Nme1 (1.64), Nme2 (1.55), Hk2 (1.45), Gfpt1 (1.38), Phgdh (1.26), Ak2 (0.89), Mdh1 (0.88), Galm (0.86), Tpi1 (0.86), 
Eno2 (0.86), Fh (0.86), Aldh9a1 (0.85), Mdh2 (0.84), Gcsh (0.83), Ldhb (0.82), Got2 (0.82), Pycr2 (0.82), Acat2 (0.82), Bckdha (0.82), Dlat 
(0.82), Pcyox1 (0.8), Tkt (0.8), Ogdh (0.79), Pfkp (0.79), Acaa1a (0.79), Sdha (0.79), Aco2 (0.78), Aldh7a1 (0.78), Idh3a (0.78), Hk1 (0.77), Dlst 
(0.77), Cs (0.77), Dld (0.76), Hsd17b10 (0.76), Pgm1 (0.74), Sdhb (0.74), Pdhb (0.73), Echs1 (0.72), Pfkm (0.71), Oat (0.71), Pcca (0.7), Hadhb 
(0.7), Idh1 (0.7), Hadha (0.69), Idh2 (0.69), Bcat2 (0.68), Ak3 (0.62), Acat1 (0.61), Hadh (0.6), Pccb (0.58), Aldh3a2 (0.58), Acaa2 (0.55), Aldh2 
(0.54), Cat (0.47) 
Valine, leucine and isoleucine degradation 
Bcat1 (1.94), Aldh9a1 (0.85), Bckdha (0.82), Acat2 (0.82), Acaa1a (0.79), Aldh7A1 (0.78), Hsd17b10 (0.76), Mccc2 (0.76), Dld (0.76), Mccc1 
(0.73), Acads (0.72), Echs1 (0.72), Hadhb (0.7), Pcca (0.7), Hadha (0.69), Bcat2 (0.68), Hibch (0.65), Acadsb (0.64), Hibadh (0.63), Acat1 (0.61), 
Ivd (0.61), Hadh (0.6), Aldh3a2 (0.58), Pccb (0.58), Aldh6A1 (0.55), Acaa2 (0.55), Aldh2 (0.54) 
Carbon metabolism 
Psph (1.67), Hk2 (1.45), Phgdh (1.26), Mdh1 (0.88), Tpi1 (0.86), Eno2 (0.86), Fh (0.86), Mdh2 (0.84), Acat2 (0.82), Got2 (0.82), Dlat (0.82), Tkt 
(0.8), Ogdh (0.79), Pfkp (0.79), Sdha (0.79), Aco2 (0.78), Idh3a (0.78), Hk1 (0.77), Dlst (0.77), Cs (0.77), Dld (0.76), Sdhb (0.74), Pdhb (0.73), 
Pc (0.73), Echs1 (0.72), Acads (0.72), Pfkm (0.71), Idh1 (0.7), Pcca (0.7), Hadha (0.69), Idh2 (0.69), Glud1 (0.66), Hibch (0.65), Acat1 (0.61), 
Pccb (0.58), Aldh6A1 (0.55), Cat (0.47) 
Fatty acid degradation 
Acsl5 (1.29), Aldh9a1 (0.85), Acat2 (0.82), Acaa1a (0.79), Aldh7A1 (0.78), Cpt1a (0.77), Acadvl (0.74), Acads (0.72), Echs1 (0.72), Acadl (0.7), 
Hadhb (0.7), Hadha (0.69), Eci1 (0.67), Cpt2 (0.67), Eci2 (0.65), Acadsb (0.64), Acat1 (0.61), Hadh (0.6), Aldh3a2 (0.58), Acaa2 (0.55), Aldh2 
(0.54) 
Citrate cycle (TCA cycle) 
Mdh1 (0.88), Fh (0.86), Mdh2 (0.84), Dlat (0.82), Ogdh (0.79), Sdha (0.79), Aco2 (0.78), Idh3a (0.78), Dlst (0.77), Cs (0.77), Dld (0.76), Sdhb 
(0.74), Pdhb (0.73), Pc (0.73), Idh1 (0.7), Idh2 (0.69) 
Metabolic pathways 
(involved highest number of proteins) 
Enpp1 (3.56), Bcat1 (1.94), Asns (1.85), Psph (1.67), Nme1 (1.64), Impdh2 (1.61), Ggt1 (1.58), Mthfd2l (1.56), Nme2 (1.55), Ugdh (1.46), Hk2 
(1.45), Gfpt1 (1.38), Acsl5 (1.29), Fasn (1.26), Phgdh (1.26), Agps (1.21), Ckb (1.21), Atp5c1 (0.89), Ak2 (0.89), Mdh1 (0.88), Gmps (0.88), 
Galm (0.86), Tpi1 (0.86), Fh (0.86), Eno2 (0.86), Thtpa (0.85), Aldh9a1 (0.85), Atp6v0a1 (0.85), Cmas (0.84), Mdh2 (0.84), Uqcrc1 (0.84), Hexa 
(0.84), P4ha1 (0.84), Gcsh (0.83), Prdx6 (0.83), Ldhb (0.82), Got2 (0.82), Pycr2 (0.82), Acat2 (0.82), Cmpk1 (0.82), Dlat (0.82), Impa1 (0.82), 
Atp5l (0.82), Bckdha (0.82), Dhfr (0.81), Gaa (0.81), Tkt (0.8), Atp5f1 (0.8), Ogdh (0.79), Galns (0.79), Atp5j (0.79), Pfkp (0.79), Dhcr7 (0.79), 
Acaa1a (0.79), Sdha (0.79), Idh3a (0.78), Aco2 (0.78), Aldh7A1 (0.78), Pcyt1a (0.77), Hk1 (0.77), Dlst (0.77), Cs (0.77), Atp5a1 (0.77), Dld 
(0.76), Hsd17b10 (0.76), Mccc2 (0.76), Atp5o (0.76), Alad (0.74), Pgm1 (0.74), Atp5b (0.74), Acadvl (0.74), Dhrs4 (0.74), Plcd1 (0.74), Sdhb 
(0.74), Pdhb (0.73), Pc (0.73), Mccc1 (0.73), Mpst (0.72), Atp5d (0.72), Acads (0.72), Echs1 (0.72), Cox4i1 (0.71), Pfkm (0.71), Oat (0.71), Sord 
(0.71), Pygb (0.71), Cox5a (0.7), Pcca (0.7), Hadhb (0.7), Idh1 (0.7), Aldh4a1 (0.7), Acadl (0.7), Fah (0.69), Hadha (0.69), Idh2 (0.69), Maoa 
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(0.69), Uqcrq (0.69), Cox5b (0.68), Atp5j2 (0.68), Bcat2 (0.68), Hsd17b4 (0.67), Glud1 (0.66), Gusb (0.65), Hibch (0.65), Acadsb (0.64), Anpep 
(0.64), Hibadh (0.63), Aldh3b1 (0.62), Spr (0.61), Acat1 (0.61), Ivd (0.61), Hadh (0.6), Scp2 (0.59), Pccb (0.58), Aldh3a2 (0.58), Bdh2 (0.58), 
Acaa2 (0.55), Aldh6A1 (0.55), Aldh2 (0.54), Ugt1A6 (0.43), Aldh3a1 (0.22) 
Fatty acid metabolism 
Acsl5 (1.29), Fasn (1.26), Acat2 (0.82), Acaa1a (0.79), Cpt1a (0.77), Acadvl (0.74), Acads (0.72), Echs1 (0.72), Tecr (0.71), Acadl (0.7), Hadhb 
(0.7), Hadha (0.69), Cpt2 (0.67), Acadsb (0.64), Acat1 (0.61), Hadh (0.6), Acaa2 (0.55) 
Pyruvate metabolism 
Mdh1 (0.88), Fh (0.86), Aldh9a1 (0.85), Mdh2 (0.84), Ldhb (0.82), Dlat (0.82), Acat2 (0.82), Aldh7A1 (0.78), Dld (0.76), Pdhb (0.73), Pc (0.73), 
Acat1 (0.61), Aldh3a2 (0.58), Aldh2 (0.54) 
Glycolysis / Gluconeogenesis 
Hk2 (1.45), Galm (0.86), Tpi1 (0.86), Eno2 (0.86), Aldh9a1 (0.85), Ldhb (0.82), Dlat (0.82), Pfkp (0.79), Aldh7A1 (0.78), Hk1 (0.77), Dld (0.76), 
Pgm1 (0.74), Pdhb (0.73), Pfkm (0.71), Aldh3b1 (0.62), Aldh3a2 (0.58), Aldh2 (0.54), Aldh3a1 (0.22) 
Glyoxylate and dicarboxylate metabolism Mdh1 (0.88), Mdh2 (0.84), Gcsh (0.83), Acat2 (0.82), Aco2 (0.78), Cs (0.77), Dld (0.76), Pcca (0.7), Acat1 (0.61), Pccb (0.58), Cat (0.47) 
Biosynthesis of amino acids 
Bcat1 (1.94), Psph (1.67), Phgdh (1.26), Tpi1 (0.86), Eno2 0.86), Got2 (0.82), Pycr2 (0.82), Tkt (0.8), Pfkp (0.79), Aco2 (0.78), Idh3a (0.78), 
Aldh7A1 (0.78), Cs (0.77), Pc (0.73), Pfkm (0.71), Idh1 (0.7), Idh2 (0.69), Bcat2 (0.68) 
Lysine degradation 
Plod2 (1.19), Aldh9a1 (0.85), Acat2 (0.82), Ogdh (0.79), Aldh7A1 (0.78), Dlst (0.77), Echs1 (0.72), Hadha (0.69), Plod1 (0.69), Acat1 (0.61), 
Hadh (0.6), Aldh3a2 (0.58), Aldh2 (0.54) 
Tryptophan metabolism 
Aldh9a1 (0.85), Acat2 (0.82), Ogdh (0.79), Aldh7a1 (0.78), Echs1 (0.72), Maoa (0.69), Hadha (0.69), Acat1 (0.61), Hadh (0.6), Aldh3a2 (0.58), 
Aldh2 (0.54), Cat (0.47) 
2-Oxocarboxylic acid metabolism Bcat1(1.94), Got2(0.82), Aco2(0.78), Idh3a (0.78), Cs (0.77), Idh1(0.7), Idh2(0.69), Bcat2(0.68) 
beta-Alanine metabolism 
Aldh9a1(0.85), Aldh7A1(0.78), Echs1(0.72), Hadha (0.69), Hibch (0.65), Aldh3b1(0.62), Aldh3a2(0.58), Aldh6a1(0.55), Aldh2(0.54), 
Aldh3a1(0.22) 
Propanoate metabolism Ldhb (0.82), Acat2 (0.82), Echs1 (0.72), Pcca (0.7), Hadha (0.69), Hibch (0.65), Acat1 (0.61), Pccb (0.58), Aldh6a1 (0.55) 
Arginine and proline metabolism 
Ckb (1.21), Aldh9a1 (0.85), P4ha1 (0.84), Got2 (0.82), Pycr2 (0.82), Aldh7a1 (0.78), Oat (0.71), Aldh4a1 (0.7), Maoa (0.69), Aldh3a2(0.58), 
Aldh2(0.54) 
Peroxisome 
Prdx5 (1.33), Acsl5 (1.29), Agps (1.21), Prdx1 (1.16), Acaa1a (0.79), Crat (0.78), Dhrs4 (0.74), Idh1 (0.7), Idh2 (0.69), Hsd17b4 (0.67), Eci2 
(0.65), Scp2 (0.59), Ech1 (0.5), Cat (0.47) 
RNA transport 
Eif2S3 (1.45), Eif4a2 (1.4), Eif3j (1.36), Eef1a1 (1.33), Eif3h (1.28), Eif3a (1.27), Eif2b1 (1.25), Eif3c (1.24), Strap (1.22), Eif3i (1.21), Eif3d 
(1.18), Eif3b (1.17), Kpnb1 (1.14), Nup153 (1.13), Pabpc1 (1.13), Tpr (0.91), Nup93 (0.82), Ube2i (0.8) 
Eif5 (0.79), Sumo2 (0.78) 
Histidine metabolism Aldh9a1 (0.85), Aldh7a1 (0.78), Maoa (0.69), Aldh3b1 (0.62), Aldh3a2 (0.58), Aldh2 (0.54), Aldh3a1 (0.22) 
Parkinson's disease 
Atp5c1 (0.89), Gnai2 (0.87), Uba1 (0.86), Uqcrc1 (0.84), Vdac1 (0.82), Atp5f1 (0.8), Park7 (0.8), Sdha (0.79), Atp5j (0.79), Atp5a1 (0.77), Atp5o 
(0.76), Atp5b (0.74), Sdhb (0.74), Atp5d (0.72), Cox4i1 (0.71), Cox5a (0.7), Uqcrq (0.69), Cox5b (0.68) 
Butanoate metabolism Acat2 (0.82), Acads (0.72), Echs1 (0.72), Hadha (0.69), Acat1 (0.61), Hadh (0.6), Bdh2 (0.58) 
Glutathione metabolism Ggt1 (1.58), Oplah (0.79), Gpx1 (0.75), Gstm2 (0.74), Idh1 (0.7), Idh2 (0.69), Gstp1 (0.67), Anpep (0.64), Mgst1 (0.62), Gsta3 (0.59) 
Oxidative phosphorylation 
Atp5c1 (0.89), Atp6v0a1 (0.85), Uqcrc1 (0.84), Atp5l (0.82), Atp5f1 (0.8), Sdha (0.79), Atp5j (0.79), Atp5a1 (0.77), Atp5o (0.76), Atp5b (0.74), 
Sdhb (0.74), Atp5d (0.72), Cox4i1 (0.71), Cox5a (0.7), Uqcrq (0.69), Atp5j2 (0.68), Cox5b (0.68) 
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Galactose metabolism Hk2 (1.45), Galm (0.86), Gaa (0.81), Pfkp (0.79), Hk1 (0.77), Pgm1 (0.74), Pfkm (0.71) 
Protein processing in endoplasmic 
reticulum 
Sec61a1 (1.61), Bax (1.38), Nsfl1C (1.33), Dnajc3 (1.33), Dnaja2 (1.31), Hsp90Ab1 (1.28), Hspa8 (1.26), Hsp90Aa1 (1.21), Hsph1 (1.21), 
Rad23b (0.95), Dnajb11 (0.92), Vcp (0.9), Pdia6 (0.88), Pdia4 (0.82), Eif2ak2 (0.79), Sel1l (0.78), Capn1 (0.74), Os9 (0.51) 
Alzheimer's disease 
Atp5c1 (0.89), Uqcrc1 (0.84), Mapk1 (0.84), Itpr3 (0.83), Atp5f1 (0.8), Sdha (0.79), Atp5j (0.79), Atp5a1 (0.77), Hsd17b10 (0.76), Atp5o (0.76), 
Atp5b (0.74), Capn1 (0.74), Sdhb (0.74), Atp5d (0.72), Cox4i1 (0.71), Cox5a (0.7), Uqcrq (0.69), Cox5b (0.68), Mapk3 (0.64) 
Huntington's disease 
Bax (1.38), Dctn1 (0.9), Atp5c1 (0.89), Ap2m1 (0.87), Hdac1 (0.85), Uqcrc1 (0.84), Clta (0.82), Vdac1 (0.82), Atp5f1 (0.8), Sdha (0.79), Atp5j 
(0.79), Atp5a1 (0.77), Atp5o (0.76), Atp5b (0.74), Sdhb (0.74), Atp5d (0.72), Cox4i1 (0.71), Cox5a (0.7), Uqcrq (0.69), Cox5b (0.68) 
Amino sugar and nucleotide sugar 
metabolism 
Ugdh (1.46), Hk2 (1.45), Gfpt1 (1.38), Cmas (0.84), Hexa (0.84), Cyb5r3 (0.81), Pgm1 (0.74), Hk1 (0.77) 
Ascorbate and aldarate metabolism Ugdh (1.46), Aldh9a1 (0.85), Aldh7a1 (0.78), Aldh3a2 (0.58), Aldh2 (0.54), Ugt1a6 (0.43) 
Fatty acid elongation Echs1 (0.72), Tecr (0.71), Hadhb (0.70), Hadha (0.69), Hadh (0.60), Acaa2 (0.55) 
Thyroid cancer Map2k1 (1.31), Tpm3 (1.12), Tpr (0.91), Mapk1 (0.84), Mapk3 (0.64), Ctnnb1 (0.56) 
Central carbon metabolism in cancer Slc7a5 (1.51), Hk2 (1.45), Map2k1 (1.31), Mapk1 (0.84), Pfkp (0.79), Hk1 (0.77), Pdhb (0.73), Pfkm (0.71), Mapk3 (0.64)  
Starch and sucrose metabolism Enpp1 (3.56), Hk2 (1.45), Gaa (0.81), Hk1 (0.77), Pgm1 (0.74), Pygb (0.71) 
Prion diseases Bax (1.38), Map2k1 (1.31), Stip1 (1.08), Mapk1 (0.84), Mapk3 (0.64), Ncam1 (0.63) 
Phenylalanine metabolism Got2 (0.82), Mif (0.74), Maoa (0.69), Aldh3b1 (0.62), Aldh3a1 (0.22) 
Proteasome Psmb7 (1.45), Psmb6 (1.28), Psma4 (1.24), Psma1 (1.14), Psmb10 (0.73), Psme1 (0.70), Psmb9 (0.70) 
Pentose and glucuronate interconversions Ugdh (1.46), Sord (0.71), Gusb (0.65), Aldh3a2 (0.58), Aldh2 (0.54), Ugt1A6 (0.43) 
Fructose and mannose metabolism Hk2 (1.45), Tpi1 (0.86), Pfkp (0.79), Hk1 (0.77), Sord (0.71), Pfkm (0.71) 
Glycine, serine and threonine metabolism Psph (1.67), Phgdh (1.26), Gcsh (0.83), Aldh7A1 (0.78), Dld (0.76), Maoa (0.69) 
Tyrosine metabolism Got2 (0.82), Mif (0.74), Maoa (0.69), Fah (0.69), Aldh3b1 (0.62), Aldh3a1 (0.22) 
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To focus on the proteins more robustly regulated by TGF-β1, a cut-off of fold-changes >1.5 
or <0.67 (TGF-β1 vs control) was applied. KEGG pathway analysis of those short-listed 
proteins demonstrated that 22 pathways were significantly regulated by TGF-β1. As shown 
in Fig. 5.6, TGF-β1 suppressed multiple proteins enriched in 16 pathways, including Fatty 
acid degradation, beta-Alanine metabolism, Tryptophan metabolism, Histidine metabolism, 
Propanoate metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - 
cytochrome P450, Pentose and glucuronate interconversions, Peroxisome, Chemical 
carcinogenesis, Lysine degradation, Fatty acid metabolism, Ascorbate and aldarate 
metabolism, Glyoxylate and dicarboxylate metabolism, Butanoate metabolism and 
Glycolysis/Gluconeogenesis. Besides, TGF-β1 dysregulated 5 pathways, including Valine, 
leucine and isoleucine degradation, Metabolic pathways, Biosynthesis of antibiotics, Carbon 
metabolism and Glutathione metabolism. Furthermore, multiple proteins of the Ribosome 
pathway were significantly induced by TGF-β1.  
 
Focusing on the interaction networks of proteins regulated by TGF-β1 with fold-
changes >1.5 or <0.67 (TGF-β1 vs control), STRING analysis revealed two major clusters of 
proteins (a and b) connected by inosine-5'-monophosphate dehydrogenase 2 (Impdh2; Fig. 
5.7A). Impdh2, a rate-limiting enzyme mainly involved in guanosine and deoxyguanosine 
biosynthesis, was induced by TGF-β1 and has been proposed as a druggable target (136). 
Indeed, non-selective Impdh inhibitors have multiple therapeutic values, including 
repressing fibrosis (136-139). The accession numbers, fold-changes and p-values of proteins 
involved in clusters a and b are listed in Table 5.2. Most proteins in cluster a, except Dpysl3, 
Slc7a1 and Slc7a5 (which are located at periphery of the cluster), were down-regulated by 
TGF-β1. In cluster b, TGF-β1 up-regulated most proteins except Ak3, a mitochondrial 
enzyme located at the periphery of the cluster.  
 
KEGG pathway analysis of proteins in these two clusters indicated that TGF-β1-induced in-
vitro model of fibrosis is mainly associated with multiple metabolic pathways (cluster a) and 
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ribosome pathway (cluster b) as highlighted in Fig. 5.7 B. There were 18 pathways involved 
in cluster a and the top 3 with lowest p-values were Valine, leucine and isoleucine 
degradation, Fatty acid degradation and Metabolic pathways. As shown in Table 5.3, it is 
interesting that almost all proteins involved in multiple metabolic pathways were down-
regulated by TGF-β1. However, TGF-β1 significantly induced 10 proteins participated in the 
ribosome pathway, including four small subunits (Rps30, Rps24, Rps23 and Rps3) and six 
large subunits (Rpl36a, Rpl35a, Rpl23a, Rpl37 Rpl27a and Rplp0, Table 5.3). Thus, it 
suggested that TGF-β1-induced fibrogenesis is associated with a previously unrecognized 
mismatch of reduced proteins involved in metabolic pathways and increased ribosomal 





Fig. 5.6. KEGG pathway analysis of 127 proteins in cell lysates significantly regulated 
by TGF-β1 with fold-change >1.5 or < 0.67 (TGF-β1 vs control). Y-axis represents 
significantly enriched KEGG pathways and X-axis indicates -Log10 p-value. 
-Log10 (P-value) 
§ 5 pathways in which TGF-β1 induced some and repressed some other proteins  
§ 16 pathways in which TGF-β1 repressed multiple proteins  
§ Only one pathway in which TGF-β1 induced multiple proteins  

























Fig. 5.7. TGF-β1 significantly regulated multiple metabolic pathways and the ribosome 
pathway, with Impdh2 sitting in between as a possible “middleman”. (A) STRING 
analysis reveals predicted direct (physical) and indirect (functional) associations among 
proteins significantly regulated by TGF-β1 with fold changes >1.5 or < 0.67. Two major 
clusters (a and b) were observed which were connected by Impdh2. (B) KEGG pathway 
analysis of proteins clustered in a and b was performed, respectively. Cluster a contains 
proteins involved in multiple metabolic pathways; Cluster b is enriched with proteins of the 
















































Table 5.2 Proteins in clusters a and b (Fig. 5.7a) listed in order of fold-change (green 
font: induced by TGF-β1, red font: reduced by TGF-β1, TGF-β1 vs control) 
Accession Protein Description Fold change p-value 
Proteins involved in cluster a  
Q62952 Dpysl3 Dihydropyrimidinase-related protein 3 2.3262 0.000002 
P30823 Slc7a1 High affinity cationic amino acid transporter 1 2.0636 0.001813 
Q63016 Slc7a5 Large neutral amino acids transporter small subunit 1 1.5106 0.001791 
P97852 Hsd17b4 Peroxisomal multifunctional enzyme type 2 0.6697 0.000066 
P10860 Glud1 Glutamate dehydrogenase 1, mitochondrial 0.6588 0.000231 
P52759 Hrsp12 Ribonuclease UK114 0.6538 0.000871 
Q5XIC0 Eci2 Enoyl-CoA delta isomerase 2, mitochondrial 0.6525 0.000008 
Q5XIE6 Hibch 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial 0.6522 0.035802 
P28037 Aldh1l1 Cytosolic 10-formyltetrahydrofolate dehydrogenase 0.6431 0.010616 
P70584 Acadsb Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial 0.6362 0.000239 
P29266 Hibadh 3-hydroxyisobutyrate dehydrogenase, mitochondrial 0.6302 0.000031 
Q5XI42 Aldh3b1 Aldehyde dehydrogenase family 3 member B1 0.6198 0.007889 
P12007 Ivd Isovaleryl-CoA dehydrogenase, mitochondrial 0.6106 0.000045 
P17764 Acat1 Acetyl-CoA acetyltransferase, mitochondrial 0.6060 0.000974 
Q9WVK7 Hadh Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 0.5985 0.000007 
P11915 Scp2 Non-specific lipid-transfer protein 0.5931 0.000252 
P07633 Pccb Propionyl-CoA carboxylase beta chain, mitochondrial 0.5820 0.000029 
D4A1J4 Bdh2 3-hydroxybutyrate dehydrogenase type 2 0.5803 0.009471 
P30839 Aldh3a2 Fatty aldehyde dehydrogenase 0.5781 0.000434 
P13437 Acaa2 3-ketoacyl-CoA thiolase, mitochondrial 0.5473 0.000061 
Q02253 Aldh6a1 Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial 0.5472 0.000002 
P11884 Aldh2 Aldehyde dehydrogenase, mitochondrial 0.5406 0.000011 
Q62651 Ech1 Delta (3,5)-Delta (2,4)-dienoyl-CoA isomerase, mitochondrial 0.4955 0.001429 
Q64591 Decr1 2,4-dienoyl-CoA reductase, mitochondrial 0.4932 0.000248 
P04762 Cat Catalase 0.4743 0.000000 
Q63028 Add1 Alpha-adducin 0.4357 0.000076 
Q62847 Add3 Gamma-adducin 0.3743 0.005222 
P11883 Aldh3a1 Aldehyde dehydrogenase, dimeric NADP-preferring 0.2221 0.000007 
Proteins involved in cluster b  
P62864 Rps30 40S ribosomal protein S30  2.0675 0.006588 
P83883 Rpl36a 60S ribosomal protein L36a  1.9455 0.015902 
P62268 Rps23 40S ribosomal protein S23  1.8894 0.000462 
P04646 Rpl35a 60S ribosomal protein L35a  1.7115 0.010021 
Q4KM49 Yars Tyrosine-tRNA ligase, cytoplasmic  1.7072 0.000006 
Q5U2Q7 Etf1 Eukaryotic peptide chain release factor subunit 1  1.7037 0.006442 
Q05982 Nme1 Nucleoside diphosphate kinase A  1.6351 0.018424 
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P61621 Sec61a1 Protein transport protein Sec61 subunit alpha isoform 1  1.6099 0.049741 
P62850 Rps24 40S ribosomal protein S24  1.6045 0.000270 
P61928 Rpl37 60S ribosomal protein L37  1.5624 0.003400 
P62752 Rpl23a 60S ribosomal protein L23a  1.5556 0.001320 
P19804 Nme2 Nucleoside diphosphate kinase B  1.5517 0.024035 
P18445 Rpl27a 60S ribosomal protein L27a  1.5435 0.002928 
Q6AYD3 Pa2g4 Proliferation-associated protein 2G4  1.5241 0.000058 
P62909 Rps3 40S ribosomal protein S3  1.5218 0.002851 
Q794F9 Slc3a2 4F2 cell-surface antigen heavy chain  1.5066 0.002933 
P19945 Rplp0 60S acidic ribosomal protein P0  1.5003 0.000487 
P29411 Ak3 GTP: AMP phosphotransferase AK3, mitochondrial  0.6212 0.000036 
 
 
Table 5.3 KEGG pathways and the involved proteins significantly regulated by TGF-β1 
in clusters a and b. (green font: induced by TGF-β1, red font: reduced by TGF-β1, TGF-β1 
vs control). 
KEGG pathways TGF-β1-regulated proteins (fold-change, TGF-β1/control) 
Cluster a 
Valine, leucine and isoleucine degradation 
Hibch (0.65), Acadsb (0.64), Hibadh (0.63), Ivd (0.61), Acat1 
(0.61), Hadh (0.60), Pccb (0.58), Aldh3a2 (0.58), Acaa2 (0.55), 
Aldh6a1 (0.55), Aldh2 (0.52) 
Fatty acid degradation Eci2 (0.65), Acadsb (0.64), Acat1(0.61), Hadh (0.60), Aldh3a2 (0.58), Acaa2 (0.55), Aldh2 (0.52) 
Metabolic pathways 
Hsd17b4 (0.67), Glud1(0.66), Hibch (0.65), Acadsb (0.64), 
Hibadh (0.63), Aldh3b1(0.62), Ivd (0.61), Acat1(0.61), Hadh 
(0.60), Scp2 (0.59), Aldh3a2 (0.58), Bdh2 (0.58), Pccb (0.58), 
Acaa2 (0.55), Aldh6a1(0.55), Aldh2 (0.52), Aldh3a1(0.22) 
beta-Alanine metabolism Hibch (0.65), Aldh3b1 (0.62), Aldh3a2 (0.58), Aldh6a1(0.55), Aldh2 (0.52), Aldh3a1 (0.22) 
Tryptophan metabolism Acat1(0.61), Hadh (0.60), Aldh3a2 (0.58), Aldh2 (0.52), Cat (0.47) 
Carbon metabolism Glud1(0.66), Hibch (0.65), Acat1(0.61), Pccb (0.58), Aldh6a1(0.55), Cat (0.47),  
Biosynthesis of antibiotics Acaa2 (0.55), Aldh2 (0.52), Cat (0.47), Hadh (0.60), Acat1(0.61), Pccb (0.58), Aldh3a2 (0.58) 
Histidine metabolism Aldh3b1 (0.62), Aldh3a2 (0.58), Aldh2 (0.52), Aldh3a1(0.22) 
Propanoate metabolism Hibch (0.65), Acat1(0.61), Pccb (0.58), Aldh6a1(0.55) 
Peroxisome Hsd17b4 (0.67), Eci2 (0.65), Scp2 (0.59), Ech1 (0.50), Cat (0.47) 
Lysine degradation Acat1(0.61), Hadh (0.60), Aldh3a2 (0.58), Aldh2 (0.52) 
Fatty acid metabolism Acadsb (0.64), Acat1(0.61), Hadh (0.60), Acaa2 (0.55) 
Glycolysis / Gluconeogenesis Aldh3b1 (0.62), Aldh3a2 (0.58), Aldh2 (0.52), Aldh3a1 (0.22) 
Glyoxylate and dicarboxylate metabolism Acat1(0.61), Pccb (0.58), Cat (0.47) 
Butanoate metabolism Acat1(0.61), Hadh (0.60), Bdh2 (0.58) 
Pyruvate metabolism Acat1(0.61), Aldh3a2 (0.58), Aldh2 (0.52) 
Synthesis and degradation of ketone bodies Acat1(0.61), Bdh2 (0.58) 
Primary bile acid biosynthesis Hsd17b4 (0.67), Scp2 (0.59) 
Cluster b 
Ribosome Rps30 (2.11), Rpl36a (1.95), Rps23 (1.89), Rpl35a (1.71), Rps24 
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(1.60), Rpl23a (1.56), Rpl37 (1.56), Rpl27a (1.54), Rps3 (1.52), 
Rplp0 (1.50) 
 
A volcano plot with fold change as the X-axis and -Log10 (p-value) as the Y-axis was used 
to demonstrate the overall distribution of differentially expressed proteins (TGF-β1 vs 
control). As shown in Fig. 5.8, there are 254 and 374 proteins up- and down-regulated by 
TGF-β1, respectively (p<0.05). These proteins with fold change >2 or <0.5 are listed in 
Table 5.4 and 5.5. Remarkably, TGF-β1 mostly dramatically induced Enpp1 and reduced 





Fig. 5.8. Volcano plot displaying the proteins differentially regulated by TGF-β1. The 
volcano plot indicates -Log10 (p-value, according to t-tests) for all identified proteins (Y-
axis) plotted against their respective fold change (X-axis). Proteins subjected to ELISA 
validation are highlighted either in green fonts (induced by TGF-β1) or red fonts (repressed 












































Table 5.4 Cell-lysate proteins most significantly up-regulated by TGF-β1 with fold 
change>2.  
Accession Protein Description Fold change  p-value 
Q924C3 Enpp1 Ectonucleotide pyrophosphatase/phosphodiesterase family member 1  3.5573 0.001098 
Q62952 Dpysl3 Dihydropyrimidinase-related protein 3  2.3262 0.000002 
P62864 Fau 40S ribosomal protein S30  2.0675 0.006588 
P30823 Slc7a1 High affinity cationic amino acid transporter 1  2.0636 0.001813 
Q3B8Q1 Ddx21 Nucleolar RNA helicase 2  2.0255 0.000041 
O08623 Sqstm1 Sequestosome-1  2.0113 0.000856 
 
Table 5.5. Cell-lysate proteins most significantly down-regulated by TGF-β1 with fold 
change <0.5.  
Accession Protein Description Fold change  p-value 
P11883 Aldh3a1 Aldehyde dehydrogenase, dimeric NADP-preferring  0.2221 0.000007 
Q8VIF7 Selenbp1 Selenium-binding protein 1  0.3363 0.000038 
Q62847 Add3 Gamma-adducin  0.3743 0.005222 
Q8R4C0 Capn5 Calpain-5  0.3877 0.002592 
O35276 Nrp2 Neuropilin-2  0.4342 0.007414 
P08430 Ugt1a6 UDP-glucuronosyltransferase 1-6  0.4348 0.000027 
Q63028 Add1 Alpha-adducin  0.4357 0.000076 
P04762 Cat Catalase  0.4743 0.000000 
O08628 Pcolce Procollagen C-endopeptidase enhancer 1  0.4854 0.000014 
Q64591 Decr1 2,4-dienoyl-CoA reductase, mitochondrial  0.4932 0.000248 
Q62651 Ech1 Delta (3,5)-Delta (2,4)-dienoyl-CoA isomerase, mitochondrial  0.4955 0.001429 
 
 
5.3. ELISA validation of selected cell-lysate proteins 
ELISA assays were performed on three proteins significantly regulated by TGF-β1 in cell 
lysates samples, including the most up-regulated protein Enpp1, the most down-regulated 
protein Aldh3a1 (Fig. 5.8), and Impdh2, which connected two clusters of TGF-β1-regulted 
proteins as shown in Fig. 5.7 A. Enpp1 and Impdh2 were confirmed to be significantly up-
regulated by TGF-β1, whereas the Aldh3a1 was confirmed to be significantly down-




Fig. 5.9. ELISA validation of selected cell-lysate proteins. Expression levels of Enpp1 (A), 
Aldh3a1 (B) and Impdh2 (C) in cell lysates were analysed by ELISA. n=4, ψψ p < 0.01 vs 
control group.  
 
5.4. Effect of Sappanone A, an Impdh2 inhibitor, on TGF-β1-induced fibrogenesis 
According to the data of STRING and KEGG pathway analysis (Fig. 5.7), multiple 
metabolic pathways and the ribosome pathway were linked by Imphd2, which was up-
regulated by TGF-β1 and its expression level was confirmed by ELISA (Fig. 5.9 C). It is 
intriguing whether Impdh2 may play an important role in TGF-β1-induced fibrogenesis. The 
inhibitors of Impdh (including Impdh1 and Impdh2), such as mycophenolic acid (138, 140) 
and BMS-566419 (137) have been reported to attenuate the progression of renal fibrosis. 
Sappanone A is known to selectively bind and inactivate Impdh2 but not Impdh1 (136). 
Thus, I set to address whether the Impdh2 inhibitor sappanone A has an anti-fibrotic effect in 
this in-vitro model of TGF-β1-induced fibrosis.  
As shown in Fig. 5.10, sappanone A at concentrations of 2-32 μM, did not significantly 
decrease total collagen accumulation in TGF-β1-induced in-vitro model of fibrosis as 
indicated by PSR-staining assay. Up to 32 μM sappanone A did not increase LDH release 
from cells and cell detachment index. The lack of anti-fibrotic activity was in contrast to 
IN1130, a TGF-β type I receptor inhibitor, which significantly inhibited the TGF-β1-induced 
collagen deposition in the same condition.  
The results do not directly support my initial hypothesis that Impdh2 could be a therapeutic 































































control of the commercial Sappanone A and its efficacy in repressing Impdh2 activity at the 
concentrations used deserve further investigation. Further studies using alternative 
techniques, such as genetic inhibition of Impdh2, are also required to further examine the 




Fig. 5.10. Sappanone A, an Impdh2 inhibitor, did not affect TGF-β1-induced 
fibrogenesis. NRK-49F cells were treated with 2-32 μM Sappanone A or 1 μM IN1130 in 
presence of 5 ng/ml TGF-β1 for 48 h. Effects on fibrogenesis were illustrated by 
representative PSR staining images (A), which visualised total collagen deposition in red 
colour (×100 magnification); eluted PSR was quantified by spectrophotometric analysis (B) 
and cytotoxicity was approximated by recording a mean cell detachment index (C) and LDH 
release assay (D). Experiments were performed in quadruplicate and shown are 
representative results of two independent experiments with similar results.  ψψ p < 0.01 vs 
control group, *** p < 0.001 vs TGF-β1 treated group. 
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5.5. Proteomic profiling analysis of conditioned media 
In total 725 proteins were identified in the conditioned media, of which 62 were significantly 
regulated by TGF-β1 (Table 5.6 and 5.7). No protein was detected only in either control or 
TGF-β1 group. GO cellular component analysis indicated that in total 20 clusters were 
generated and the highest number of proteins regulated by TGF-β1 were components of 
extracellular exosomes, followed by cytoplasm, extracellular space, extracellular region, 
extracellular matrix, and so on (Fig. 5.11). The lists of the proteins involved in enriched GO 
cellular components are shown in Table 5.8. Forty clusters of proteins were identified under 
GO biological processes. The highest numbers of proteins regulated by TGF-β1 participated 
in cell adhesion, angiogenesis, proteolysis, cellular response to interleukin-1, positive 
regulation of ERK1 and ERK2 cascade, etc (Fig. 5.12). The lists of the proteins involved in 
the enriched GO biological processes are shown in Table 5.9. As shown in Fig. 5.13, GO 
molecular functions of TGF-β1-regulated proteins in conditioned media were related to 
bindings with heparin, calciumion, integrin, proteoglycan, insulin-like growth factor, 
kininogen, CCR2 chemokine receptor. The lists of the proteins involved in enriched GO 
molecular functions are shown in Table 5.10. 
 
Table 5.6. Proteins significantly up-regulated by TGF-β1 in conditioned media.  
Accession Protein Description Fold change  p-value 
P20961 Serpine1 (PAI-1) Plasminogen activator inhibitor 1  4.41 0.0003 
P14844 Ccl2 C-C motif chemokine 2  3.47 0.0012 
Q6QMY6 Tsku Tsukushin  2.60 0.0178 
Q9QXY8 Ccl7 C-C motif chemokine 7  2.43 0.0014 
Q9ES72 Cyr61 Protein CYR61  2.14 0.0082 
Q9R0K8 Stc2 Stanniocalcin-2  1.82 0.0360 
Q811A3 Plod2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2  1.81 0.0005 
O35806 Ltbp2 Latent-transforming growth factor beta-binding protein 2  1.78 0.0310 
Q9R1E9 Ctgf Connective tissue growth factor  1.73 0.0024 
P17209 Myl4 Myosin light chain 4  1.68 0.0027 
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Q9JI03 Col5a1 Collagen alpha-1(V) chain 1 1.56 0.0442 
P54690 Bcat1 Branched-chain-amino-acid aminotransferase, cytosolic  1.55 0.0243 
Q9WV75 Spon2 Spondin-2  1.54 0.0480 
Q9Z0W7 Clic4 Chloride intracellular channel protein 4  1.53 0.0379 
Q62736 Cald1 Non-muscle caldesmon  1.49 0.0024 
Q4V7E8 Lrrfip2 Leucine-rich repeat flightless-interacting protein 2  1.49 0.0494 
Q62908 Csrp2 Cysteine and glycine-rich protein 2  1.46 0.0126 
Q3B8Q1 Ddx21 Nucleolar RNA helicase 2  1.35 0.0043 
Q2LAP6 Tes Testin  1.27 0.0231 
P39069 Ak1 Adenylate kinase isoenzyme 1  1.27 0.0332 
Q9Z2G8 Nap1l1 Nucleosome assembly protein 1-like 1  1.25 0.0421 
P23514 Copb1 Coatomer subunit beta  1.21 0.0468 
P62752 Rpl23a 60S ribosomal protein L23a  1.19 0.0270 
Q6AXS5 Serbp1 Plasminogen activator inhibitor 1 RNA-binding protein  1.15 0.0098 
P13084 Npm1 Nucleophosmin  1.14 0.0325 
 
Table 5.7. Proteins significantly down-regulated by TGF-β1 in conditioned media.  
Accession Protein Description Fold change  p-value 
Q9QZQ5 Nov Protein NOV homolog  0.28 0.0339 
B5DFC9 Nid2 Nidogen-2  0.34 0.0393 
Q63548 Sema3a Semaphorin-3A  0.35 0.0412 
Q64610 Enpp2 Ectonucleotide pyrophosphatase/phosphodiesterase family 
member 2  
0.36 0.0435 
Q6P6T1 C1s Complement C1s subcomponent  0.39 0.0412 
Q6IE64 C1rl Complement C1r subcomponent-like protein  0.41 0.0487 
P03957 Mmp3 Stromelysin-1  0.43 0.0475 
Q6P7C7 Gpnmb Transmembrane glycoprotein NMB  0.49 0.0180 
O70513 Lgals3bp Galectin-3-binding protein  0.5 0.0424 
P01322 Ins1 Insulin-1  0.52 0.0122 
Q62894 Ecm1 Extracellular matrix protein 1  0.53 0.0372 
O55004 Rnase4 Ribonuclease 4  0.54 0.0357 
Q08420 Sod3 Extracellular superoxide dismutase [Cu-Zn]  0.55 0.0283 
P05964 S100a6 Protein S100-A6  0.56 0.0394 
P07092 Serpine2 Glia-derived nexin  0.56 0.0041 
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P05371 Clu Clusterin  0.57 0.0342 
P52303 Ap1b1 AP-1 complex subunit beta-1  0.58 0.0198 
P11883 Aldh3a1 Aldehyde dehydrogenase, dimeric NADP-preferring  0.59 0.0189 
O35276 Nrp2 Neuropilin-2  0.59 0.0034 
P15087 Cpe Carboxypeptidase E  0.6 0.0286 
P00787 Ctsb Cathepsin B  0.61 0.0046 
P17164 Fuca1 Tissue alpha-L-fucosidase  0.62 0.0006 
P97546 Nptn Neuroplastin  0.63 0.0316 
P07154 Ctsl Cathepsin L1  0.66 0.0420 
Q5U4F3 Fam107b Protein FAM107B  0.67 0.0107 
P35053 Gpc1 Glypican-1  0.68 0.0169 
B0BNI5 Olfml3 Olfactomedin-like protein 3  0.69 0.0435 
Q6P502 Cct3 T-complex protein 1 subunit gamma  0.69 0.0041 
Q32KJ6 Galns N-acetylgalactosamine-6-sulfatase  0.7 0.0175 
Q6IRK9 Cpq Carboxypeptidase Q  0.75 0.0082 
Q66H12 Naga Alpha-N-acetylgalactosaminidase  0.76 0.0276 
Q6P7A9 Gaa Lysosomal alpha-glucosidase  0.78 0.0209 
P70615 Lmnb1 Lamin-B1  0.79 0.0250 
P28077 Psmb9 Proteasome subunit beta type-9  0.8 0.0180 
Q4KM35 Psmb10 Proteasome subunit beta type-10  0.82 0.0341 
Q68FP1 Gsn Gelsolin  0.84 0.0122 
O35217 Minpp1 Multiple inositol polyphosphate phosphatase 1  0.85 0.0200 
 112 
 
Fig. 5.11. GO cellular component enrichment analysis of the proteins in conditioned media significantly regulated by TGF-β1. The numbers of 







































































































































































Table 5.8. GO cellular component analysis of proteins in conditioned media 
significantly regulated by TGF-β1. (“•”: induced by TGF-β1; “•”: repressed by TGF-β1). 
GO cellular components Protein (fold change, TGF-β1 vs control) 
Extracellular exosome 
• PAI-1(4.41), Plod2 (1.81), Ltbp2 (1.78), Col5a1 (1.56), Spon2 (1.54), 
Clic4 (1.53), Ak1 (1.27), Rpl23a (1.19), Serbp1 (1.15) 
• Nid2 (0.34), C1s (0.39), C1rl (0.41), Lgals3bp (0.50), Ecm1 (0.53), 
Rnase4 (0.54), Sod3 (0.55), S100a6 (0.56), Clu (0.57), Cpe (0.60), Ctsb 
(0.61), Fuca1 (0.62), Ctsl (0.66), Gpc1 (0.68), Cct3 (0.69), Galns (0.70), 
Cpq (0.75), Naga (0.76), Gaa (0.78), Psmb9 (0.80), Gsn (0.84), Minpp1 
(0.85) 
Cytoplasm 
• PAI-1(4.41), Ccl2 (3.47), Bcat1 (1.55), Clic4 (1.53), Tes (1.27), Ak1 
(1.27), Nap1l1 (1.25), Copb1 (1.21), Rpl23a (1.19), Serbp1 (1.15), Npm1 
(1.14) 
• Nov (0.28), Enpp2 (0.36), Ins1 (0.52), Sod3 (0.55), S100a6 (0.56), Clu 
(0.57), Aldh3a1 (0.59), Ctsb (0.61), Ctsl (0.66), Cct3 (0.69), Cpq (0.75), 
Naga (0.76), Lmnb1 (0.79), Psmb9 (0.80), Psmb10 (0.82), Gsn (0.84)  
Extracellular space 
• PAI-1(4.41), Ccl2 (3.47), Tsku (2.60), Ccl7 (2.43), Stc2 (1.82), Ltbp2 
(1.78), Ctgf (1.73), Spon2 (1.54) 
• Sema3a (0.35), Enpp2 (0.36), C1rl (0.41), Mmp3 (0.43), Lgals3bp (0.50), 
Ins1 (0.52), Ecm1 (0.53), Sod3 (0.55), Serpine2 (0.56), Clu (0.57), 
Aldh3a1 (0.59), Cpe (0.60), Ctsb (0.61), Ctsl (0.66), Gpc1 (0.68), Cpq 
(0.75), Gsn (0.84)  
Extracellular region 
• PAI-1(4.41), Ccl2 (3.47), Tsku (2.60), Cyr61 (2.14), Ctgf (1.73)  
• Nov (0.28), C1s (0.39), C1rl (0.41), Rnase4 (0.54), Serpine2 (0.56), Clu 
(0.57), Cpe (0.60), Ctsb (0.61), Olfml3 (0.69), Gsn (0.84)  
Extracellular matrix 
• PAI-1(4.41), Cyr61 (2.14), Col5a1 (1.56), Spon2 (1.54), Ltbp2 (1.78) 
• Nov (0.28), Nid2 (0.34), Mmp3 (0.43), Lgals3bp (0.50), Ecm1 (0.53), 
Sod3 (0.55), Serpine2 (0.56), Clu (0.57) 
Cytosol 
• Clic4 (1.53), Ctgf (1.73), Bcat1 (1.55), Npm1 (1.14) 
• Mmp3 (0.43), Ins1 (0.52), S100a6 (0.56), Serpine2 (0.56), Clu (0.57), 
Aldh3a1 (0.59), Psmb9 (0.80), Gsn (0.84) 
Proteinaceous extracellular 
matrix 
• Cyr61 (2.14), Ltbp2 (1.78), Ctgf (1.73), Col5a1 (1.56), Spon2 (1.54) 
• Nov (0.28), Nid2 (0.34), Mmp3 (0.43), Lgals3bp (0.50), Ecm1 (0.53), 
Gpc1 (0.68) 
Perinuclear region of 
cytoplasm 
• Ccl2 (3.47), Stc2 (1.82), Ctgf (1.73), Clic4 (1.53), Ak1 (1.27), Serbp1 
(1.15) 
• S100a6 (0.56), Clu (0.57), Ctsb (0.61), Gsn (0.84) 
Lysosome • Ctsb (0.61), Fuca1 (0.62), Ctsl (0.66), Galns (0.70), Cpq (0.75), Naga (0.76), Gaa (0.78)  
Dendrite 
• Ccl2 (3.47), Cald1 (1.49) 
• Nov (0.28), Sema3a (0.35), Mmp3 (0.43), Cpe (0.60), Nptn (0.63) 
Endoplasmic reticulum 
• Stc2 (1.82), Plod2 (1.81), Clic4 (1.53), Copb1 (1.21) 
• Clu (0.57), Aldh3a1 (0.59), Cpq (0.75) 
Golgi apparatus 
• Stc2 (1.82), Ctgf (1.73), Copb1 (1.21) 
• Enpp2 (0.36), Ap1b1 (0.58), Cpe (0.60), Cpq (0.75) 
Neuronal cell body 
• Ccl2 (3.47), Cald1 (1.49) 
• Nov (0.28), Serpine2 (0.56), Cpe (0.60), Gpc1 (0.68) 
Blood microparticle • Gsn (0.84), Clu (0.57), Lgals3bp (0.50), C1s (0.39) 
Melanosome 
• Nap1l1 (1.25) 
• Gpnmb (0.49), Ctsb (0.61) 
Nuclear matrix 
• Clic4 (1.53), Npm1 (1.14) 
• Lmnb1 (0.79) 




• Clu (0.57)  
Actin cap 
• Cald1 (1.49) 
• Gsn (0.84) 




Fig. 5.12. GO biological processe enrichment analysis of the proteins in conditioned media significantly regulated by TGF-β1. The numbers of involved 


































































































































































































































































































































































































































































































































































Table 5.9. GO biological process analysis of proteins in conditioned media significantly 
regulated by TGF-β1. (“•”: induced by TGF-β1; “•”: repressed by TGF-β1).  
GO biological processes Protein (fold change, TGF-β1 vs control) 
Cell adhesion 
• Cyr61 (2.14), Ctgf (1.73), Col5a1 (1.56), Spon2 (1.54) 
• Nov (0.28), Gpnmb (0.49), Lgals3bp (0.50) 
Angiogenesis 
• PAI-1(4.41), Ctgf (1.73), Clic4 (1.53) 
• Nov (0.28), Ecm1 (0.53), Nrp2 (0.59) 
Proteolysis • C1s (0.39), C1rl (0.41), Mmp3 (0.43), Ctsb (0.61), Ctsl (0.66), Cpq (0.75) 
Cellular response to interleukin-1 
• PAI-1(4.41), Ccl2 (3.47), Ccl7 (2.43) 
• Mmp3 (0.43), Psmb9 (0.80) 
Positive regulation of ERK1 and ERK2 cascade 
• Ccl2 (3.47), Ccl7 (2.43), Ctgf (1.73) 
• Gpnmb (0.49), Nptn (0.63) 
Response to hypoxia 
• Ccl2 (3.47), Plod2 (1.81) 
• Mmp3 (0.43), Sod3 (0.55), Aldh3a1 (0.59) 
Aging 
• Ccl2 (3.47), Ctgf (1.73) 
• Clu (0.57), Aldh3a1 (0.59), Gsn (0.84) 
Decidualization 
• PAI-1(4.41), Stc2 (1.82) 
• Ctsb (0.61), Ctsl (0.66) 
Proteolysis involved in cellular protein catabolic 
process • Psmb10 (0.82), Psmb9 (0.80), Ctsl (0.66), Ctsb (0.61) 
Response to wounding 
• Ccl2 (3.47) 
• Serpine2 (0.56), Clu (0.57), Ctsb (0.61) 
Negative regulation of cell death 
• Cyr61 (2.14), Ctgf (1.73) 
• Nov (0.28), Ctsb (0.61) 
Response to cytokine 
• PAI-1(4.41) 
• Mmp3 (0.43), Ins1 (0.52), Ctsb (0.61) 
Response to peptide hormone 
• Stc2 (1.82), Ctgf (1.73) 
• Ins1 (0.52), Ctsb (0.61) 
Positive regulation of protein phosphorylation 
• Cyr61 (2.14), Ctgf (1.73) 
• Gpnmb (0.49), Nptn (0.63) 
Negative regulation of gene expression • PAI-1(4.41), Stc2 (1.82), Ctgf (1.73), Npm1 (1.14) 
Nerve development • Sema3a (0.35), Nrp2 (0.59), Ctsl (0.66) 
Collagen catabolic process • Mmp3 (0.43), Ctsb (0.61), Ctsl (0.66) 
Tissue regeneration 
• PAI-1(4.41) 
• Cpq (0.75), Gsn (0.84) 
Positive regulation of cell differentiation 
• Cyr61 (2.14), Ctgf (1.73) 
• Clu (0.57) 
Positive regulation of tumor necrosis factor 
production 
• Ccl2 (3.47), Spon2 (1.54) 
• Clu (0.57) 
Response to amino acid 
• Ccl2 (3.47), Ctgf (1.73) 
• Mmp3 (0.43) 
Positive regulation of inflammatory response • PAI-1(4.41), Ccl2 (3.47), Ccl7 (2.43) 
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Response to camp • Aldh3a1 (0.59), Ins1 (0.52), C1s (0.39) 
Cell-cell signalling 
• Cyr61 (2.14), Ctgf (1.73) 
• Nov (0.28) 
Facioacoustic ganglion development • Nrp2 (0.59), Sema3a (0.35) 
Gonadotrophin-releasing hormone neuronal 
migration to the hypothalamus • Nrp2 (0.59), Sema3a (0.35) 
Semaphorin-plexin signaling pathway involved in 
neuron projection guidance • Nrp2 (0.59), Sema3a (0.35)  
Sympathetic neuron projection extension • Nrp2 (0.59), Sema3a (0.35) 
Ventral trunk neural crest cell migration • Nrp2 (0.59), Sema3a (0.35) 
Sympathetic neuron projection guidance • Nrp2 (0.59), Sema3a (0.35) 
Negative regulation of plasminogen activation • PAI-1(4.41) 
• Serpine2 (0.56) 
Trigeminal ganglion development • Nrp2 (0.59), Sema3a (0.35) 
Neural crest cell migration involved in autonomic 
nervous system development • Nrp2 (0.59), Sema3a (0.35) 
Glycoside catabolic process • Naga (0.76), Fuca1 (0.62) 
Sympathetic ganglion development • Nrp2 (0.59), Sema3a (0.35) 
Facial nerve structural organization • Nrp2 (0.59), Sema3a (0.35) 
Extracellular fibril organization • Ltbp2 (1.78), Col5a1 (1.56) 
Cellular response to ATP • PAI-1(4.41), Ccl2 (3.47) 
Response to transforming growth factor beta • PAI-1(4.41), Cald1 (1.49) 
























Fig. 5.13. GO molecular function enrichment analysis of the proteins in conditioned 
media significantly regulated by TGF-β1. The numbers of involved proteins are indicated 
by the left y-axis shown as orange bars and the p-values (as -Log10 values) are indicated by 
the right y-axis shown as green dots, respectively.  
 
 
Table 5.10. GO molecular function analysis of proteins in conditioned media 
significantly regulated by TGF-β1 (“•”: induced by TGF-β1; “•”: repressed by TGF-β1).  
GO molecular functions Protein (fold change, TGF-β1 vs control) 
Heparin binding 
• Ccl2 (3.47), Ccl7 (2.43), Cyr61 (2.14), Ltbp2 (1.78), Ctgf (1.73), 
Col5a1 (1.56) 
• Nov (0.28), Gpnmb (0.49), Serpine2 (0.56), Nrp2 (0.59) 
Calcium ion binding 
• Ltbp2 (1.78), Myl4 (1.68) 
• Nid2 (0.34), Enpp2 (0.36), C1s (0.39), Mmp3 (0.43), S100a6 (0.56), 
Gsn (0.84) 
Integrin binding 
• Cyr61 (2.14), Ctgf (1.73) 
• Nov (0.28), Gpnmb (0.49) 
Proteoglycan binding 
• Col5a1 (1.56) 
• Ctsb (0.61), Ctsl (0.66) 
Insulin-like growth factor binding 
• Cyr61 (2.14), Ctgf (1.73) 
• Nov (0.28) 
Kininogen binding • Ctsb (0.61), Ctsl (0.66) 




















































































As shown in Fig. 5.14, STRING analysis of the conditioned media reveals that increased 
PAI-1, a potent inhibitor of collagen degradation, and repressed collagen-degradation 
enzyme Mmp3, centred the secretomic interaction map of TGF-β1-regulated proteins, 
suggesting that TGF-β1 repression of collagen degradation might play an important role in 
TGF-β1 induced fibrogenesis. Also locating at the centre of this secretomic interaction map 
are TGF-β1-induced chemokines Ccl2 (MCP-1) and Ccl7 (MCP-3), suggesting that TGF-β1-
induced fibrogenesis is inherently coupled with inflammation by promoting chemotactic 
effects. Indeed, PAI-1, Ccl2 and Ccl7 regulation by TGF-β1 is involved in positive 
regulation of inflammation resonse, according to GO biological process analysis (Table 5.9).  
 
KEGG pathway analysis suggested that TGF-β1 regulated the Lysosome and the 
Rheumatoid arthristis pathways (Fig. 5.15). Six proteins were involved in the Lysosome 
pathway, including Gaa, Naga, Galns, Ctsl, Ctsb and Ap1b1, which were all significantly 
reduced by TGF-β1. In addition, GO cellular component analysis showed that 7 proteins 
located in lysosome, including Ctsb, Fuca1, Ctsl, Galns, Cpq, Naga and Gaa, were all 
reduced by TGF-β1 (Table 5.8). In the rheumatoid arthritis pathway, TGF-β1 induced Ccl2 







                
Fig. 5.14. STRING analysis illustrates predicted direct (physical) and indirect 
(functional) associations among proteins in conditioned media significantly regulated 
by TGF-β1. TGF-β1-induced PAI-1 and -repressed Mmp3 (red circle) and TGF-β1-induced 






Fig. 5.15. KEGG pathways of proteins in conditioned media regulated by TGF-β1. Y-
axis represents significantly enriched KEGG pathway terms and X-axis indicates -Log10 p-
value. The p-value and involved proteins (fold change, TGF-β1 vs control) were 
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Volcano plot analysis was applied to demonstrate TGF-β1-induced and -suppressed proteins 
in conditioned media, including 25 up-regulated and 37 down-regulated proteins. As shown 
in Fig. 5.16, PAI-1 was the most significantly and most dramatically induced by TGF-β1, 
accompanying up-regulation of chemokines Ccl2 and Ccl7, signalling mediators Cyr61 
(Ccn1), Ctgf (Ccn2) and Tsku, and collagen crosslinking enzyme Plod2. In addition, TGF-β1 
most dramatically repressed another CCN family member, Nov (Ccn3), and suppressed 
collagen degradation enzyme Mmp3, among other proteins.  
              
 
Fig. 5.16. Volcano plot shows the proteins in conditioned media regulated by TGF-β1. 
Those proteins of interest for further validation are highlighted in green font (induced by 
TGF-β1) and red font (suppressed by TGF-β1), respectively.  
 
5.6. ELISA validation of selected proteins in conditioned media 
Nine proteins in conditioned media were selected for validation by ELISA. They are: (1) five 
TGF-β1-induced proteins with fold changes>2: PAI-1, Ccl2, Ccl7, Tsku and Cyr61; (2) two 
TGF-β1-induced proteins with likely relevance to fibrosis: collagen crosslinking enzyme 
Plod2 and fibrotic mediator Ctgf; (3) the protein most significantly down-regulated by TGF-
β1, Nov; and (4) collagen degradation enzyme Mmp3. In agreement with the mass 
spectrometric data, ELISA assay of PAI-1, Ccl2, Ccl7, Tsku, Plod2, Cyr61 and Ctgf 
confirmed that they were significantly induced by TGF-β1, Nov and Mmp3 were both 
significantly lower in TGF-β1 group (Fig. 5.17).  
 




































Fig. 5.17. Validation of selected proteins in conditioned media by ELISA. ELISA results 
of PAI-1(A), Ctgf (B), Plod2 (C), Tsku (D), Ccl2 (E), Ccl7 (F), Cyr61 (G), Mmp3 (H) and 





























































































































































































5.7. Discussions  
5.7.1. Comparison with a proteomic study of TGF-β1-induced fibrogenesis in NRK-49F 
cells in the literature 
As far as I know, there is only one proteomic anlysis of TGF-β1 induced fibrogenesis in 
NRK-49F cells (and indeed any fibroblasts) in the literature (141). Although the same cell 
line NRK-49F was used in both studies, different experimental design and technical details 
resulted in varied findings. The main differences between the two studies are summarised in 
Table 5.11.  
 
Table 5.11. Comparison of proteomic studies of TGF-β1-induced fibrogenesis in NRK-
49F cells. 
 Reference (141) Present study 
Cell  
cluture  
Cells were grown to 60%-70% confluence in 
10%FBS-DMEM for 12h, change to serum-
free medium after washing twice.  
Cells were grown in DMEM with 2.5% 
FCS and 2.5% Nu-serum replacement 
for 3 days, then changed the medium to 
1% ITS-DMEM for another 4 days. 
Cells were washed with serum free, 
phenol red-free DMEM twice. 
Treatment  2 ng/mL TGF-β1 for 6 h 5 ng/mL TGF-β1 for 48 h 
Protein extration 
• The conditioned media were not collected 
for proteomics analysis; 
• Cells lysates were harvested using a buffer 
containing 5mM EDTA,9.5M urea, 4%v/v 
CHAPS, 65mM DTT and protease 
inhibitors for 1 h at 24℃ and subjected to 
proteomic analysis 
• The conditioned media were collected 
for proteomics analysis; 
•  Cells lysates were harvested using a 
RIPA buffer with protease and 
phosphatase inhibitors for 10 min at 
room temperature, and were subjected 




• 2D-gel electrophoresis and in-gel digestion 
of selected spots  
• MALDI-TOF-MS with reference to NCBI 
and Swiss-Prot databases 
• In-solution digestion and TMT-
labelling 
•  (nESI) Orbitrap-MS with reference 
to Protein Discover and Mascot 
databases 
Note: MALDI: matrix assisted laser desorption/ionisation; TOF: time‐of‐flight; (nESI): 
nano‐electrospray ionisation (nESI). 
 
Kang et al. missed all proteins in conditione media. Using a much less sensitive, 2D-gel 
electrophoresis-based proteomic technology, they only found 74 proteins significantly 
regulated by TGF-β1 (141). This is in contrast to 628 proteins regulated by TGF-β1 in the 
present study. As shown in Fig. 5.18, there were 13 overlapping proteins and their accession 
numbers, p-values and fold-changes are listed in Table 5.12. Among them, TGF-β1 
significantly suppressed Gstp1, Oat, Sdhb and Lrpap1 and induced Cald1, Pdlim1, Nme2 
and Stip1 in both studies. However, 5 proteins, including Aldh3a1, Icam1, Stmn1, Prdx2 and 
Ruvbl1, showed different trends after TGF-β1 treatment. In addition, several differentially 





activated receptor, prohibitin, intercellular adhesion molecule-1, however, they were not 
detected in the present study. Those descrepanies can be explained by the different 
experimental designs and methods summarised in Table 5.10 (142). Of interest, although 
PAI-1 was induced by TGF-β1 in cell lysates 6 hours (141) after treatment, PAI-1 induced 
by TGF-β1 48 h after treatment in the present work was only observed in conditioned media, 
but not in cell lysates. 
 
 
Fig. 5.18. Venn diagram showing similarities and differences between the proteins 
significantly changed by TGF-β1 in reference data (141) and the proteins detected in 
present study. 
 
Table 5.12. The overlapping proteins significantly changed by TGF-β1 in reference data 
and the present study. The fold change columns correspond to the expression of each 
protein relative to its expression in control cells. 
Accession Protein Description 
Present data Reference  




Aldehyde dehydrogenase, dimeric NADP-
preferring  0.000007 −4.5 1.6 
Q00238 Icam1 Intercellular adhesion molecule 1  0.000536 −1.5 2.1 
P04906 Gstp1 Glutathione S-transferase P  0.013291 −1.5 −2.0 
P04182 Oat Ornithine aminotransferase, mitochondrial  0.004721 −1.4 −2 
P21913 Sdhb 
Succinate dehydrogenase [ubiquinone] iron-
sulfur subunit, mitochondrial  0.020986 −1.4 −2.0 
Q99068 Lrpap1 
Alpha-2-macroglobulin receptor-associated 
protein  0.001466 −1.4 −2.5 
P13668 Stmn1 Stathmin  0.009580 −1.2 1.2 
P35704 Prdx2 Peroxiredoxin-2  0.005688 −1.2 8.6 
Q62736 Cald1 Non-muscle caldesmon  0.000117 2.0 3.4 
P52944 Pdlim1 PDZ and LIM domain protein 1  0.000008 1.9 3.5 





P19804 Nme2 Nucleoside diphosphate kinase B  0.024035 1.6 3.0 
P60123 Ruvbl1 RuvB-like 1  0.005566 1.2 −1.2 
O35814 Stip1 Stress-induced-phosphoprotein 1  0.000292 1.1 2.2 
 
 
5.7.2. TGF-β1-induced fibrogenesis may be an intracellular metabolic disorder  
TGF-β1-induced fibrogenesis in fibroblasts may be an intracellular metabolic disorder 
characterised by increased intracellular proteins of the ribosome pathway and reduced 
proteins of multiple metabolic pathways.  
As shown in Fig. 5.5, TGF-β1 most significantly regulated the ribosome pathway and 
induced numerous cytosolic ribosomal proteins, while repressing Mrpl3, a mitochondrial 
ribosomal protein (Table 5.1), suggesting that TGF-β1-induced fibrogenesis may be 
differentially associated with cytosolic and mitochondrial ribosomal proteins. TGF-β1 is 
well known to induce cell hypertrophy (143), which is associated with increased protein 
synthesis through regulation of mTOR, a key kinase involved in protein synthesis and 
growth (144). mTORC1 positively regulates ribosomal RNA transcription, the synthesis of 
ribosomal proteins and other components required for ribosome assembly (145, 146). Given 
the roles of ribosome in protein synthesis, it may not be surprising that the ribosome pathway 
is induced by TGF-β1. However, to my best knowledge, the functions of those ribosomal 
proteins in fibrosis remain largely unknown, which deserve further study.  
Fig. 5.5 shows mutiple metablic pathways were significantly regulated by TGF-β1 in cell 
lysates, in particularly, energy metabolism, including the citrate acid (TCA) cycle, fatty acid 
metabolism/degradation/elongation, glycolysis/gluconeogenesis. The TCA cycle, with the 
primary responsibility for cellular energy production, is the final common oxidative pathway 
for fats, carbohydrates and amino acids and is the most important central pathway 
connecting almost all individual metabolic pathways (145). Addtionally, the TCA cycle has 
a close relationship with fibrotic diseases. Zhao et al. reported that overall decreased TCA 
cycle metabolites and enzymes in lungs of patients with idiopathic pulmonary fibrosis  (147). 
At the early stage of liver fibrosis in rat, the TCA cycle was slowed by cellular regulation to 
reduce the natural production of reactive oxygen species (ROS) (148). Similarly, in the 
present study, the proteins enriched in the TCA cycle were all repressed by TGF-β1 (Table 
5.1), potentially indicating a down-regulated TCA cycle. Fatty acid metabolism occurs 
primarily in the mitochondria and is important for generating ATP for energy production and 
participates in the TCA cycle, ultimately leading to ATP synthesis. In the present study, the 





Acsl5 and Fasn) and fatty acid elongation were reduced by TGF-β1 (Table 5.1), suggesting 
that multiple fatty acid metabolism pathways may participate in TGF-β1-induced fibrosis. 
Xiong et al. demonstrated that endothelial fatty acid oxidation is a critical in-vitro and in-
vivo regulator of TGF-β1-induced endothelial-to-mesenchymal transition (EndoMT).  TGF-
β1-induced EndoMT is accompanied by an inhibition of fatty acid oxidation (149). In 
addition, humans and mouse models with tubulointerstitial fibrosis had lower expression of 
key enzymes and regulators of fatty acid oxidation (150). Togather these studies indicate a 
potential associassion between fatty acid metabolism and TGF-β1-induced fibrosis in 
fibroblasts that may merit further evaluation. Almost all the proteins involved in 
glycolysis/gluconeogenesis pathway were reduced by TGF-β1 (Table 5.1), suggesting that 
glycolysis contributed to energy production by generating ATP and participating in the TCA 
cycle (151). In addition, amino acid metabolism was regulated by TGF-β1 (Fig. 5.5, Table 
5.1), i.e. valine, leucine, and isoleucine degradation, biosynthesis of amino acids, lysine 
degradation, tryptophan metabolism, beta-alanine metabolism, arginine and proline 
metabolism, histidine metabolism, phenylalanine metabolism, glycine, serine and threonine 
metabolism, tyrosine metabolism. These findings are in keeping with the facts that the 
ribosome pathway was most significantly regulated by TGF-β1 and that the ribosome 
mediates the incorporation of amino acids into proteins.  
 
5.7.3. TGF-β1 most significantly induced Enpp1 and repressed Aldh3a1 and Cat  
Enpp1, a membrane-bound protein, plays a role in regulating pyrophosphate levels, and 
functions in bone mineralisation and soft tissue calcification (152). Shimokado et al. 
reported that Enpp1 was decreased at the mRNA, protein and enzymatic acivity levels in 
Smad3(-/-) vascular smooth muscle cells (vSMCs) compared with Smad3(+/+) vSMCs. 
Smad3 is a well-known intracellular signalling molecule of TGF-β. In their study, a ChIP 
assay also revealed that phosphorylated Smad3 directly binds to the promotor region of 
Enpp1 gene, leading to TGF-β/Smad3 signalling and translation of Enpp1 (153). Xu et al. 
showed that Enpp1 expression was increased when end-plate chondrocytes were exposed to 
TGF-β1, but decreased after TGF-β knockdown with siRNA. It suggested that expression of 
Enpp1 is likely dependent on TGF-β1 in end-plate chondrocytes (154, 155). However, no 
study has examined whether Enpp1 is involved in TGF-β1-induced fibrogenesis in renal 
fibroblasts yet. 
Aldh3a1, a member of the aldehyde dehydrogenase superfamily, protects the ocular tissue 
from ultraviolet radiation (UVR)-induced oxidative stress through multiple mechanisms 
including directly absorbing UV light, metabolising toxic aldehydes derived from lipid 





157). In particular, Aldh3a1 showed antioxidant activities in stromal fibroblasts in vitro 
(158). However, the importance of dramatic repression of Aldh3a1 in TGF-β1-induced 
fibrosgenesis is unknown and deserves further investigation. In addition, TGF-β1 most 
significantly repressed the abundance of catalase (Cat), an important enzyme in protecting 
the cell from oxidative damage (159). Indeed, Sunami, R. et al reported that catalase 
deficiency promoted tubulointerstitial injury and fibrosis after unilateral ureteral obstruction 
(160). Furthermore, Kobayashi, M. et al demonstrated that catalase deficiency enhanced 
renal fibrosis in mice (159). These studies support the protective role of catalase in renal 
fibrosis and suggest catalase repression may play an important role in TGF-β1-induced 
fibrogenesis. 
 
5.7.4. TGF-β1 triggered pro-fibrotic and anti-fibrotic signals 
Fibrosis is characterised by excessive accumulation of ECM, resulting from increased 
synthesis and/or decreased degradation of ECM. The plasminogen activation system plays an 
important role in ECM degradation, whereas PAI-1 (serpine 1) is a potent inhibitor of 
plasminogen activators (161, 162). Accordingly, PAI-1 was most significantly and 
dramatically induced by TGF-β1 in present study, and a number of studies have established 
the association of elevated expression of PAI-1 in glomerulosclerosis and kidney fibrosis and 
PAI-1 deficiency reduced TGF-β1-induced collagen accumulation and kidney fibrosis (163, 
164). Thus, PAI-1 is a critical element of the TGF-β network which could be considered as a 
therapeutic target for fibrosis (165). Of note, in the aforementioned proteomic study by Kang 
et .al, the expression of PAI-1 was induced by TGF-β1 in cell lysates of NRK- 49F cells 
(141), but in the present study, PAI-1 only can be detected in conditioned media but not in 
cell lysates.  
In addition, the matrix metalloproteinase (MMP) system is also known for their critical role 
in degradation and remodelling of ECM (166). The results of the present study demonstrated 
that Mmp3 was decreased after TGF-β1 treatment whereas the possible roles of Mmp3 in the 
pathogenesis of kidney fibrosis are largely unknown. Additionally, the specific roles of 
Mmp3 in fibrosis may dependent on diverse organs and cell types. It has been found that the 
mRNA and protein expression of Mmp3 was upregulated in patients with idiopathic 
pulmonary fibrosis (167) as well as in bleomycin induced lung fibrosis (168, 169). Moreover, 
transient adenoviral vector-mediated expression of recombinant Mmp3 in rat lungs resulted 
in accumulation of myofibroblasts and fibrosis (169). It suggested that Mmp3 may have 





Collagen cross linking is another important structural modification that can prevent ECM 
degradation in fibrosis (170). Plod2, a collagen cross-linking enzyme, was increased in 
fibrogenesis induced by TGF-β1. Plod2 is responsible for the hydroxylation of lysine 
residues in collagen telopeptides and is essential for collagen pyridinoline cross-link 
formation (171, 172). The increase in pyridinoline cross-links leads to irreversible 
accumulation of collagen and difficulty of collagen degradation (170, 173). It is interesting 
to find out whether Plod2 could be targeted as a viable anti-fibrotic strategy.  
Ctgf, also known as Ccn2, a member of the CCN family, is regarded a major pro-fibrotic 
molecule, acting downstream of TGF-β1 and resulting in ECM accumulation and fibrosis. 
As an established fibrogenic mediator, Ctgf (Ccn2) is considered a therapeutic target of renal 
fibrosis (174-176). In contrast to pro-fibrotic Ctgf (Ccn2), two other CCN family members, 
Cyr61 (Ccn1) and Nov (Ccn3) appear to have anti-fibrotic activities, although through 
distinct mechanisms. Overexpression of Cyr61 (Ccn1) triggers cellular senescence, which 
contributes to wound healing (177) and tissue repair (178), where senescent cells can 
increase expression of ECM-degrading enzymes such as MMPs (179) and downregulation of 
ECM components such as collagen (180). In addition, Kim et al. (178) reported that Cyr61 
accumulated in livers of patients with cirrhosis as well as murine models of hepatic injury. 
Cyr61 acts as a key regulator that triggers cellular senescence through reactive oxygen 
species-dependent activation of the p53- and p16INK4/pRb pathway in activated hepatic 
stellate cells and portal fibroblasts, thereby limiting fibrogenesis and promoting regression of 
liver fibrosis induced by carbon tetrachloride intoxication and bile duct ligation. Further, tail 
vein delivery of purified Cyr61 protein in mice with established fibrosis accelerates fibrosis 
regression. These findings suggest that activation of the Cyr61-induced senescence pathway 
may hold therapeutic promise. Furthermore, Nov (Ccn3) acts as a negative regulator of Ctgf 
(Ccn2) in in-vitro (181) and in-vivo models (182) with the capacity to limit ECM 
accumulation and ameliorate fibrosis. Except Ctgf (Ccn2) inhibitors, clinical trials have not 
been carried out on selectively regulating other CCN proteins, it will be interesting to 
investigate the full range of CCN members as multiple therapeutic targets in the future (183).  
Tsku (Tsukushi), a member of the secreted small leucine-rich repeat proteoglycan (SLRP) 
family, interact with signalling molecules such as BMP (184), Wnt (185) and TGF-β1 (186). 
In particular, Tsku can enhance macrophage activation (187), whereas macrophages are 
critically involved in pro- and anti-fibrotic procedures (188). Tsku also inhibited 
myofibroblast differentiation by competing with endogenous TGF-β1 (187, 189). Therefore, 
Tsku may play dual functions in TGF-β1-induced fibrosis and its role as a target for anti-






5.7.5. TGF-β1 induced chemokines Ccl2 and Ccl7 
Notably, two chemokines Ccl2 (MCP-1) and Ccl7 (MCP-3) were significantly up-regulated 
by TGF-β1. Many studies have emphasised that fibrosis is tightly linked with inflammation 
and chemokines mediate tissue fibrosis of many different organs (190). Especially Ccl2, as a 
major promoter of inflammation, has been highlighted in renal fibrosis in animal models of 
UUO (191) and diabetic nephropathy (192). A mouse model of UUO indicated that Ccl2, 
through its cognate receptor, Ccr2, is responsible for progression of renal fibrosis and that 
inhibition of Ccl2/Ccr2 signalling may serve a beneficial therapeutic application for renal 
fibrosis (191). Evidence from animal models of diabetes also suggested that Ccl2 can 
directly and indirectly promote renal fibrosis. Ccl2-deficient diabetic kidneys showed that a 
lack of Ccl2 reduces accumulation of interstitial myofibroblasts and deposition of glomerular 
and interstitial collagen type IV (192). In addition, therapeutic blockade of Ccl2 in type 1 
diabetic mice reduced glomerular deposition of TGF-β1 and collagen IV (193). Notably, in 
each of these studies, a deficiency or blockade of Ccl2 was associated with a marked decline 
in the number of kidney macrophages, suggesting that Ccl2-mediated macrophage 
accumulation and activation promotes fibrosis in diabetic nephropathy. Systematic reviews 
of the literature have identified Ccl2, as well as TGF-β and Mmp2, as promising biomarkers 
with diagnostic and prognostic potential in patients with renal disease (194, 195).  
Ccl7 was overexpressed in dermal fibroblasts in systemic sclerosis and suggested that it may 
have pro-fibrotic effects (196). Subsequent study showed that Ccl7-induced collagen type I 
secretion is partially mediated by Smad3-dependent signalling, meanwhile, Ccl7 gene 
expression was stimulated by recombinant TGF-β1. Comparison of downstream signalling 
that regulates collagen gene activation by both cytokines confirmed the central role 
of MAPK pathway activation in mediating the effects of both factors (197). A mouse model 
of UUO indicated the role of Ccl7 in renal TIF differs depending on the stage of the 
pathology. In early stages (0-8 days), Ccl7 deficient (Ccl7-KO) mice displayed attenuated 
TIF potentially involving two mechanisms: an early (0-3 days) decrease of inflammatory cell 
infiltration followed (3-8 days) by a decrease in tubular ECM production independent of 
inflammation. In contrast, during later stages of obstruction (10-14 days), Ccl7-KO mice 
displayed increased TIF which was again associated with reduced inflammation (198). 
Taken together, targeting chemokines Ccl2/7 or related pathways may be an alternative 









This project has successfully established a proteomic view on an in-vitro model of TGF-β1-
induced fibrogenesis in NRK-49F cells. Analysis of data on cell lysates and conditioned 
media has led to complementary insights into TGF-b1-induced fibrosis and related 
biological mechanisms and contexts (Fig. 5.19). 
• It was characterised with increased ribosomal proteins and reduced proteins involved in 
multiple metabolic pathways. The dysregulated pathways were linked by Impdh2, a 
druggable target (Fig. 5.7).  
• It is characterised by most robustly induced Enpp1 and supressed Aldh3a1, although 
their roles in renal fibrosis are little known (Fig. 5.8).  
• It is characterised by most significantly repressed expression of catalase, a very 
important enzyme in protecting the cell from oxidative damage by reactive oxygen 
species (Fig. 5.8). 
• It was mediated by dysregulation of key matrix degradation regulators (PAI-1 and 
Mmp3), signalling mediators (Cyr61/Ccn1, Ctgf/Ccn2, Nov/Ccn3 and Tsku) and a 
collagen crosslinker (Plod2), and was inherently coupled with inflammation mediated by 
chemokines Ccl2 and Ccl7 (Fig. 5.16). 
 
 
Fig. 5.19. Possible mechanisms and potential therapeutic targets of TGF-β1-induced 
fibrosis in NRK-49F cells. TGF-β1-induced fibrosis is characterized by dysregulation of 
key matrix degradation regulators (PAI-1↑ and Mmp3 ↓), signalling mediators (Cyr61/Ccn1 
↑, Ctgf/Ccn2 ↑, Nov/Ccn3 ↓ and Tsku ↑) and a collagen crosslinker (Plod2 ↑), and is coupled 
with inflammation mediated by chemokines (Ccl2 ↑ and Ccl7 ↑). Induced and repressed 



































Chapter 6: Comparative proteomic analysis of the fibrotic effects of 
SRM, baicalein and IN1130  
 
In chapter 4, anti-fibrotic activities of two SR extracts (SRA and SRM) and five SR derived-
flavonoids commonly used for SR quality control (baicalin, baicalein, wogonoside, wogogin 
and oroxylin-A) were examined by quantitative analysis of total collagen and fibrogenic 
molecular markers. SRM, which contained 8-fold more flavonoids than SRA (Table 4.1), 
had 4-fold higher anti-fibrotic activities (Fig. 4.5). Among the five SR flavonoids, baicalein 
showed the highest anti-fibrotic activity, with little toxicity (Fig. 4.9). Accordingly, SRM 
and baicalein were selected for further proteomic analysis of their mechanisms of action, in 
parallel with proteomic studies of TGF-β1-induced in-vitro model of fibrogenesis (Chapter 
5). IN1130 was also studied, both as a positive control for anti-fibrotic activities and as an 
inhibitor of Alk5, the TGF-β type I recerptor.  
 
6.1. Experimental design and workflow 
To explore the anti-fibrotic mechanisms of SRM, baicalein and IN1130, NRK-49F cells 
were treated with or without 5 ng/mL TGF-β1, in the presence of 5 ng/mL TGF-β1 plus 40 
μg/mL SRM, 80 μg/mL SRM, 40 μM baicalein, 80 μM baicalein and 1 μM IN1130, (Fig. 
6.1). The cell lysates and conditioned media were harvested after 48 h treatment. In order to 
verify successful biological and pharmacological experiments, collagen contents in cell 
lysates and conditioned media were measured by hydroxyproline assay and soluble collagen 
assay, respectively, as described in Section 2.10 and 2.11. As shown in Fig. 6.1B, TGF-β1 
significantly increased total collagen content in cell lysates, which was significantly 
repressed by both concentrations of SRM and baicalein, as well as 1 μM IN1130. TGF-β1-
induced soluble collagen accumulation in conditioned media was significantly reduced by 80 
μM baicalein and IN1130, and there were decreasing trends in 80 μg/mL SRM and 40 μM 
baicalein groups (Fig. 6.1C). Cell lysates and conditioned media were then trypsinised, 








Fig. 6.1. Experimental design, workflow and establishment of TGF-β1-induced in-vitro 
model of fibrogenesis in NRK-49F cells and effects of anti-fibrotic drugs. (A) 
Experimental design and proteomic workflow. Cells were cultured in absence and presence 
of 5 ng/mL TGF-β1, and in the presence of 5 ng/mL TGF-β1 plus 40 μg/mL, 80 μg/mL 
SRM, 40 μM, 80 μM baicalein or 1 μM IN1130 for 48 h. Both cell lysates and conditioned 
media were harvested for hydroxyproline assay (B), soluble collagen assay (C), proteomic 
analysis and ELISA. Data represent mean ± SEM of 4 independent cell culture studies. 
Statistical analysis was performed on transformed data using repeated measures ANOVA. 
ψψψ p<0.001 vs control group, * p<0.05, ** p<0.01, *** p<0.001 vs TGF-β1 group. The 













































































































































6.2. Results on cell lysates 
6.2.1. Proteomic analysis and data interpretation  
Fig. 6.2 shows the numbers of proteins significantly regulated by different treatments, in 
comparison with TGF-β1 alone group. In total, 72 and 68 proteins were significantly 
regulated by 40 μg/mL and 80 μg/mL SRM, respectively, with 31 proteins regulated by both 
concentrations (Fig. 6.2A); 122 and 304 proteins were significantly regulated by 40 μM and 
80 μM baicalein, respectively, with 94 shared by two groups (Fig. 6.2B); of the 297 proteins 
significantly regulated by IN1130, 155 proteins were only regulated by IN1130, with the rest 
also regulated by SRM or baicalein (Fig. 6.2C).  
 
 
Fig. 6.2. Venn diagram analysis of cell-lysate proteins regulated by SRM, baicalein and 
IN1130 in TGF-β1-induced in-vitro model of fibrosis. Venn diagrams show numbers of 
proteins significantly regulated by (A) 40 and 80 μg/mL SRM, (B) 40 and 80 μM baicalein, 
and (C) 1 μM IN1130 and either concentration of SRM or baicalein. (TGF-β1 plus either 
drug vs TGF-β1 alone, p<0.05). 
 
To identify the biological pathways regulated by SRM, baicalein and IN1130, proteins 
significantly changed in each group as suggested by proteomic analysis (Fig. 6.2) were 
analysed by KEGG pathway analysis. In total 49 significantly regulated pathways were 
enriched, as shown in Fig. 6.3A. Overlay of pathways regulated by SRM, baicalein and 
IN1130 is illustrated in Fig. 6.3B. Taken together, comparative pathway analysis of cell 
lysates indicated the following (green/red/blue fonts indicate up-/down-/dys-regulated 
proteins of given pathways, listed in order of p-value):  
• SRM, baicalein and IN1130 all regulated Ribosome (Table 6.1) and Focal adhesion 
pathways (Supplementary Table 2);  
• SRM and baicalein, but not IN1130, regulated the Lysosome pathway (Table 6.2);   
• SRM and IN1130, but not baicalein, regulated the Amoebiasis pathway 
(Supplementary Table 3); 
 40μM Baicalein   80μM Baicalein   40μg/mL SRM      80μg/mL SRM   
SRM   Baicalein   
IN1130 





• Baicalein and IN1130, but not SRM, regulated 13 pathways, including Drug 
metabolism- cytochrome P450, Histidine metabolism, Carbon metabolism, Metabolic 
pathways, Glycolysis/ Gluconeogenesis, Tyrosine metabolism, Glutathione 
metabolism, Metabolism of xenobiotics by cytochrome P450, Chemical 
carcinogenesis, Peroxisome, Biosynthesis of antibiotics, Valine, leucine and 
isoleucine degradation and Glyoxylate and dicarboxylate metabolism 
(Supplementary Table 4);   
• Five pathways were regulated by SRM only, including ECM-receptor interaction, 
Platelet activation, Protein digestion and absorption, PI3K-Akt signalling pathway 
and Tight junction (Supplementary Table 5);   
• Eightteen pathways were regulated by baicalein only, including Galactose 
metabolism, Fructose and mannose metabolism, Cardiac muscle contraction, Dilated 
cardiomyopathy, Hypertrophic cardiomyopathy (HCM), Adrenergic signaling in 
cardiomyocytes, Phenylalanine metabolism, Adherens junction, Alzheimer's disease, 
Parkinson's disease, Biosynthesis of amino acids, Citrate cycle (TCA cycle), 
Oxidative phosphorylation, Pentose and glucuronate interconversions, Porphyrin and 
chlorophyll metabolism, Huntington's disease, Arginine and proline metabolism and 
Folate biosynthesis (Supplementray Table 6); and 
• Nine pathways were regulated by IN1130 only, including Fatty acid degradation, 
Fatty acid metabolism, beta-Alanine metabolism, Colorectal cancer, Propanoate 
metabolism, Fatty acid elongation, Endometrial cancer, Lysine degradation and Prion 







Fig. 6.3. KEGG pathway analysis of cell-lysate proteomics significantly regulated by 
SRM, baicalein and IN1130. (A) KEGG analysis shows 49 pathways significantly 
regulated by SRM, baicalein and IN1130, among which the ribosome pathway shows the 
highest significance. (B) Venn diagram illustrates the similarities and differences of the 
pathways regulated by SRM, baicalein and IN1130.  
 
As shown in Fig. 6.3, the pathway most significantly regulated by all three drugs was the 
ribosome pathway. 9, 42 and 36 ribosomal proteins of the ribosome pathway were regulated 
by SRM, baicalein and IN1130, respectively. As shown in Fig. 6.4 and Table 6.1, the 9 
ribosomal proteins regulated by SRM were also regulated by both baicalein and IN1130, 































































including 3 small ribosomal subunits (Rps30, Rps23, Rps3) and 6 large ribosomal subunits 
(Rpl36a, Rpl35a, Rpl27a, Rplp0, Rpl35, Rpl32). Both baicalein and IN1130 suppressed 18 
ribosomal proteins, including 4 small ribosomal subunits (Rps10, Rps11, Rps14 and Rps24) 
and 14 large ribosomal subunits (Rpl6, Rpl7, Rpl10, Rpl13, Rpl13a, Rpl17, Rpl18, Rpl18a, 
Rpl21, Rpl22, Rpl23a, Rpl27, Rpl38 and Rplp1). In addition, 13 ribosomal proteins 
including 2 small ribosomal subunits (Rps2, Rps29), and 11 large ribosomal subunits (Rpl23, 
Rpl12, Rpl5, Rpl36, Rpl0a, Rpl26, Rpl3, Rpl34, Rpl7a, Rpl15 and Rplp2) were repressed by 
baicalein only. While Mrpl3 (39S ribosomal protein L3) and Rps27a were induced by 
baicalein. IN1130 suppressed 9 ribosomal proteins, including 6 small ribosomal subunits 
(Rps16, Rps8, Rps18, Rps26, Rps13 and Rpsa) and 3 large ribosomal subunits (Rpl37, 
Rpl30 and Rpl9).  
 
Fig. 6.4. Venn diagram analysis of ribosomal proteins regulated by SRM, baicalein and 
IN1130 (TGF-β1 plus either drug vs TGF-β1 alone, p<0.05).  
 
Table 6.1. SRM, baicalein and IN1130 all significantly regulated the proteomic profiling 
of the ribosome pathway. Shown are mean fold-changes of propteomic abundance versus 
TGF-β1 group, p<0.05, NS: not significantly regulated by drug(s).  










P62864 Rps30 0.48 1.00 0.76 0.67 0.70 0.71 0.52 
P18445 Rpl27a 0.65 1.00 0.80 0.79 0.74 0.42 0.69 
P83883 Rpl36a 0.51 1.00 0.70 0.74 0.75 0.46 0.62 
P04646 Rpl35a 0.58 1.00 0.70 0.79 0.78 0.50 0.62 
P62909 Rps3 0.66 1.00 0.75 0.80 NS 0.61 0.71 
P62912 Rpl32 0.70 1.00 0.76 NS 0.78 0.58 0.71 
P17078 Rpl35 0.67 1.00 0.81 NS NS 0.57 0.77 
P19945 Rplp0 0.67 1.00 0.80 NS NS 0.74 0.71 
P62268 Rps23 0.53 1.00 NS 0.69 NS 0.78 0.60 
P24049 Rpl17 0.69 1.00 NS NS 0.77 0.64 0.73 
P19944 Rplp1 0.82 1.00 NS NS 0.77 0.86 0.77 






P62718 Rpl18a 0.70 1.00 NS NS 0.78 0.67 0.79 
P61354 Rpl27 0.69 1.00 NS NS 0.78 0.66 0.71 
P20280 Rpl21 0.79 1.00 NS NS 0.79 0.68 0.79 
P41123 Rpl13 0.77 1.00 NS NS 0.79 - 0.76 
P63174 Rpl38 0.76 1.00 NS NS 0.80 0.75 0.78 
Q6PDV7 Rpl10 0.77 1.00 NS NS 0.80 0.67 0.80 
P12001 Rpl18 0.74 1.00 NS NS 0.80 0.78 0.75 
P62752 Rpl23a 0.64 1.00 NS NS 0.80 0.65 0.73 
P35427 Rpl13a 0.75 1.00 NS NS 0.81 0.77 NS 
P05426 Rpl7 0.77 1.00 NS NS NS 0.70 0.79 
P63326 Rps10 0.67 1.00 NS NS NS 0.72 0.71 
P47198 Rpl22 0.73 1.00 NS NS NS 0.72 0.75 
P21533 Rpl6 0.75 1.00 NS NS NS 0.75 0.78 
P62850 Rps24 0.62 1.00 NS NS NS 0.76 0.73 
P13471 Rps14 0.68 1.00 NS NS NS 0.76 0.69 
P62282 Rps11 0.68 1.00 NS NS NS 0.78 0.74 
P23358 Rpl12 0.78 1.00 NS NS 0.76 0.73 NS 
P11250 Rpl34 0.79 1.00 NS NS 0.77 0.66 NS 
P62425 Rpl7a 0.79 1.00 NS NS 0.78 0.76 NS 
P62275 Rps29 0.75 1.00 NS NS 0.78 NS NS 
P62832 Rpl23 0.76 1.00 NS NS 0.80 0.68 NS 
P62907 Rpl10a 0.79 1.00 NS NS 0.80 0.76 NS 
P21531 Rpl3 0.79 1.00 NS NS 0.80 0.68 NS 
P39032 Rpl36 0.75 1.00 NS NS NS 0.66 NS 
P61314 Rpl15 0.77 1.00 NS NS NS 0.72 NS 
P12749 Rpl26 0.75 1.00 NS NS NS 0.75 NS 
P02401 Rplp2 0.77 1.00 NS NS NS 0.76 NS 
P27952 Rps2 0.75 1.00 NS NS NS 0.76 NS 
P09895 Rpl5 0.76 1.00 NS NS NS 0.78 NS 
P18665 Mrpl3 1.19 1.00 NS NS NS 1.35 NS 
P62982 Rps27a 0.96 1.00 NS NS NS 1.36 NS 
P61928 Rpl37 0.64 1.00 NS NS NS NS 0.68 
P62243 Rps8 0.76 1.00 NS NS NS NS 0.75 
P62856 Rps26 0.78 1.00 NS NS NS NS 0.77 
P62278 Rps13 0.73 1.00 NS NS NS NS 0.78 
P62890 Rpl30 0.79 1.00 NS NS NS NS 0.78 
P62271 Rps18 0.75 1.00 NS NS NS NS 0.78 
P62250 Rps16 0.71 1.00 NS NS NS NS 0.78 
P38983 Rpsa 0.70 1.00 NS NS NS NS 0.80 





Comparative KEGG pathway analysis of cell lysates indicated that 40, 80 μg/mL SRM and 
80 μM baicalein significantly regulated the proteins enriched in the lysosome pathway (Fig. 
6.3). As shown in Table 6.2, Dnase2 was induced by SRM at both concentrations; both 40 
μg/mL SRM and 80 μM baicalein suppressed Ctsb and induced Aga; Ppt1 and Ctsd were 
induced by 80 μg/mL SRM and 80 μM baicalein; only 40 μg/mL SRM repressed Lamp1 and 
induced Arsb; Ctsl was induced by 80 μg/mL SRM only; only 80 μM baicalein suppressed 
Acp2 and Naga and induced Gusb and Atp6v0a1.  
 
Table 6.2. SRM and baicalein, but not IN1130, significantly regulated proteins involved 
in the lysosome pathway. Shown here are mean fold changes of proteins expression versus 
TGF-β1 group, p<0.05, " NS ": not significantly regulated by drug(s).  
Accession Protein Control TGF-β1 
TGF-β1 
40 μg/mL SRM 80 μg/mL SRM 80 μM Baicalein 
P14562 Lamp1 0.63 1.00 0.64 NS NS 
P00787 Ctsb 0.82 1.00 0.74 NS 0.65 
P50430 Arsb 1.23 1.00 1.24 NS NS 
Q9QZK8 Dnase2 1.18 1.00 1.32 1.49 NS 
P30919 Aga 1.90 1.00 1.71 NS 1.86 
P07154 Ctsl 1.59 1.00 NS 1.36 NS 
P45479 Ppt1 1.24 1.00 NS 1.58 1.44 
P24268 Ctsd 1.05 1.00 NS 1.65 1.63 
P20611 Acp2 1.07 1.00 NS NS 0.73 
Q66H12 Naga 1.13 1.00 NS NS 0.77 
P06760 Gusb 1.54 1.00 NS NS 1.28 
P25286 Atp6v0a1 1.17 1.00 NS NS 1.46 
 
 
The differential expression patterns of proteins in response to treatment conditions were 
shown as volcano plots. As shown in Fig. 6.5, Enpp1, the protein most significantly induced 
by TGF-β1, was also mostly suppressed by SRM, baicalein and IN1130; Aldh3a1, the 
protein most repressed by TGF-β1, was also dramatically reversed by IN1130 and 80 μg/mL 
SRM. TGF-β1-induced Sqstm1 was further induced by 80 μM baicalein. Ccdc80, one of the 
proteins most induced by SRM, was also induced by 80 μM baicalein. Tfrc was up-regulated 












Fig. 6.5. Volcano plots of cell-lysate proteins regulated by SRM, baicalien and IN1130 in 
TGF-β1-induced in-vitro model of fibrosis. Proteins significantly regulated by (A) TGF-β1 
(TGF-β1 vs control) and (B-F) 1μM IN1130, 40 μg/mL SRM, 80 μg/mL SRM, 40 μM 
baicalein and 80 μM baicalein, in the presence of TGF-β1.  X-axes show fold-change values 
and Y-axes display the -Log10 (p-value, according to t-tests). In each plot, proteins above 
the horizontal dashed line were differentially up-regulated or down-regulated by respective 
treatments. Proteins subjected to ELISA validation are highlighted either in green fonts 
(induced by TGF-β1) or red fonts (repressed by TGF-β1) or blue fonts (no significant 
difference between TGF-β1 and control groups).  
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6.2.2. ELISA validation 
Five proteins, including Enpp1, Aldh3a1, Ccdc80, Tfrc and Sqstm1 were selected for ELISA 
validation primarily on the basis of large fold-changes induced by different treatments. In 
addition, Impdh2 was also chosen as a candidate protein because it connected two clusters of 
TGF-β1-regulted proteins as shown in STRING map (Fig. 5.7A). The changes in abundance 
of proteins as suggested by ANOVA analysis of proteomics data are shown in Fig. 6.6 A-F, 
with corresponding ELISA results shown in Fig. 6.6 G-L. The expression patterns of Enpp1, 
Aldh3a1, Impdh2 and Trfc were largely validated by ELISA, consistent with proteomic data. 
Nevertheless, proteomic data showed that Enpp1 was suppressed by baicalein dose 
dependently (Fig. 6.6A), but this dose-dependency was not confirmed by ELISA (Fig. 6.6G). 
According to proteomic data, Ccdc80 was significantly suppressed by TGF-β1 and induced 
by 80 μg/mL SRM and 80 μM baicalein (Fig. 6.6D), while Ccdc80 regulation by TGF-β1 
was not significant according to ELISA. Besides, Ccdc80 was induced by both 
concentrations of SRM and baicalein but the dose-dependency observed in proteomic data 
were not confirmed by ELISA (Fig. 6.6J). Proteomic analysis showed that Sqstm1 was 
significantly induced by TGF-β1 and further induced by both concentrations of baicalein 
(Fig. 6.6F). ELISA confirmed that TGF-β1 significantly induced Sqstm1 and this was 









Fig. 6.6. Comparison of proteomoic analysis and ELISA validation of selected cell-
lysate proteins regulated by SRM, baicalein and/or IN1130. Shown are relative 
abundance in proteomic data (left) and ELISA data (right) of Enpp1 (A, G), Aldh3a1 (B, H), 
Impdh2 (C, I), Ccdc80 (D, J), Tfrc (E, K) and Sqstm1 (F, L). n=4, ψ p<0.05, ψψ p< 0.01, 
ψψψ p< 0.001 vs control group. *p<0.05, **p< 0.01, ***p<0.001 vs TGF-β1 group. ϕ 











































































































































































































































































6.3. Results on conditioned media 
6.3.1. Proteomic analysis and data interpretation  
Proteomic analysis indicated that 95 and 138 proteins were significantly regulated by 40 and 
80 μg/mL SRM, respectively. As shown in Fig. 6.7, 79 of these proteins were regulated at 
both concentrations; 86 and 161 proteins were significantly regulated by 40 and 80 μM 
baicalein, respectively, with 59 regulated by both concentrations; among 46 IN1130-
regulated proteins, 11 were regulated by both SRM and baicalein, 16 were uniquely 
regulated by IN1130, 2 and 17 were regulated by at least one concentration of baicalein and 
SRM, respectively.  
 
 
Fig. 6.7. Venn diagram analysis of secreted proteins significantly regulated by SRM, 
baicalein and IN1130. Proteins regulated by (A) 40 and 80 μg/mL SRM, (B) 40 and 80 μM 
baicalein, and (C) 1 μM IN1130 and at least one concentration of SRM or baicalein. (TGF-
β1 plus either drug vs TGF-β1 alone, p<0.05). 
 
KEGG pathway analysis of secretomic data was performed to identify biological pathways 
regulated by SRM, baicalein and IN1130. Results were as illustrated in Fig. 6.8:  
• Treatment by both concentrations of SRM and the higher concentration of baicalein, 
but not 40 μM baicalein or 1 μM IN1130, significantly regulated proteins of the 
Ribosome pathway in conditioned media in TGF-β1-induced in-vitro model of 
fibrosis (Table 6.3); 
• Only baicalein regulated the proteins enriched in other 10 pathways (Table 6.4), 
including: 
o Both concentrations of baicalein increased proteins increased proteins enriched 
in the Lysome and Tyosine metabolism pathways and complexly regulated the 
ECM-receptor interaction pathway; 
o Lower concentration of baicalein selectively up- and down-regulated of proteins 
enriched in Galactose metabolism and Amoebiasis pathway, respectively; 
o Higher concentration of baicalein selectively up-regulated proteins enriched in 
Proteasome, Glycolysis / Gluconeogenesis and Insulin signalling pathway; and 
40μg/mL SRM     80μg/mL SRM    40μM Baicalein   80μM Baicalein   
SRM   Baicalein   
IN1130 





dysregulated proteins enriched in Biosynthesis of antibiotics and Lysine 
degradation pathways. 
• No KEGG pathway was enriched among IN1130-regulated proteins; 
 
 
Fig. 6.8. KEGG pathway analysis of proteins in conditioned media significantly 
regulated by SRM and baicalein in TGF-β1-induced in-vitro model of fibrosis. sKEGG 
analysis shows 11 pathways significantly regulated by SRM and baicalein, among which the 




Fig. 6.9. Venn diagram analysis of secreted proteins involved in the ribosome pathway, 
which were regulated by SRM and/or baicalein. (TGF-β1 plus either drug vs TGF-β1 
alone, p<0.05). 
 
Comparative analyses of conditioned media indicated that both concentrations of SRM and 
80 μM baicalein, but not IN1130, significantly regulated the ribosome pathway. Of note, 44, 
52, and 27 ribosomal proteins were respectively regulated by 40 μg/mL SRM, 80 μg/mL 
SRM and 80 μM baicalein (Fig. 6.9). As shown in Table 6.3, both concentrations of SRM 
and 80 μM baicalein increased 21 small ribosomal subunits (Rps2, Rps3, Rps3a, Rps4x, 
Rps5, Rps6, Rps7, Rps8, Rps9, Rps13, Rps15, Rps16, Rps17, Rps18, Rps19, Rps23, Rps24, 
Rps25, Rps26, Rps30 and Rpsa) and 3 large ribosomal subunits (Rpl26, Rpl31, Rpl37); both 
concentrations of SRM increased 20 large ribosomal subunits (Rpl3, Rpl4, Rpl7a, Rpl8, 
Rpl10, Rpl11, Rpl13, Rpl13a, Rpl14, Rpl15, Rpl17, Rpl18, Rpl18a, Rpl19, Rpl29, Rpl30, 
Rpl32, Rpl34, Rpl36a, Rplp1); only 80 μg/mL SRM increased 3 small ribosomal subunits 
















Note: There is no pathway indicated in IN1130 group.






(Rps11, Rps15a and Rps20) and 5 large ribosomal subunits (Rpl6, Rpl24, Rpl27, Rpl28 and 
Rpl35a); only 80 μM baicalein increased one small ribosomal subunit Rps14 and slightly 
suppressed two large ribosomal subunits (Rpl38 and Rpl9).  
 
Table 6.3. Both concentrations of SRM and 80 μM baicalein regulated proteins in 
conditioned media enriched in the ribosome pathway. Shown here are mean fold changes 
of proteins expression versus TGF-β1 group, p<0.05, " NS ": not significantly regulated by 
drug(s). 
Accession Protein Control TGF-β1 
TGF-β1 
40 μg/mL SRM 80 μg/mL SRM 80 μM Baicalein 
P62909 Rps3 0.90 1.00 1.56 1.78 1.60 
P61928 Rpl37 0.94 1.00 1.95 1.81 1.86 
P38983 Rpsa 0.96 1.00 1.87 1.87 1.66 
P62864 Rps30 0.98 1.00 1.41 1.79 1.55 
P62083 Rps7 1.02 1.00 2.06 2.84 2.00 
P29314 Rps9 1.03 1.00 1.74 1.98 1.80 
P62268 Rps23 1.04 1.00 1.71 2.10 1.87 
P62755 Rps6 1.04 1.00 1.82 2.14 1.89 
P27952 Rps2 1.07 1.00 2.07 2.69 2.33 
P62856 Rps26 1.09 1.00 1.73 2.17 2.09 
P62250 Rps16 1.09 1.00 1.78 2.14 1.91 
P24050 Rps5 1.11 1.00 2.10 2.44 2.11 
P04644 Rps17 1.12 1.00 2.14 2.74 2.20 
P62243 Rps8 1.15 1.00 2.10 2.32 1.97 
P17074 Rps19 1.16 1.00 1.60 2.10 1.82 
P62902 Rpl31 1.21 1.00 2.16 3.23 2.15 
P12749 Rpl26 1.21 1.00 2.00 2.38 1.86 
P62853 Rps25 1.23 1.00 2.18 2.80 2.49 
P49242 Rps3a 1.27 1.00 2.21 2.79 2.70 
P62845 Rps15 1.37 1.00 2.94 3.29 3.54 
P62271 Rps18 1.38 1.00 1.99 2.54 2.22 
P62850 Rps24 1.40 1.00 3.25 4.07 3.59 
P62703 Rps4x 1.45 1.00 2.77 3.46 3.16 
P62278 Rps13 1.65 1.00 3.40 4.46 3.70 
P61314 Rpl15 0.76 1.00 1.66 2.16 NS 
P84100 Rpl19 0.76 1.00 1.73 2.08 NS 
Q6PDV7 Rpl10 0.83 1.00 1.48 2.05 NS 
P62890 Rpl30 0.83 1.00 1.67 2.38 NS 
P62425 Rpl7a 0.89 1.00 1.58 2.20 NS 
P24049 Rpl17 0.89 1.00 1.68 2.00 NS 





P62718 Rpl18a 0.90 1.00 1.71 2.20 NS 
P12001 Rpl18 0.91 1.00 1.67 2.28 NS 
P50878 Rpl4 0.93 1.00 1.73 2.20 NS 
Q63507 Rpl14 0.94 1.00 1.81 2.37 NS 
P21531 Rpl3 0.95 1.00 1.70 1.95 NS 
P19944 Rplp1 0.95 1.00 1.36 1.34 NS 
P35427 Rpl13a 0.96 1.00 2.09 2.58 NS 
P11250 Rpl34 0.97 1.00 1.64 2.32 NS 
P62912 Rpl32 0.97 1.00 1.81 2.30 NS 
P62914 Rpl11 0.98 1.00 1.61 2.02 NS 
P83883 Rpl36a 1.04 1.00 1.56 1.45 NS 
P25886 Rpl29 1.05 1.00 1.64 2.04 NS 
P41123 Rpl13 1.33 1.00 1.57 1.94 NS 
P04646 Rpl35a 0.82 1.00 NS 1.58 NS 
P83732 Rpl24 0.86 1.00 NS 1.82 NS 
P21533 Rpl6 0.86 1.00 NS 1.79 NS 
P62246 Rps15a 0.89 1.00 NS 1.75 NS 
P60868 Rps20 0.93 1.00 NS 1.74 NS 
P61354 Rpl27 0.94 1.00 NS 1.64 NS 
P62282 Rps11 1.09 1.00 NS 2.12 NS 
P17702 Rpl28 1.24 1.00 NS 1.91 NS 
P63174 Rpl38 0.88 1.00 NS NS 0.47 
P17077 Rpl9 0.95 1.00 NS NS 0.60 
P13471 Rps14 1.28 1.00 NS NS 2.35 
 
 
Table 6.4. Baicalein significantly regulated proteins in conditioned media enriched in 10 
KEGG pathways. Shown here are mean fold-changes of protein abundance in conditioned 
media versus TGF-β1 group, p<0.05, " NS ": not significantly regulated by 40 μM or 80 μM 
Baicalein. 
Accession Protein Control TGF-β1 
TGF-β1 
40 μM Baicalein 80 μM Baicalein 
Lysosome 
O54715 Atp6ap1 1.02 1.00 1.44 1.64 
Q6P7A9 Gaa 1.27 1.00 1.53 1.61 
P30919 Aga 1.35 1.00 1.97 2.35 
Q9R0J8 Lgmn 1.35 1.00 1.80 1.98 
P24268 Ctsd 1.36 1.00 1.92 2.28 
P10960 Psap 1.36 1.00 2.10 2.72 
P00787 Ctsb 1.65 1.00 2.11 2.42 





P08081 Clta 0.99 1.00 NS 0.60 
P08082 Cltb 1.00 1.00 NS 0.56 
ECM-receptor interaction 
Q9JI03 Col5a1 0.64 1.00 0.48 0.33 
P02466 Col1a2 0.71 1.00 0.36 0.24 
P02454 Col1a1 0.95 1.00 0.55 0.60 
P04937 Fn1 0.96 1.00 0.40 0.29 
P34901 Sdc4 1.13 1.00 NS 3.02 
Tyrosine metabolism 
P30904 Mif 1.28 1.00 1.59 1.94 
P25093 Fah 1.36 1.00 1.47 1.51 
P11883 Aldh3a1 1.68 1.00 1.67 NS 
P12711 Adh5 0.95 1.00 NS 1.82 
P22734 Comt 1.05 1.00 NS 1.56 
Proteasome 
P17220 Psma2 1.06 1.00 NS 1.64 
P62193 Psmc1 1.09 1.00 NS 1.44 
Q63347 Psmc2 1.13 1.00 NS 1.64 
Q4KM35 Psmb10 1.22 1.00 NS 1.61 
P28077 Psmb9 1.24 1.00 NS 1.54 
Glycolysis / Gluconeogenesis 
P12711 Adh5 0.95 1.00 NS 1.82 
P04797 Gapdh 0.96 1.00 NS 2.32 
Q9JLJ3 Aldh9a1 1.03 1.00 NS 1.77 
P11884 Aldh2 1.17 1.00 NS 1.64 
P47860 Pfkp 1.51 1.00 NS 1.66 
Biosynthesis of antibiotics 
P39069 Ak1 0.79 1.00 NS 0.67 
P12711 Adh5 0.95 1.00 NS 1.48 
P04797 Gapdh 0.96 1.00 NS 1.82 
Q9JLJ3 Aldh9a1 1.03 1.00 NS 2.32 
Q8VHF5 Cs 1.05 1.00 NS 1.77 
P11884 Aldh2 1.17 1.00 NS 1.54 
P04762 Cat 1.22 1.00 NS 1.64 
P47860 Pfkp 1.51 1.00 NS 1.66 
Lysine degradation 
Q811A3 Plod2 0.55 1.00 NS 1.59 
Q9JLJ3 Aldh9a1 1.03 1.00 NS 0.75 
P11884 Aldh2 1.17 1.00 NS 1.77 
Q63321 Plod1 1.24 1.00 NS 1.66 
Insulin signalling pathway 





P63074 Eif4e 0.99 1.00 NS 1.57 
P62755 Rps6 1.04 1.00 NS 1.89 
P12369 Prkar2b 1.10 1.00 NS 1.79 
P62161 Calm1 1.36 1.00 NS 2.30 
P01322 Ins1 1.91 1.00 NS 1.53 
Galactose metabolism     
Q5RJP0 Akr1b7 0.99 1.00 1.67 NS 
Q6P7A9 Gaa 1.27 1.00 1.53 NS 
P47860 Pfkp 1.51 1.00 2.17 NS 
Amoebiasis 
P02466 Col1a2 0.71 1.00 0.36 NS 
P02454 Col1a1 0.95 1.00 0.55 NS 
Q9JI03 Col5a1 0.64 1.00 0.48 NS 
P04937 Fn1 0.96 1.00 0.40 NS 
 
Volcano plots are used to illustrate the proteins in conditioned media regulated by SRM, 
baicalein and IN1130. As shown in Fig. 6.10 A&B, TGF-β1-regulated PAI-1, Ccl2, Ccl7, 
Tsku, Cyr61 and Nov were dramatically reversed by IN1130. This suggests that expression 
of these proteins may be Alk5-dependent, and further confirmation experiments are 
warranted. More proteins were increased than reduced in SRM groups, especially the 
ribosomal proteins such as Rps13, Rps15, Rps24, Rps4x. Csrp1 was mostly reduced by both 
concentrations of SRM (Fig. 6.10 C&D). Baicalein most repressed the expression of PAI-1, 
Ccl2 and Ccl7, which among the most induced by TGF-β1. TGF-β1-repressed Mmp3, 
however, was not reversed by IN1130 or SRM, but was reversed by both concentrations of 
baicalein, suggesting TGF-β1 and baicalein regulation of Mmp3 was Alk5-independent (Fig. 







Fig. 6.10. Volcano-plot analysis of SRM, baicalien and IN1130 effects on proteomics of 
conditioned media in TGF-β1-induced in-vitro model of fibrosis. Proteins significantly 
regulated by (A) TGF-β1 (TGF-β1 vs control); (B-F) 1 μM IN1130, 40 μg/mL SRM, 80 
μg/mL SRM, 40 μM baicalein and 80 μM baicalein, in the presence of TGF-β1. In each plot, 
proteins above the horizontal dashed line were differentially increased or reduced by 
respective treatments. Proteins subjected to ELISA validation are highlighted either in green 
fonts (induced by TGF-β1) or red fonts (repressed by TGF-β1). 
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Fig. 6.11. Comparison of proteomic analysis and ELISA validation of selected proteins 
in conditioned media regulated by SRM, baicalein and IN1130. The relative abundance 
in proteomic data (left) and ELISA data (right) of PAI-1 (Ai, Aii), Ctgf (Bi, Bii), Plod2 (Ci, 
Cii), Ccl2 (Di, Dii), Ccl7 (Ei, Eii), Tsku (Fi, Fii), Cyr61 (Gi, Gii), Nov (Hi, Hii) and Mmp3 
(Ii, Iii). n=4, ψ p<0.05, ψψ p< 0.01, ψψψ p< 0.001 vs control group. *p<0.05, **p< 0.01, 
***p<0.001 vs TGF-β1 group. ϕ p<0.05, according to one-way ANOVA analysis. 
 
 
6.3.2. ELISA validation 
Based on fold-changes induced by TGF-β1 and the published literature on relevance to 
fibrosis, nine proteins in conditioned media, including PAI-1, Ctgf, Plod2, Ccl2, Ccl7, Tsku, 
Cyr61, Nov and Mmp3, were selected for validation by ELISA. The changes in abundance 
of proteins as suggested by proteomic analysis are shown in Fig. 6.11Ai-Ii, with 
corresponding ELISA results shown in Fig. 6.11Aii-Iii. The effects of TGF-β1 as well as 
antifibrotic SRM, baicalein and IN1130 on Plod2, Ccl7, Tsku, Cyr61 and Nov as suggested 
by LC-MS/MS-based protteomic data were fully validated by ELISA (Fig. 6.11C, E, F, G 


































































































































































dose dependently (Fig. 6.11Ai and Di), ELISA results only confirmed that they were 
suppressed by SRM but not in a dose-dependent manner (Fig. 6.11Aii and Dii). Similarly, 
baicalein were suggested to dose dependently suppressed Ctgf and Mmp3 (Fig. 6.11Bi and 
Ii), whereas ELISA data showed that they were suppressed by baicalein, but not dose- 


































6.4. Discussions  
6.4.1. Discussion on cell-lysate results 
Based on ELISA results, the effects of TGF-β1 and three drugs on cell-lysate proteins are 




Fig. 6.12. Effect of SRM, baicalein and IN1130 on proteins of interest in cell lysates of 
TGF-β1-induced fibrosis. TGF-β1-induced Enpp1 was reversed by SRM, baicalein and 
IN1130 (marked in red); Ccdc80 was induced by SRM & baicalein, but not IN1130 (marked 
in purple); Tfrc was only induced by baicalein (marked in green); TGF-β1-induced Impdh2 
& Sqstm1 and -repressed Aldh3a1 was only reversed by IN1130 (marked in blue). Arrow 
after protein names refer to induction (­) and suppression (¯).  
 
 
Enpp1 was most induced by TGF-β1 (Fig. 6.5A and Fig. 6.6A) and most supressed by SRM, 
baicalein and IN1130 (Fig. 6.5B-F and Fig. 6.6G), raising a possibility that all three anti-
fibrotic drugs may be anti-fibrotic by suppressing the induction of Enpp1 by TGF-β1. 
However, the precise role for Enpp1 in TGF-β1-induced fibrosis and inflammation remain 
unclear (Chapter 5, page 122) and how SRM, baicalein and IN1130 decrease the Enpp1 
also deserve further investigation.  
Ccdc80, also known as steroid-sensitive gene-1, DRO1 or URB, is a secreted protein that 
binds to ECM proteins and promotes cell adhesion (199). Ccdc80 was not significantly 
regulated by TGF-β1 but was induced by both SRM and bacalein, rather than IN1130 (Fig. 
6.6J). IN1130 acts as an established TGF-β type I receptor kinase (ALK5) inhibitor and 
suppresses renal fibrosis (200), suggesting SRM and baicalein may share ALK5-independent 
mechanisms. Brennan et al. reported that the gene expression of Ccdc80 in human renal 
SRM











epithelial cells were significantly up-regulated by TGF-β1 (201), however, the role of 
Ccdc80 in fibrosis and inflammation is little known.   
Tfrc was not significantly regulated by TGF-β1 but was only induced by baicalein (Fig. 
6.6K). Tfrc, a transmembrane glycoprotein that binds to iron-bound transferrin and mediates 
extracellular iron delivery into cells (202, 203). Tfrc is widely believed to be important for 
iron acquisition by all mammalian cells (204). Shpyleva et al. reported that non-alcoholic 
fatty liver disease-associated fibrogenesis was correlated with a marked increase in Tfrc 
expression (205). Soluble Tfrc in urine has been considered a potential biomarker for IgA 
nephropathy (IgAN) and Henoch-Schönlein purpura nephritis (HSPN) as significant higher 
urinary Tfrc was detected in IgAN and HSPN patients (206). Thus, whether baicalein-
induced Trfc can contribute to therapeutic deserve further studies. 
Akr1b7, also known as MVDP or Akr1b14, is a member of the Aldo-keto reductase 
superfamily (207), which is characterised by catalysing reduced nicotinamide adenine 
dinucleotide (phosphate) (NAD(P)H)-dependent oxido-reduction of carbonyl groups (208, 
209). The proteomic data indicated that Akr1b7 was induced by baicalein with fold 
change>2 (Fig. 6.5 E&F), but it was not subjected to ELISA validation in view that this 
protein is not conserved in human species. The rat Akr1b7 has 87% amino-acid sequence 
identity to the corresponding mouse Akr1b7 (210, 211). Akr1b1, another AKR1 subfamily 
member, is conserved in human (209) and was significantly induced by baicalein according 
to proteomic data. Lu et al. reported that the expression of Akr1b1 was decreased in cell 
culture-induced senescent human primary proximal tubule epithelial cells (212). Akr1b1 
variants have been shown to be associated with diabetic neuropathy and nephropathy (213). 
Thus, roles of Akr1b7 and Akr1b1 in mediating therapeutic effects may deserve further 
investifation.  
Aldh3a1 was mostly repressed by TGF-β1, and mostly reversed by IN1130 but not SRM or 
baicalein (Fig. 6.6H), suggesting that IN1130 may play anti-fibrotic role in reversing TGF-
β1-repressed Aldh3a1. As dicussed in Chapter 5 (page 122), the functions of Aldh3a1 in 
TGF-β1-induced fibrosis remain unclear and how IN1130 increase the Aldh3a1 also deserve 
further study.  
Impdh2 was induced by TGF-β1, and only reversed by IN1130 but not SRM or baicalein 
(Fig. 6.6I), suggesting that IN1130 may play anti-fibrotic role by repressing TGF-β1-
induced Impdh2. As discussed in Chapter 5 (page 95, 102-103), Impdh2 could be an anti-






TGF-β1-induced Sqstm1 was only suppressed by IN1130 in the present study, suggesting 
that their expression may be Alk5-dependent (Fig. 6.6L).  Sqstm1, also called p62, is a 
ubiquitinbinding scaffold protein, acting as an adapter protein in multiple signalling 
pathways (214, 215). Because its degradation is dependent on autophagy, accumulation of 
Sqstm1 has been used as a marker for inhibition of autophagy or defects in autophagic 
degradation (216, 217). Several studies have discussed the roles of autophagy in renal 
fibrosis (218-221). Livingston et al. recently reported that persistent activation of autophagy 
in kidney proximal tubules promotes renal interstitial fibrosis during UUO. The pro-fibrotic 
function of autophagy is related to the regulation on tubular cell death, interstitial 
inflammation, and the production of pro-fibrotic factors (221). In contrast, Ding et al. 
suggested an anti-fibrotic role of autophagy in kidneys by regulating the degradation of 
mature TGF-β1 (219). Given that the conflicting evidence aforementioned, it will be 
essential to examine in this particular in-vitro model that the role of Sqstm1 in autophagy 
and TGF-β1-induced fibrosis and whether IN1130 plays an anti-fibrotic role, at least in part, 
by repressing TGF-β1-induced Sqstm1.  
 
6.4.2. Discussion on condition-media results 
The possible roles of validated proteins in conditioned media are illustrated in Fig. 6.13.  
 
Fig. 6.13. Effects of TGF-β1, SRM, baicalein and IN1130 on proteins in conditioned 
media and their possible roles in fibrosis and inflammation. TGF-β1-induced PAI-1, Ctgf 
(Ccn2), Plod2, Ccl2 (MCP-1) and Ccl7 (MCP-3) were reversed by SRM, baicalein and 
IN1130 (marked in red); TGF-β1-induced Ccn1 (Cyr61) and Tsku were reversed by 
baicalein & IN1130, but not SRM (marked in purple); TGF-β1 repression of Ccn3 was only 
reversed by IN1130 (marked in blue); and TGF-β1 repression of Mmp3 was only reversed 































SRM, baicalein and IN1130 all suppressed TGF-β1-induced PAI-1, Plod2 and Ctgf (Fig. 
6.11Aii, Bii and Cii), suggesting that SRM, baicalein and IN1130 may share similar anti-
fibrotic mechanisms by regulating collagen synthesis, crosslinking and degradation in this 
in-vitro model of fibrosis. The balance of collagen synthesis and degradation is crucial to 
maintain the normal tissue structure (222). In renal fibrosis, collagen degradation does not 
keep pace with collagen synthesis, resulting in increased accumulation of collagens, which 
prevents the tissue repair and remodelling and leads to renal failure (46). The plasminogen 
activation system has an established role in degrading ECM components (165, 222, 223). 
PAI-1 is a major inhibitor of urokinase plasminogen activator (uPA) and tissue plasminogen 
activator (tPA), which cleave plasminogen into active plasmin (161, 162). The role of  PAI-1 
in kidney fibrosis has been well described (223, 224). PAI-1 is a critical element of the TGF-
β network which could be considered as a therapeutic option for fibrosis (165). Collagen 
cross-linking is another important structural modification that can prevent degradation in 
fibrosis (170). Pold2 acts as a collagen cross-linker (173) and is responsible for the 
hydroxylation of lysine residues in collagen telopeptides (172), although its role in fibrosis 
has been little studied. Ctgf (Ccn2), a downstream of TGF-β1 and an established fibrogenic 
mediator, were thought to account for extracellular matrix accumulation and renal fibrosis, 
and has been proposed an anti-fibrotic target (174-176). In the present study, SRM and 
baicalein, similar to IN1130, have shown promises to be developed further as antifibrotics, 
by repressing TGF-β1-induced PAI-1, Plod2 and Ctgf.  
SRM, baicalein and IN1130 suppressed TGF-β1-induced chemokines Ccl2 and Ccl7 (Fig. 
6.11Dii&Eii), suggesting that they may alleviate TGF-β1-induced inflammation in 
inflammatory fibrotic disorders. Indeed, Wang et al. found that baicalein inhibited Ccl2 
release and ECM accumulation and concluded that the anti-fibrotic mechanism of baicalein 
may involve its anti-inflammatory effects via inactivation of the NF-κB and MAPK signal 
pathways in UUO mice model (98). In addition, an increasing number of studies 
demonstrated that the anti-inflammatory effects of baicalein in renal fibrosis is associated 
with inhibition of EMT process, which is induced by TGF-β1 through activation of NF-κB in 
fibrotic kidney (207). The activated NF-κB mediated expression of inflammatory cytokines 
such as Ccl2, TNF-α and IL-1β (225, 226). Therefore, these findings indicate that 
suppression of inflammatory responses could contribute to the therapeutic of effects of 
baicalein, SRM and IN1130, and may play an anti-inflammatory role in renal fibrosis and 
could be considered as a therapeutic candidate against kidney diseases.  
Baicalein, similar to IN1130, suppressed TGF-β1-induced Tsku and Cyr61 (Fig. 6.11 
Fii&Gii). It suggested that the anti-fibrotic activity of baicalein may be associated with 





Chapter 5 (page 123), the functions of Tsku and Cyr61 in fibrosis remain to be fully 
established, thus the potential values of them as anti-fibrotic and/or anti-inflammatory targets 
and their roles in the therapeutic of baicalein deserve further investigation. 
Only baicalein reversed TGF-β1-suppressed Mmp3 (Fig. 6.11Iii), suggesting that anti-
fibrotic mechanism of baicalein may differ from both SRM and IN1130 by increasing Mmp3 
accumulation in conditioned media. MMPs has major roles in degrading ECM components 
(166, 224), indicating that Mmp3 may contribute to the pathogenesis of fibrosis. As 
discussed in Chapter 5 (page 122), current data on roles of Mmp3 in fibrosis and anti-
fibrotic therapies are limited. Thus, the roles of Mmp3 in the antifibrotic effect of baicalein 
deserve further study.  
Only IN1130 reversed TGF-β1-suppressed Nov (Fig. 6.11Hii). Given the reported anti-
fibrotic properties of Nov, this finding suggests that the anti-fibrotic property of IN1130 may 
be at least in part mediated by increasing Nov. Interestingly, although TGF-β1-induced PAI-
1, Plod2, Ctgf, Ccl2 and Ccl7, which were repressed by IN1130 and thus likely Alk5-
depedent, were also repressed by SRM and baicalein. While TGF-β1-induced Tsku and 
Cyr61 were repressed by both baicalein and IN1130, TGF-β1-repressed Nov was only 
repressed by IN1130, but not SRM and baicalein. It’s important to find out if IN1130-
reduced Nov was due to repression of Alk5, and if so, why baicalein and SRM failed to 
repress this but not other Alk5-dependent proteins.  
 
6.4.3. Discussion on integrated analysis of findings on cell-lysate and condition-media 
proteins  
In cell lysates, SRM, baicalein and IN1130 more or less reversed TGF-β1-induced ribosomal 
proteins. Increasing evidence suggests that eukaryotic 80S ribosome is a viable target for 
anti-cancer drugs (227) and alternative therapeutic treatment of cardiovascular diseases (228). 
Functions of ribosomal proteins in fibrosis and in effects of SRM, baicalein and IN1130 
remain largely unknown and deserve further investigation. The ribosomal protein S6 kinase 
(S6K) is a crucial effector of the mechanistic target of rapamycin (mTOR) signalling (229, 
230). mTORC1 activates downstream target S6K, whose first identified substrate was 
ribosomal protein S6 (Rps6), a component of the 40S ribosome (229). mTOR activation was 
demonstrated to increase phosphorylation of S6K in albumin-treated primary proximal 
tubular epithelial cells (231) and mesangial cells exposed to high glucose (232). In an in vivo 
model of aldosterone-induced tubulointerstitial fibrosis, western blot analysis for 
phosphorylated S6K and mTOR in kidney tissues revealed that high expression in fibrotic 





was activated in several in vitro and in vivo models of fibrosis, emphasising the importance 
to develop a greater understanding on the relevance of the mTORC-S6K pathway, and 
indeed ribosomal proteins, in kidney fibrosis. In present the study, the proteomic abundance 
of Rps6 in cell lysates was significantly increased in TGF-β1 group (Table 5.1), but was not 
further changed by either SRM, baicalein or IN1130 treatment; in contrast, the proteomic 
abundance of Rps6 in conditioned media was not affected by TGF-β1, but it was 
significantly increased in both 40 μM and 80 μM SRM groups, as well as in the 80 μM 
baicalein group (Table 6.3). These results need further validation by alternative methods. In 
view that Rps6 can be phosphorylated by S6K, it raises that questions whether other ribosoal 
problems could be modified post-translationally. This could mean that proteomic abundance 
could be due to changes in post-translational modifications, which change the visibility of 
the proteins by MS rather than by real changes of protein abundance.  
In addition, given that the ribosome is an intracellular organelle, the reduced proteins 
involved in the ribosome pathway in cell lysates may suggest that all the three drugs 
repressed the intracellular ribosome pathway, while the ribosomal proteins involved in the 
ribosome pathway in conditioned media induced by SRM and baicalein may suggest that 
they increased release of intracellular proteins into media, possibly due to cytotoxic effects, 
although other possibilities unrelated to toxicity can not be ruled out.  
Comparative KEGG pathway analyses of cell lysate indicated that SRM and baicalein 
significantly regulated proteins enriched in the lysosome pathway. Lysosomes are 
membrane-bound organelles responsible for macromolecule degradation and recycling, and 
involved in various cellular processes, including secretion, plasma membrane repair, cell 
signalling and energy metabolism (234). For example, collagen fragments are mainly 
degraded by lysosome (222, 235). In addition,  lysosomal proteases cathepsins are 
implicated in multiple cellular processes, such as regulation of cell cycle, cell death and 
autophagy  (236).  Cathepsins, originally found in the lysosomes, also have been detected in 
cytosol, nucleus as well as extracellular space, and multiple specific functions have been 
assigned to individual cathepsins (237). To date, 15 cathepsins have been identified and 
classified into three families: serine (cathepsin A and G), aspartate (cathepsins D and E), or 
cysteine (cathepsin B, C, F, H, K, L, O, S, V, X, and W) proteases (238). In the present 
study, cathepsin B, D and L (Ctsb, Ctsd and Ctsl) were detected in cell lysates. Ctsb was 
induced by TGF-β1 and reversed by 40 μg/mL SRM and 40 μM baicalein, in contrast, both 
Ctsd and Ctsl were reduced by TGF-β1 and increased after SRM and baicalein 
administration (Table. 6.2). 
Several studies have demonstrated the critical role of cathepsins in kidney disease 





demonstrated that Ctsb may promote glomerular inflammation and other cell damages 
resulting into glomerular injury and end-stage renal disease by activating inflammasome, a 
complex of proteins containing NOD-like receptor with pyrin domain 3 (NLRP3), which 
drives production of pro-inflammatory cytokines in response to infection and tissue injury 
(245). Increasing knowledge has implicated that inflammasomes are involved in the 
pathogenesis of AKI and CKD (246, 247). Therefore, NLRP3 has been considered a 
potential target for the treatment of progressive CKD (248). Fox et al. reported that the 
expression of Ctsb was increased in UUO mouse model (242). In addition, Ctsb was 
overexpressed in various models of liver injury and patients with chronic liver diseases, 
suggesting its potential as diagnostic biomarkers for chronic liver diseases (249). Ctsd was 
highly expressed in damaged tubular cells in nephrotoxic and ischaemia reperfusion-induced 
AKI (241). Inhibition of Ctsd by Pepstatin A resulted in a reduction in apoptosis and a 
decrease in tubular cell damage, suggesting a possible contribution of Ctsd in apoptosis 
during AKI. Up-regulation of Ctsd has been detected in a panel of human CKD renal 
biopsies and two mouse CKD models (UUO and chronic ischaemia reperfusion injury) (242). 
Ctsd inhibition using Pepstatin A in CKD models led to reduction in kidney fibrosis via 
increasing collagenolytic activity and extracellular protease activity of urokinase-type 
plasminogen activator (uPA). uPA processes plasminogen into plasmin, which participate in 
ECM degradation (250).  In CKD patients, Ctsd serum levels were significantly higher and 
correlated with endothelial dysfunction (251). Induction of Ctsl expression in podocytes 
contributed to the development of proteinuria in streptozotocin-induced diabetic nephropathy 
(252). Sever et al. showed that mRNA levels of Ctsl were increased in renal biopsy samples 
of patients with proteinuric kidney diseases, including membranous glomerulonephritis, 
focal segmental glomerulosclerosis, and diabetic nephropathy (253). In addition, serum Ctsl 
activity was markedly elevated in CKD patients and these levels were positively correlated 
with the severity of proteinuria (254). An increased risk of mortality and morbidity in 
patients with CKD is associated with higher levels of proteinuria (255). Urinary excretion of 
Ctsl was higher in children with type I diabetes, suggesting the value of Ctsl as potential 
predictors for early diabetic kidney disease (256). In summary, Ctsb, Ctsd and Ctsl have 
been reported to mediate extracellular matrix homeostasis (242), inflammation (245),  
apoptosis (242) in kidney disease, whereas the functions of Lamp1, Acp2, Naga, Arsb, 
Dnase2, Aga, Ppt1, Gusb and Atp6v0a1 in fibrotic diseases are little understood. In view of 
that potential role of cathepsins in renal fibrosis, further validation of their expression and 
related mechanisms may deserve consideration in the future. 
In conditioned media, only baicalein significantly regulated secreted proteins enriched in the 





by baicalein at both concentrations; Galns was induced by 40 μM baicalein; while Clta and 
Cltb were reduced by 80 μM baicalein (Table 6.4). The functions of those lysosomal 
proteins have been rarely reported in fibrosis diseases. Lgmn, or legumain, a cysteine 
peptidase that specifically hydrolyses asparaginyl bonds, is known to exist in many organs 
and is particularly abundant in the kidney (257). Lgmn is mainly expressed in proximal 
tubules of the rat (258) and mouse (259) kidney. It has been found that fibronectin was 
degraded by Lgmn in cultured renal proximal tubular cells and the accumulation of 
fibronectin in the renal tubulointerstitial area was significantly increased in UUO kidneys 
from Lgmn-deficient mice (260). These findings indicated that Lgmn may regulate 
extracellular matrix remodelling by mediating fibronectin degradation. In addition, the 
processing of lysosomal cathepsins (Ctsb, Ctsh and Ctsl), from single-chain forms into two-
chain forms, was completely defective in Lgmn-deficient mice, suggesting that Lgmn may 
play a role in lysosomal degradation system (259). Given that the lysosome is an 
intracellular organelle, the changed proteins involved in the lysosome pathway in cell lysates 
may suggest that SRM and baicalein regulated the intracellular lysosome pathway, while the 
increased proteins involved in the lysosome pathway in conditioned media induced by 
baicalein may suggest that baicalein increased release of intracellular proteins into media, 
either due to cytotoxic effects, i.e. by increase cell death, or by other unknown mechanisms, 



















6.5. Conclusions  
In this chapter, proteomic analysis has uncovered shared, dose-dependent and drug-specific 
mechanisms of three antifibrotics, SRM, baicalein and IN1130: 
• SRM, baicalein and IN1130 have shared anti-fibrotic and anti-inflammatory mechanisms, 
involving repressing TGF-β1-indeuced PAI-1, Plod2, Ctgf, Ccl2 and Ccl7.  
• SRM, baicalein and IN1130 differed in regulating proteins such as Nov and Mmp3. 
• Roles for Aldh3a1, Enpp1, Cyr61, Tsku, Impdh2, Ccdc80 and Tfrc in fibrogenesis and 
anti-fibrotic therapy deserve further studies. 
• SRM, baicalein and IN1130 all repressed the intracellular ribosome pathway, while they 
differed in regulating ribosomal proteins in conditioned media. The pharmacological and 
toxicological implications of these findings deserve further studies.  
• SRM and baicalein, but not IN1130, regulated the intracellular lysosome pathway, while 
they differentially regulated multiple metabolism pathways. The importance of those 



















Chapter 7. General discussion and future work 
 
7.1. General discussion 
7.1.1. Quality control of materials and methods 
Authentication and quality control of research materials are fundamental for safeguarding 
integrity of scientific research and to boost reproducibility of research findings (262, 263). In 
this project, identities of SR, AR and ALR were thoroughly examined by morphological, 
genetic and chemical criteria to ensure that they were derived from the correct species and 
met the legal standards in terms of general characteristics, macroscopic and microscopic 
morphology, bioactive constituents and contaminants, e.g. heavy metals and pesticides. The 
voucher samples have been deposited in our own lab and at Royal Botanical Gardens Kew 
and will be made available upon request to facilitate independent comparison of results with 
the international community in the future. These stringent procedures have ensured that our 
research materials met good practice guidelines (264, 265). Through a collaboration with 
Kew, I have learnt that, from a botanist point of view, the scientific value of voucher 
samples would be significantly improved if herbarium specimens (i.e. dried and flattened 
aerial parts of each of the corresponding plant species from the same crop) had been 
included. This would, of course, require even closer collaborations with botanists when 
harvesting the medicinal plants in future projects. Herbs were procured from regions known 
for producing geo-authentic herbs of these species. In the future, it will be desirable to 
harvest from Good Agricultural Practice (GAP)-certified farms, if there are any. 
AR and ALR have to be processed to meet pharmacopoeial standards to be used as legal 
materia medica. Although there are legal standards for quality control of processed herbs, 
there are no standard operating procedures for processing these herbs in China and 
internationally. I have collaborated with experts at the frontiers leading the development of 
national guidelines (264), and we have also confirmed that the processed AR and ALR met 
legal requirements according to pharmacopoeias. With respect to the herbal extracts, 
chemical analysis of each extraction was undertaken using HPLC, although selectively 
enriching and depleting certain groups of compounds failed due to the complexity of the 
compositions and limitations of the existing chemical separation technology. 
To avoid mislabelling, misidentification and impurity of herbal compounds, molecular 
weights of all compounds used in the project were validated by HPLC-MS/MS.  
Similarly, antibodies cannot be taken for granted as specific (266). In this project, for all 
antibodies used for cytoimmunostaining, non-immune IgGs, positive and negative control 





Misidentification of cell cultures is another major pitfall that affects reproducibility and the 
integrity of scientific research (267, 268). In a cellular model-based project, it is crucial to 
ensure that cells used are authenticated. Following the current best practice, NRK-49F cell 
line has been successfully authenticated as a normal rat kidney fibroblast-like cells; this 
supports the use of this cell line to model fibrosis for the discovery of anti-fibrotic and pro-
fibrotic activities, which can be further validated in-vivo in rodent models. However, to 
establish human relevance, it is desirable to confirm findings in human kidney fibroblast cell 
lines (269, 270), but unfortunately, we found that two cell lines expected to be derived from 
human kidneys were proven to be misidentified. This did highlight the necessity to 
authenticate cells for this project. 
 
7.1.2. Choice of cellular model and in-vitro model of fibrosis  
NRK-49F cell line was chosen as a suitable renal fibroblast cell model in my work. NRK-
49F cells are derived from normal rat kidneys and are morphologically and behaviourally 
similar to fibroblasts. In the past, NRK-49F cells have been widely used in fibrogenesis 
studies, especially those induced by TGF-β1(271, 272). Furthermore, the NRK-49F cell 
culture conditions to minimise cell proliferation and maximise the fibrogenic response to 
TGF-β have already been established (272). The initial plan was to use two human renal 
fibroblasts “TK173” and “TK188” cells to validate findings in NRK-49F cells to establish 
human relevance of findings. Unexpectedly, these cells were proven to be of mouse origin, 
as shown in Fig.2.3 and Fig.2.4. In interest of time, I decided to stick to NRK-49F cells only 
in present work.  
The in-vitro model of fibrosis represents as a reproducible cell model of fibrosis currently 
available and uses the dye PSR to visualise total collagen protein deposition, which can be 
further quantified by spectrophotometric analysis of eluted stain (65). However, this model 
has its limitations. Firstly, it cannot be used if TGF-β1-treated cells do not produce enough 
collagen for the change to be detected by PSR staining. Indeed, this model provide 
unsuitable for a variety of cell types that are known to be important in TIF and 
glomerulosclerosis (data not shown). Secondly, as PSR stains for collagen, relevant changes 
in non-collagenous ECM components will be overlooked in this model. Finally, this model 
relies on an intact cell monolayer and disruption of this monolayer or contraction of cells 
could affect the readout. To address this limitation, additional parameters, hydroxyproline 
assay and immunoassays of selected ECM proteins, were used to further validate key results 
in this study, as shown in Fig. 4.6, 4.7, 4.9 and 4.10. Moreover, as reported by Qureshi et.al. 





it allows us to focus directly on the mature deposited ECM by stripping the cellular 
component and only imaging the remaining ECM.  
In addition, cytotoxicity might contribute towards anti-fibrotic activity. The in-vitro model 
of fibrosis relies on cells remaining in the culturing system for reliable data on total collagen 
accumulation. It is important to know how many viable cells are remaining at the end of the 
experiment. Thus, throughout the whole study, I monitored cell attachment to control the 
credibility of the assays. Furthermore, LDH assay were applied to further examine the 
cytotoxitiy (Fig. 4.9B). However, I don’t exclude the possibility of herbal 
compounds/extracts playing anti-fibrotic roles by growth arrest or lowered cell metabolism. 
Additional cytotoxicity assays, such as MTT assay, Presto blue or trypan blue, would be 
provided in the further (273).   
In order to evaluate the reproducibility of anti-fibrotic activities of SRM and balcalein 
reported previously by my supervisor’s lab (65), same in-vitro model, timing and dose of 
treatments were chosen in this work. Indeed, it presents good reproducibility but it also has 
limitations by choosing a late time point, some immediate early genes and signal 
transductions responsible for progressive fibrosis may have been missed out. Nonetheless, 
by focusing on sustainable changes of proteomic profiling, signalling and pathways (274, 
275), findings of the present study might open a broad avenue for developing new strategies 
to target sustainable events responsible for refractory fibrosis and progressive CKD. In the 
future, it would be desirable to examine whether findings in NRK-49F cells are comparable 
to those in human renal fibroblast cell lines, rat and human renal fibroblast primary cultures, 
as well as in in-vivo models and in CKD patients. 
 
7.1.3. Toxicity of SR and SR flavonoids  
Previous studies have demonstrated that SR and their flavonoids posscess a variety of 
biological activities mainly including anti-inflammatory (276), antioxidant (91), anti-cancer 
(81, 277) and anti-fibrotic effects (118). There have been few reports about their safety and 
toxicity. In the present study, in-vitro cytotoxicity was assessed by an approximated cell 
detachment index and a LDH release assay. Up to 80 μg/mL SR methanolic extract and 80 
μM baicalein did not significantly increased cell detachment, while 60 μM baicalin and 
wogonin increased LDH release in keeping with results of cell detachment index, suggesting 
baicalin and wogonin had higher cytotoxicity. 
The cytotoxicity of SR methanolic extracts has been hardly reported before. The cytotoxicity 
of a SR aqueous extract, however, has been investigated in human corneal epithelial cells by 
trypan blue staining, MTT assay and flow cytometry. SR aqueous extract showed no 





(278). In another toxicological study, SR aqueous extract did not induce any dermal 
irritation/corrosion in rabbits or skin sensitisation in guinea pigs (279). Recently, a Phase I, 
randomised, double-blinded trial of a single ascending dose (100-2800 mg) of baicalein 
chewable tablets was carried out in 72 healthy Chinese subjects (6-8 subjects per group). 11 
mild treatment-related adverse events were observed and resolved without any treatment, 
including two cases of abdominal distention, blurred vision and decreased plasma fibrinogen 
levels, and a single case of hyperactive bowel sounds, constipation, dizziness, somnolence 
and decreased blood leukocyte dcount, respectively. No serious adverse event occurred and 
clinical laboratory assessments showed no signs of liver or kidney toxicity. Importantly, 
much of the ingested bacalein appeared in the circulation in the form of its metabolite 
baicalin (280), thus the anti-fibrotioc activity and cytotoxicity of baicalin observed in my 
project urge to take in-vivo metabolism into consideration when considering the efficacy and  
toxicity of baicalein as a therapy. It may worth mentioning that Cai et al. have even reported 
kidney injury and fibrosis induced by oral administration of high doses of baicalin (400, 800 
and 1600 mg/kg) for 8 days in SD rats (281). 
Furthermore, cases of hepatotoxicity of Move Free ® arthritis supplement have been 
attributed to SR (282-284). In all cases, SR was proposed to have caused liver injury 
confirmed by liver histology and in one case it was also proposed that this supplement 
caused pulmonary complications (283). Moreover, laboratory studies of SR flavonoids in 
vivo have also revealed toxic effects. The acute and sub-chronic toxicity of wogonin was 
examined in B6 albino mice and Sprague-Dawley (SD) rats (285), revealing that a long 
period of treatment with high dose of wogonin (120 mg/kg) could induce reversible heart 
injury in rats. Sub-chronic toxicity of wogonin was further examined in Beagle dog at 
dosages of 60, 30 and 15 mg/kg per day for 90 days via intravenous administration (286). 
Typical adverse effects such as hyperptyalism, somatasthenia, swollen snout accompanied 
with the scratching and the discontinuity urine dripping were observed especially in high-
dose group. 
 
7.1.4. Proteomic approach to guide mechanistic studies 
Proteomic methodology is a powerful tool for unbiased global analysis of biological systems 
and also has enormous potential to complement targeted studies. In the present study, 
besides known druggable targets e.g. PAI-1 and Ccn2/Ctgf, potential roles for Aldh3a1, 
Enpp1, Impdh2, Ccn1/Cyr61, Ccn3/Nov, Mmp3, Plod2 and Tsku, as well as the ribosome, 
lysosome and metabolic pathways in fibrogensis and as anti-fibrotic targets have been 
highlighted as being deserving further investigation. However, some common fibrotic 





others presented unexpected results. For example, fibronectin and vimentin did not change 
significantly in both cell lysates and conditioned media in TGF-β1-treated group; Col1a1, 
Col1a2, and Col5a1 significantly decreased after TGF-β1 treatment in cell lysate samples, 
while there was no significant change in conditioned media. While the expression of α-SMA, 
fibronectin, collengen I&III were successfully measured by immunofluorescence and/or 
hydorxyproline assays or soluble collagen assays, as shown in Fig. 4.7 & 4.10 and Fig. 6.1, 
presenting significantly difference in TGF-β1 treatment groups. The most possible reason is 
protein post-translational modification (PTMs). PTMs present analytical difficulties to 
proteomic strategies due to their complexity and particular biochemical properties. To date, 
over 300 different PTMs have been described and the most common PTMs include 
phosphorylation, crosslinking, acetylation and glycosylation, etc (288). PTMs massively 
increase the complexity of organismal proteomes and have a wide array of functions during 
the cellular processes, e.g., altering protein structure and localisation, causing protein-protein 
interactions to activate or inactivate a protein. In particular, ECM proteins interact with 
many other proteins and are often highly covalently crosslinked resulting in low solubility. 
Fibronectin, for example, consists of a series of repeating modules (type I, II and III 
fibronectin repeats), several of which serve as binding sites for other ECM components, such 
as heparin, fibrin and collagens (289). Hence, proteomic approaches face the difficult to 
detect and quantify these modifications and many strategies incorporating various isolation, 
enrichment or fractionation methodologies are required to increase the signal-noise ratio and 
enable the detection of a wide range of molecule concentrations (290, 291).  
Currently the key technology used in proteomics is mass spectrometry, which ionises sample 
molecules and separates the ions according to their mass-to-charge ratio and measures the 
signal intensity of the ions. Tandem MS results in the fragmentation of peptide ions to 
provide structural information about the ions, which enables the determination of their amino 
acid sequence. Tandem MS is the core technology used in “bottom-up” proteomics, in which 
proteins are extracted from the sample of interest then enzymatically digested into peptides 
prior to analysis (292). Thus, it is an essential step to enrich the modified peptides by 
depleting the bulk of non-modified peptides that hamper PTMs analysis (293, 294).  
To address some of the aforementioned problems, specific technical innovation is needed. 
Techniques firstly include improving extract and lysis performance either with ammonium 
hydroxide to remove the cells effectively from 2D cell cultures (295), or with hypotonic 
buffers to extract proteins preserving the architecture and bioactivity of the protein scaffold 
(296), or combining ammonium hydroxide and detergent extraction and DNase treatment to 
remove nuclei (297). Secondly, the strategies target either PTMs structure, such as affinity 





example, resulting in specific retention characteristics in reversed phase (300) or hydrophilic 
interaction chromatography (301). Strong cation exchange chromatography can be used to 
selectively enrich charge-reduced peptides, e.g., phosphopeptides, glycopeptides, N-
terminally acetylated peptides (302). In order to increase specificity and additionally 
fractionate complex samples, two and more enrichment methods are commonly combined, 
such as combining affinity chromatography and hydrophilic interaction chromatography for 
the selective enrichment of phosphopeptides (303). Phosphorylation is the most well-studied 
PTMs, the improvement in purification of phosphorylated proteins and peptides and current 
proteomic strategies used to qualitatively and quantitatively probe these enriched 
phosphoproteomes have been developed and exploited (293, 304).  
Another major challenge when performing proteomic analysis is extracting important 
information from these large datasets. Here, to pursue a better understanding of the holistic 
view of TGF-β1-induced fibrogenesis and the mechanism of the anti-fibrotic activities of 
three drugs, STRING network and KEGG pathway analysis were performed in Chapters 5 
and 6. Analysis of interaction networks based on previously reported protein-protein 
interactions, could provide insights into the functional roles of the identified proteins. For 
example, as shown in Fig. 5.7A, STRING analysis has led to the emergence of two major 
clusters (a and b), indicating that proteins in network with many common interaction 
partners are more likely to function together. Indeed, KEGG pathway analysis has shown 
that the proteins in these two clusters were mainly associated with multiple metabolic 
pathways and the ribosome pathway (Fig. 5.7B). However, how to identify and validate 
those pathways and functions regulated by TGF-β1 and three antifibtotics is another task.  
  
7.2. Future work 
7.2.1. Confirmation of the effects of AR/ALR on fibrogenesis 
One of the issues remains unsolved in this project is the effect of AR/ALR on fibrogenesis. 
As described in Chapter 3, the pro-fibrotic activity of AR identified by a screening studies 
of my Supervisor’s lab was not reproduced in my project. To draw solid conclusions, the 
activities of AR in TGF-β1-induced fibrogenesis should be further examined using 
additional batches of well-authenticated AR, preferably also using alternative assays for total 
collagens (e.g. hydroxyproline assay) and fibrotic molecular markers (e. g. collagen type I & 
III). In addition, processed and unprocessed ALR extracts have been produced and their 
quality control conducted in the present study, however, their effects on fibrogenesis have 
not been tested due to the limited time. The next studies should thus examine the effects of 





7.2.2. Anti-fibrotic activities of synthetic baicalein derivatives 
Flavonoids are known for their numerous biological activities, such as anti-fibrotic (118, 
305), anti-inflammatory (207), antioxidant (306), anti-cancer (277), cardiovasculoprotective 
(95) and neuroprotective activities (307).  Like other flavonoids, one major concern in the 
clinical application of baicalein is its low aqueous solubility, which leads to poor oral 
bioavailability. After oral administration, baicalein undergoes extensive first-pass 
metabolism in intestine and liver in human and rats, and it is quickly metabolised to baicalin 
in the blood (308-310). To improve the bioavailability of baicalein, various strategies have 
been developed, e.g. nanocrystal (311) and self-microemulsifying drug delivery system 
(312). Modification of baicalein molecules to create analogs is another strategy. A series of 
synthetic derivatives of baicalein (Fig. 7.1) have been synthesised and gifted by Prof. Yung-
Chi Cheng’s laboratory at Yale University (313).  In total, 27 synthetic baicalein derivatives 
were received and examined by HRMS to validate their molecular weights. As shown in 
Supplementary Table 8, all synthetic baicalein derivatives, except S2 and S3, were found 
with the expected molecular weights. In the present study, baicalein showed most potent in-
vitro efficacy, with little cytotoxicity. However, its efficacy is still relatively moderate (IC50 
=38.2±2.7 μM). To address those problems, it is desirable to examine if better anti-fibrotic 
and less toxic bacalein derivatives can be discovered and if any structure-activity 
relationship can be explored by using these structural analogs.  
 
 
Fig. 7.1. Structures of synthetic baicalein derivatives. 
 
Compound R1 R2 R3 R4 
S2 H Ac H H 
S3 H Ac Ac H 
S5 Me Ac Me H 
S6 Me Me Me H 
S7 Me Ac Ac H 
S8 H Me Me H 
S9 Bn Ac Ac H 
S10 H Bn Ac H 
S14 Ac Ac Bn H 
S15 H Bn H H 
S24 H Ac Ac Br 
S25 H H H Br 
S32 H CH2CH3 H H 
S38 H CH2CH3 Me H 
 
Compound R1 n 
S18 H 2 
S23 Me 2 
S33 H 1 
S34 H 7 
S40 H 4 
S41 Me 4 
S42 H 5 
S43 Me 5 
S45 H 3 






7.2.3. Further validation 
Given the limitations of proteomic approach discussed in section 7.1.4, further validation of 
proteomic findings on any candidate proteins in cell lysates and conditioned media presents 
the first step towards understanding their possible roles in TGF-β1-induced fibrogenesis and 
mechanisms of the anti-fibrotic activities of SRM, baicalein and IN1130. In the next step, it 
is imperative to perform further studies focusing on two major aspects. Firstly, in view that 
the ribosome pathway was most significantly regulated in this in-vitro system, validation of 
ribosomal proteins should be done. Rps13, Rps15, Rps24 and Rps4x, which were most 
significantly regulated by SRM and baicalein (Fig. 6.10), could be planned for validation by 
ELISA or western blot experiments. Secondly, in view that Impdh2 connected two clusters 
of TGF-β1-regulted proteins as shown in STRING map (Fig. 5.7A), and it has also been 
reported as a druggable target to attenuate the progression of renal fibrosis (138, 140). In the 
present study, sappanone A (an Impdh2 inhibitor), up to concentrations 32 μM, did not 
significantly decrease total collagen accumulation in TGF-β1-induced in-vitro model of 
fibrosis (Fig. 5.10). However, the quality control of the commercial sappanone A and its 
efficacy in repressing Impdh2 activity at the concentrations used deserve further 
investigation. The effects of Sappanone A and/or genetic inhibitors of Impdh2 (e.g. Impdh2 
siRNA or gene delation) on TGF-β1-induced fibrogenesis should be examined in in vitro and 
in vivo work in the future to establish whether Impdh2 could be an anti-fibrotic target. 
 
7.2.4. Integrating proteomics and metabolomics 
This work has focused on the proteomic analysis of TGF-β1-induced fibrogenesis and 
mechanisms of the anti-fibrotic activities of SRM, baicalein and IN1130. The proteomic data 
have highlighted important changes in metabolic pathways in TGF-β1-induced fibrogenesis 
and in SRM, baicalein and IN1130 effects on fibrogenesis, thus justifying further studies 
using a metabolomic analysis, another unbiased means to identify and quantify changes of 
metabolites, which are the end products of cellular processes (314). Therefore, to take this 
work further, the remaining cell lysates and conditioned media samples of this project have 
been sent to Dr. Jonathan Swann’s laboratory at Imperial College London and will be further 
analysed in a metabolomic approach. Integration of proteomics and metabolomics may 
further advance the understanding of TGF-β1-induced fibrogenesis and the mechanism of 
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Supplementary Table. 1. Cell-lysate proteins significantly regulated by TGF-β1. (listed 
in the order of fold change (TGF-β1/control). 
No. Accession To Description TGF/control  t-test 
1 Q924C3 Enpp1 Ectonucleotide pyroph phatase/ph phodiesterase family member 1   3.56 0.001098 
2 Q62952 Dpysl3 Dihydropyrimidinase-related protein 3   2.33 0.000002 
3 P62864 Fau 40S ribomal protein S30   2.07 0.006588 
4 P30823 Slc7a1 High affinity cationic amino acid transporter 1   2.06 0.001813 
5 Q3B8Q1 Ddx21 Nucleolar RNA helicase 2   2.03 0.000041 
6 O08623 Sqstm1 Sequest ome-1   2.01 0.000856 
7 Q5U1Z0 Rab3gap2 Rab3 GTPase-activating protein non-catalytic subunit   1.96 0.011780 
8 Q62736 Cald1 Non-muscle caldesmon   1.96 0.000117 
9 P83883 Rpl36a 60S ribomal protein L36a   1.95 0.015902 
10 P54690 Bcat1 Branched-chain-amino-acid aminotransferase, cytolic   1.94 0.000008 
11 P62268 Rps23 40S ribomal protein S23   1.89 0.000462 
12 Q62908 Csrp2 Cysteine and glycine-rich protein 2   1.89 0.000010 
13 P15205 Map1b Microtubule-associated protein 1B   1.87 0.000310 
14 P52944 Pdlim1 PDZ and LIM domain protein 1   1.86 0.000008 
15 P49088 Asns Asparagine synthetase [glutamine-hydrolyzing]   1.85 0.000019 
16 Q9Z1Z9 Pdlim7 PDZ and LIM domain protein 7   1.84 0.000252 
17 P18666 Myl12b Myosin regulatory light chain 12B   1.82 0.021371 
18 Q7TP54 Ripor2 Protein FAM65B   1.82 0.029861 
19 P69736 Edf1 Endothelial differentiation-related factor 1   1.81 0.001183 
20 P41777 Nolc1 Nucleolar and coiled-body ph phoprotein 1   1.79 0.000048 
21 P0C5E3 Palld Palladin (Fragment)   1.77 0.0014380 
22 P47875 Csrp1 Cysteine and glycine-rich protein 1   1.72 0.0082442 
23 P04646 Rpl35a 60S ribomal protein L35a   1.71 0.0100208 
24 Q4KM49 Yars Tyr ine--tRNA ligase, cytoplasmic   1.71 0.0000057 
25 Q5U2Q7 Etf1 Eukaryotic peptide chain release factor subunit 1   1.70 0.0064419 
26 A1L1L2 Tmem214 Transmembrane protein 214   1.68 0.0070073 
27 Q5M819 Psph Ph ph erine ph phatase   1.67 0.0258053 
28 Q5RJT2 Ftsj3 pre-rRNA processing protein FTSJ3   1.64 0.0046964 
29 Q05982 Nme1 Nucle ide diph phate kinase A   1.64 0.0184238 
30 P62501 Tsc22d1 TSC22 domain family protein 1   1.62 0.0117020 
31 P61621 Sec61a1 Protein transport protein Sec61 subunit alpha isoform 1   1.61 0.0497411 
32 E9PU28 Impdh2 In ine-5'-monoph phate dehydrogenase 2   1.61 0.0000230 
33 P62850 Rps24 40S ribomal protein S24   1.60 0.0002702 
34 P62634 Cnbp Cellular nucleic acid-binding protein   1.60 0.0017603 
35 O70536 Soat1 Sterol O-acyltransferase 1   1.59 0.0114370 
36 P13084 Npm1 Nucleoph min   1.59 0.0013604 
37 P07314 Ggt1 Gamma-glutamyltranspeptidase 1   1.58 0.0002644 





39 Q5I0G4 Gars Glycine--tRNA ligase (Fragment)   1.56 0.0000174 
40 D3ZUA0 Mthfd2l Probable bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2   1.56 0.0023511 
41 P62752 Rpl23a 60S ribomal protein L23a   1.56 0.0013196 
42 P23347 Slc4a2 Anion exchange protein 2   1.55 0.0030767 
43 P19804 Nme2 Nucle ide diph phate kinase B   1.55 0.0240352 
44 P13832 Rlc-a Myosin regulatory light chain RLC-A   1.55 0.0432235 
45 P18445 Rpl27a 60S ribomal protein L27a   1.54 0.0029282 
46 Q6AYD3 Pa2g4 Proliferation-associated protein 2G4   1.52 0.0000577 
47 P62909 Rps3 40S ribomal protein S3   1.52 0.0028506 
48 Q63016 Slc7a5 Large neutral amino acids transporter small subunit 1   1.51 0.0017910 
49 Q794F9 Slc3a2 4F2 cell-surface antigen heavy chain   1.51 0.0029327 
50 Q66HF9 Lrrfip1 Leucine-rich repeat flightless-interacting protein 1   1.50 0.0079293 
51 P19945 Rplp0 60S acidic ribomal protein P0   1.50 0.0004868 
52 P63326 Rps10 40S ribomal protein S10   1.50 0.0090580 
53 P17078 Rpl35 60S ribomal protein L35   1.50 0.0033750 
54 O35821 Mybbp1a Myb-binding protein 1A   1.48 0.0000782 
55 Q6P799 Sars Serine--tRNA ligase, cytoplasmic   1.47 0.0000214 
56 Q62920 Pdlim5 PDZ and LIM domain protein 5   1.47 0.0000037 
57 P61515 Rpl37a-ps1 Putative 60S ribomal protein L37a   1.47 0.0002564 
58 P62282 Rps11 40S ribomal protein S11   1.47 0.0021085 
59 O70199 Ugdh UDP-gluc e 6-dehydrogenase   1.46 0.0005065 
60 P63029 Tpt1 Translationally-controlled tumor protein   1.46 0.0003560 
61 P13471 Rps14 40S ribomal protein S14   1.46 0.0037187 
62 P61354 Rpl27 60S ribomal protein L27   1.45 0.0000590 
63 Q9JHW0 Psmb7 Proteasome subunit beta type-7   1.45 0.0266744 
64 P81795 Eif2s3 Eukaryotic translation initiation factor 2 subunit 3   1.45 0.0417285 
65 P27881 Hk2 Hexokinase-2   1.45 0.0014123 
66 Q9Z0W7 Clic4 Chloride intracellular channel protein 4   1.45 0.0001658 
67 P24049 Rpl17 60S ribomal protein L17   1.45 0.0098013 
68 Q3KRD8 Eif6 Eukaryotic translation initiation factor 6   1.44 0.0083137 
69 Q5U216 Ddx39a ATP-dependent RNA helicase DDX39A   1.44 0.0055149 
70 P13383 Ncl Nucleolin   1.44 0.0000286 
71 O35763 Msn Moesin   1.43 0.0000559 
72 P62718 Rpl18a 60S ribomal protein L18a   1.42 0.0002582 
73 P06762 Hmox1 Heme oxygenase 1   1.42 0.0014895 
74 P38983 Rpsa 40S ribomal protein SA   1.42 0.0009925 
75 P62912 Rpl32 60S ribomal protein L32   1.42 0.0026946 
76 Q9Z1P2 Actn1 Alpha-actinin-1   1.42 0.0006346 
77 Q1RP77 Nop16 Nucleolar protein 16   1.42 0.0023185 
78 Q5U318 Pea15 Astrocytic ph phoprotein PEA-15   1.41 0.0440684 





80 Q6P7B0 Wars Tryptophan--tRNA ligase, cytoplasmic   1.41 0.0095567 
81 Q5RKI1 Eif4a2 Eukaryotic initiation factor 4A-II   1.40 0.0000144 
82 P62963 Pfn1 Profilin-1   1.39 0.0116613 
83 Q9QXQ0 Actn4 Alpha-actinin-4   1.39 0.0005752 
84 Q7TP47 Syncrip Heterogeneous nuclear ribonucleoprotein Q   1.38 0.0009017 
85 Q63690 Bax Apopt is regulator BAX   1.38 0.0105709 
86 P82808 Gfpt1 Glutamine--fruct e-6-ph phate aminotransferase [isomerizing] 1   1.38 0.0252299 
87 P63245 Rack1 Guanine nucleotide-binding protein subunit beta-2-like 1   1.37 0.0045998 
88 Q05175 Basp1 Brain acid soluble protein 1   1.37 0.0230789 
89 P47198 Rpl22 60S ribomal protein L22   1.37 0.0013333 
90 Q63560 Map6 Microtubule-associated protein 6   1.37 0.0497353 
91 P62278 Rps13 40S ribomal protein S13   1.36 0.0001329 
92 A0JPM9 Eif3j Eukaryotic translation initiation factor 3 subunit J   1.36 0.0025824 
93 Q9ES21 Sacm1l Ph phatidylin itide ph phatase SAC1   1.36 0.0088705 
94 Q5U2X6 Ccdc47 Coiled-coil domain-containing protein 47   1.35 0.0395551 
95 P12001 Rpl18 60S ribomal protein L18   1.35 0.0041345 
96 Q712U5 Arpp19 cAMP-regulated ph phoprotein 19   1.35 0.0048518 
97 P11762 Lgals1 Galectin-1   1.35 0.0372277 
98 Q63525 Nudc Nuclear migration protein nudC   1.34 0.0124122 
99 Q641X8 Eif3e Eukaryotic translation initiation factor 3 subunit E   1.34 0.0035566 
100 P62961 Ybx1 Nuclease-sensitive element-binding protein 1   1.34 0.0029660 
101 Q68FR6 Eef1g Elongation factor 1-gamma   1.34 0.0000589 
102 Q8K1Q0 Nmt1 Glycylpeptide N-tetradecanoyltransferase 1   1.34 0.0004197 
103 P62275 Rps29 40S ribomal protein S29   1.34 0.0475435 
104 P12749 Rpl26 60S ribomal protein L26   1.34 0.0017594 
105 O35987 Nsfl1c NSFL1 cofactor p47   1.33 0.0026978 
106 P62755 Rps6 40S ribomal protein S6   1.33 0.0008892 
107 P21533 Rpl6 60S ribomal protein L6   1.33 0.0000008 
108 P62271 Rps18 40S ribomal protein S18   1.33 0.0036672 
109 Q63692 Cdc37 Hsp90 co-chaperone Cdc37   1.33 0.0083535 
110 Q9R0T3 Dnajc3 DnaJ homolog subfamily C member 3   1.33 0.0051897 
111 Q9QVC8 Fkbp4 Peptidyl-prolyl cis-trans isomerase FKBP4   1.33 0.0024050 
112 D4A4T9 Chordc1 Cysteine and histidine-rich domain-containing protein 1   1.33 0.0147319 
113 Q6IRE4 Tsg101 Tumor susceptibility gene 101 protein   1.33 0.0066914 
114 P39032 Rpl36 60S ribomal protein L36   1.33 0.0071969 
115 Q9R063 Prdx5 Peroxiredoxin-5, mitochondrial   1.33 0.0002008 
116 P62630 Eef1a1 Elongation factor 1-alpha 1   1.33 0.0000234 
117 P27952 Rps2 40S ribomal protein S2   1.33 0.0000325 
118 P35427 Rpl13a 60S ribomal protein L13a   1.33 0.0000040 
119 P69682 Necap1 Adaptin ear-binding coat-associated protein 1   1.33 0.0173329 





121 P62832 Rpl23 60S ribomal protein L23   1.32 0.0038515 
122 P17074 Rps19 40S ribomal protein S19   1.32 0.0017947 
123 Q62658 Fkbp1a Peptidyl-prolyl cis-trans isomerase FKBP1A   1.32 0.0011745 
124 P62243 Rps8 40S ribomal protein S8   1.32 0.0000114 
125 P05197 Eef2 Elongation factor 2   1.32 0.0001188 
126 G3V9R8 Hnrnpc Heterogeneous nuclear ribonucleoprotein C   1.31 0.0077468 
127 O35824 Dnaja2 DnaJ homolog subfamily A member 2   1.31 0.0008499 
128 P62845 Rps15 40S ribomal protein S15   1.31 0.0043307 
129 Q01986 Map2k1 Dual specificity mitogen-activated protein kinase kinase 1   1.31 0.0075095 
130 P09895 Rpl5 60S ribomal protein L5   1.31 0.0000082 
131 P63174 Rpl38 60S ribomal protein L38   1.31 0.0020781 
132 Q68FR9 Eef1d Elongation factor 1-delta   1.31 0.0002742 
133 P41123 Rpl13 60S ribomal protein L13   1.31 0.0200022 
134 Q6PDV7 Rpl10 60S ribomal protein L10   1.30 0.0002967 
135 P05426 Rpl7 60S ribomal protein L7   1.30 0.0002517 
136 P02401 Rplp2 60S acidic ribomal protein P2   1.30 0.0159066 
137 Q9QZ86 Nop58 Nucleolar protein 58   1.30 0.0002125 
138 P25886 Rpl29 60S ribomal protein L29   1.30 0.0104309 
139 P61314 Rpl15 60S ribomal protein L15   1.29 0.0006893 
140 O88813 Acsl5 Long-chain-fatty-acid--CoA ligase 5   1.29 0.0066855 
141 P23358 Rpl12 60S ribomal protein L12   1.29 0.0000076 
142 Q6AYZ1 Tuba1c Tubulin alpha-1C chain   1.29 0.0116303 
143 Q71TY3 Rps27 40S ribomal protein S27   1.29 0.0005498 
144 Q3T1J1 Eif5a Eukaryotic translation initiation factor 5A-1   1.28 0.0058972 
145 P28073 Psmb6 Proteasome subunit beta type-6   1.28 0.0006328 
146 P34058 Hsp90ab1 Heat shock protein HSP 90-beta   1.28 0.0091371 
147 Q6P9U8 Eif3h Eukaryotic translation initiation factor 3 subunit H   1.28 0.0000794 
148 P62856 Rps26 40S ribomal protein S26   1.28 0.0023543 
149 P62703 Rps4x 40S ribomal protein S4, X isoform   1.28 0.0015485 
150 P22509 Fbl rRNA 2'-O-methyltransferase fibrillarin   1.28 0.0133284 
151 Q641Y8 Ddx1 ATP-dependent RNA helicase DDX1   1.27 0.0281427 
152 P20280 Rpl21 60S ribomal protein L21   1.27 0.0007097 
153 Q5M7W5 Map4 Microtubule-associated protein 4   1.27 0.0014243 
154 Q1JU68 Eif3a Eukaryotic translation initiation factor 3 subunit A   1.27 0.0000029 
155 P62425 Rpl7a 60S ribomal protein L7a   1.27 0.0002663 
156 P21531 Rpl3 60S ribomal protein L3   1.27 0.0010299 
157 P62907 Rpl10a 60S ri omal protein L10a   1.27 0.0030049 
158 P62890 Rpl30 60S ribomal protein L30   1.27 0.0005207 
159 P62919 Rpl8 60S ribomal protein L8   1.26 0.0048897 
160 Q6VV72 Eif1a Eukaryotic translation initiation factor 1A   1.26 0.0079177 
161 P11250 Rpl34 60S ribomal protein L34   1.26 0.0004188 





163 Q5XIP1 Pelo Protein pelota homolog   1.26 0.0036600 
164 P22062 Pcmt1 Protein-L-isoaspartate(D-aspartate) O-methyltransferase   1.26 0.0465209 
165 O08651 Phgdh D-3-ph phoglycerate dehydrogenase   1.26 0.0123408 
166 P12785 Fasn Fatty acid synthase   1.26 0.0000126 
167 P49242 Rps3a 40S ribomal protein S3a   1.26 0.0001581 
168 P83732 Rpl24 60S ribomal protein L24   1.26 0.0322061 
169 P60868 Rps20 40S ribomal protein S20   1.26 0.0001764 
170 Q6AZ50 Atg3 Ubiquitin-like-conjugating enzyme ATG3   1.26 0.0368564 
171 D3ZBE5 Nek7 Serine/threonine-protein kinase Nek7   1.25 0.0101863 
172 Q5RJR8 Lrrc59 Leucine-rich repeat-containing protein 59   1.25 0.0095242 
173 B1WC88  N/A UPF0729 protein C18orf32 homolog   1.25 0.0309817 
174 Q64270 Eif2b1 Translation initiation factor eIF-2B subunit alpha   1.25 0.0287751 
175 P50878 Rpl4 60S ribomal protein L4   1.25 0.0057550 
176 Q9R1T1 Banf1 Barrier-to-autointegration factor   1.25 0.0167957 
177 P21670 Psma4 Proteasome subunit alpha type-4   1.24 0.0483779 
178 P43245 Abcb1 Multidrug resistance protein 1   1.24 0.0028145 
179 B5DFC8 Eif3c Eukaryotic translation initiation factor 3 subunit C   1.24 0.0007518 
180 Q9JMJ4 Prpf19 Pre-mRNA-processing factor 19   1.23 0.0082776 
181 P17077 Rpl9 60S ribomal protein L9   1.23 0.0002490 
182 Q5XIM5 Cdv3 Protein CDV3 homolog   1.23 0.0449842 
183 P38062 Metap2 Methionine aminopeptidase 2   1.23 0.0340740 
184 P29314 Rps9 40S ribomal protein S9   1.23 0.0004207 
185 Q9WVB1 Rab6a Ras-related protein Rab-6A   1.23 0.0372107 
186 P62246 Rps15a 40S ribomal protein S15a   1.22 0.0133251 
187 P17702 Rpl28 60S ribomal protein L28   1.22 0.0023717 
188 Q63356 Myo1e Unconventional myosin-Ie   1.22 0.0236681 
189 P82995 Hsp90aa1 Heat shock protein HSP 90-alpha   1.21 0.0004333 
190 F1LYQ8 Farp1 FERM, RhoGEF and pleckstrin domain-containing protein 1   1.21 0.0008080 
191 Q66HA8 Hsph1 Heat shock protein 105 kDa   1.21 0.0021275 
192 B0BNA7 Eif3i Eukaryotic translation initiation factor 3 subunit I   1.21 0.0008732 
193 P07335 Ckb Creatine kinase B-type   1.21 0.0312553 
194 Q9EQR2 Agps Alkyldihydroxyacetoneph phate synthase, peroxisomal   1.21 0.0257579 
195 P37397 Cnn3 Calponin-3   1.20 0.0026069 
196 P04644 Rps17 40S ribomal protein S17   1.20 0.0185435 
197 O89049 Txnrd1 Thioredoxin reductase 1, cytoplasmic   1.20 0.0058558 
198 Q5XHY5 Tars Threonine--tRNA ligase, cytoplasmic   1.19 0.0013528 
199 Q7TNY6 Acbd3 Golgi resident protein GCP60   1.19 0.0208809 
200 Q811A3 Plod2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2   1.19 0.0426380 
201 P60123 Ruvbl1 RuvB-like 1   1.19 0.0055658 
202 Q5RJR2 Twf1 Twinfilin-1   1.19 0.0497102 
203 P84100 Rpl19 60S ribomal protein L19   1.19 0.0189263 





205 Q2PQA9 Kif5b Kinesin-1 heavy chain   1.19 0.0034128 
206 P38656 Ssb Lupus La protein homolog   1.19 0.0344342 
207 P24051 Rps27l 40S ribomal protein S27-like   1.18 0.0006568 
208 Q5U312 Rai14 Ankycorbin   1.18 0.0009869 
209 Q62881 Nol3 Nucleolar protein 3   1.18 0.0301995 
210 P40615 Dkc1 H/ACA ribonucleoprotein complex subunit 4   1.18 0.0466678 
211 Q6AYK8 Eif3d Eukaryotic translation initiation factor 3 subunit D   1.18 0.0060480 
212 Q63507 Rpl14 60S ribomal protein L14   1.18 0.0178203 
213 Q9Z270 Vapa Vesicle-associated membrane protein-associated protein A   1.18 0.0101869 
214 Q9Z1A6 Hdlbp Vigilin   1.18 0.0015655 
215 Q9JIH7 Wnk1 Serine/threonine-protein kinase WNK1   1.17 0.0284400 
216 P05765 Rps21 40S ribomal protein S21   1.17 0.0208823 
217 Q4G061 Eif3b Eukaryotic translation initiation factor 3 subunit B   1.17 0.0178759 
218 Q63228 Gmfb Glia maturation factor beta   1.17 0.0371693 
219 Q63716 Prdx1 Peroxiredoxin-1   1.16 0.0010450 
220 Q66HR2 Mapre1 Microtubule-associated protein RP/EB family member 1   1.16 0.0000741 
221 Q68FQ0 Cct5 T-complex protein 1 subunit epsilon   1.16 0.0004009 
222 P45592 Cfl1 Cofilin-1   1.15 0.0199921 
223 Q66HL2 Cttn Src substrate cortactin   1.15 0.0188479 
224 P28480 Tcp1 T-complex protein 1 subunit alpha   1.15 0.0165744 
225 P43138 Apex1 DNA- (apurinic or apyrimidinic site) lyase   1.15 0.0129767 
226 P30427 Plec Plectin   1.15 0.0098421 
227 Q62812 Myh9 Myosin-9   1.15 0.0269145 
228 P52296 Kpnb1 Importin subunit beta-1   1.14 0.0218246 
229 P18420 Psma1 Proteasome subunit alpha type-1   1.14 0.0195399 
230 Q6AXS5 Serbp1 Plasminogen activator inhibitor 1 RNA-binding protein   1.14 0.0303913 
231 Q9QZA2 Pdcd6ip Programmed cell death 6-interacting protein   1.14 0.0032095 
232 Q04462 Vars Valine--tRNA ligase   1.14 0.0417600 
233 P62859 Rps28 40S ribomal protein S28   1.14 0.0445586 
234 P24155 Thop1 Thimet oligopeptidase   1.14 0.0046095 
235 Q9Z269 Vapb Vesicle-associated membrane protein-associated protein B   1.14 0.0065536 
236 P37285 Klc1 Kinesin light chain 1   1.14 0.0289927 
237 Q5EGY4 Ykt6 Synaptobrevin homolog YKT6   1.13 0.0308115 
238 P49791 Nup153 Nuclear pore complex protein Nup153   1.13 0.0043654 
239 Q9EPH8 Pabpc1 Polyadenylate-binding protein 1   1.13 0.0026369 
240 Q6P502 Cct3 T-complex protein 1 subunit gamma   1.12 0.0021966 
241 Q63610 Tpm3 Tropomy in alpha-3 chain   1.12 0.0050609 
242 Q5XIG8 Strap Serine-threonine kinase receptor-associated protein   1.12 0.0154925 
243 Q5HZY0 Ubxn4 UBX domain-containing protein 4   1.11 0.0188267 
244 D3ZTX0 Tmed7 Transmembrane emp24 domain-containing protein 7   1.11 0.0338770 
245 P35281 Rab10 Ras-related protein Rab-10   1.11 0.0449360 





247 Q6MG08 Abcf1 ATP-binding cassette sub-family F member 1   1.10 0.0284181 
248 P40329 Rars Arginine--tRNA ligase, cytoplasmic   1.10 0.0318503 
249 Q5XIM9 Cct2 T-complex protein 1 subunit beta   1.10 0.0055078 
250 Q794E4 Hnrnpf Heterogeneous nuclear ribonucleoprotein F   1.10 0.0265802 
251 O35814 Stip1 Stress-induced-ph phoprotein 1   1.08 0.0002923 
252 Q07266 Dbn1 Drebrin   1.08 0.0466116 
253 P05712 Rab2a Ras-related protein Rab-2A   1.07 0.0127148 
254 Q66H80 Arcn1 Coatomer subunit delta   1.05 0.0461805 
255 Q4KMA2 Rad23b UV excision repair protein RAD23 homolog B   0.95 0.0287152 
256 Q9Z1X1 Esyt1 Extended synaptotagmin-1   0.93 0.0115308 
257 Q64560 Tpp2 Tripeptidyl-peptidase 2   0.93 0.0356649 
258 Q6TUG0 Dnajb11 DnaJ homolog subfamily B member 11   0.92 0.0200398 
259 Q9WVC0 Sept7 Septin-7   0.92 0.0450362 
260 Q00438 Ptbp1 Polypyrimidine tract-binding protein 1   0.91 0.0354257 
261 B0BNG0 Emc2 ER membrane protein complex subunit 2   0.91 0.0251889 
262 O08629 Trim28 Transcription intermediary factor 1-beta   0.91 0.0122504 
263 F1MA98 Tpr Nucleoprotein TPR   0.91 0.0376338 
264 P31977 Ezr Ezrin   0.91 0.0263836 
265 P61980 Hnrnpk Heterogeneous nuclear ribonucleoprotein K   0.91 0.0000497 
266 P15791 Camk2d Calcium/calmodulin-dependent protein kinase type II subunit delta   0.91 0.0443771 
267 Q9JIL3 Ilf3 Interleukin enhancer-binding factor 3   0.90 0.0028383 
268 Q63355 Myo1c Unconventional my in-Ic   0.90 0.0029042 
269 P46462 Vcp Transitional endoplasmic reticulum ATPase   0.90 0.0027992 
270 P28023 Dctn1 Dynactin subunit 1   0.90 0.0166048 
271 O54975 Xpnpep1 Xaa-Pro aminopeptidase 1   0.90 0.0008480 
272 Q91Y78 Uchl3 Ubiquitin carboxyl-terminal hydrolase isozyme L3   0.89 0.0227242 
273 P35435 Atp5c1 ATP synthase subunit gamma, mitochondrial   0.89 0.0434718 
274 Q6IUR5 Nenf Neudesin   0.89 0.0087244 
275 P16036 Slc25a3 Ph phate carrier protein, mitochondrial   0.89 0.0054680 
276 P63331 Ppp2ca Serine/threonine-protein ph phatase 2A catalytic subunit alpha isoform   0.89 0.0095396 
277 P29410 Ak2 Adenylate kinase 2, mitochondrial   0.89 0.0384143 
278 Q91Y81 Sept2 Septin-2   0.89 0.0028444 
279 O88989 Mdh1 Malate dehydrogenase, cytoplasmic   0.88 0.0024969 
280 Q4V7C6 Gmps GMP synthase [glutamine-hydrolyzing]   0.88 0.0216074 
281 P00388 Por NADPH--cytochrome P450 reductase   0.88 0.0276875 
282 O88370 Pip4k2c Ph phatidylin itol 5-ph phate 4-kinase type-2 gamma   0.88 0.0000250 
283 Q63081 Pdia6 Protein disulfide-isomerase A6   0.88 0.0043397 
284 Q4FZT0 Stoml2 Stomatin-like protein 2, mitochondrial   0.88 0.0099038 
285 P06685 Atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1   0.88 0.0017899 
286 P37996 Arl3 ADP-ribylation factor-like protein 3   0.88 0.0291822 





288 Q6AY23 Pycr2 Pyrroline-5-carboxylate reductase 2   0.87 0.0169387 
289 Q9JK72 Ccs Copper chaperone for superoxide dismutase   0.87 0.0006857 
290 P10111 Ppia Peptidyl-prolyl cis-trans isomerase A   0.87 0.0107640 
291 P04897 Gnai2 Guanine nucleotide-binding protein G(i) subunit alpha-2   0.87 0.0178793 
292 Q68FW9 Cops3 COP9 signal ome complex subunit 3   0.87 0.0113669 
293 O08839 Bin1 Myc box-dependent-interacting protein 1   0.87 0.0091920 
294 Q5U211 Snx3 Sorting nexin-3   0.86 0.0052603 
295 Q5SGE0 Lrpprc Leucine-rich PPR motif-containing protein, mitochondrial   0.86 0.0014064 
296 P48500 Tpi1 Tri eph phate isomerase   0.86 0.0471810 
297 Q6AY09 Hnrnph2 Heterogeneous nuclear ribonucleoprotein H2   0.86 0.0011837 
298 Q66HG4 Galm Ald e 1-epimerase   0.86 0.0260616 
299 Q5U300 Uba1 Ubiquitin-like modifier-activating enzyme 1   0.86 0.0082328 
300 Q66H94 Fkbp9 Peptidyl-prolyl cis-trans isomerase FKBP9   0.86 0.0036294 
301 Q3MIE4 Vat1 Synaptic vesicle membrane protein VAT-1 homolog   0.86 0.0293934 
302 P14408 Fh Fumarate hydratase, mitochondrial   0.86 0.0449060 
303 Q5XIH7 Phb2 Prohibitin-2   0.86 0.0002638 
304 Q2LAP6 Tes Testin   0.86 0.0060924 
305 P04550 Ptms Parathym in   0.86 0.0173610 
306 P63312 Tmsb10 Thym in beta-10   0.86 0.0272058 
307 P16636 Lox Protein-lysine 6-oxidase   0.86 0.0083618 
308 Q5XIN6 Letm1 LETM1 and EF-hand domain-containing protein 1, mitochondrial   0.86 0.0107029 
309 P07323 Eno2 Gamma-enolase   0.86 0.0178061 
310 P85515 Actr1a Alpha-centractin   0.86 0.0014028 
311 Q3KR86 Immt MIC complex subunit Mic60 (Fragment)   0.86 0.0284774 
312 Q5U2U0 Clpx ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial   0.85 0.0090503 
313 Q4QQW4 Hdac1 Histone deacetylase 1   0.85 0.0026765 
314 Q9JLJ3 Aldh9a1 4-trimethylaminobutyraldehyde dehydrogenase   0.85 0.0019633 
315 Q505J8 Farsa Phenylalanine--tRNA ligase alpha subunit   0.85 0.0429945 
316 O35094 Timm44 Mitochondrial import inner membrane translocase subunit TIM44   0.85 0.0304649 
317 P25286 Atp6v0a1 V-type proton ATPase 116 kDa subunit a isoform 1   0.85 0.0359705 
318 P35704 Prdx2 Peroxiredoxin-2   0.85 0.0056877 
319 Q4QQW8 Plbd2 Putative ph pholipase B-like 2   0.85 0.0034790 
320 Q8CGV7 Thtpa Thiamine-triph phatase   0.85 0.0159680 
321 P43244 Matr3 Matrin-3   0.85 0.0295578 
322 Q80X08 Washc2 WASH complex subunit FAM21   0.85 0.0044541 
323 Q62991 Scfd1 Sec1 family domain-containing protein 1   0.85 0.0106231 
324 Q9JM53 Aifm1 Apopt is-inducing factor 1, mitochondrial   0.85 0.0071194 
325 P69060 Cmas N-acylneuraminate cytidylyltransferase   0.84 0.0291077 
326 Q6PCT3 Tpd52l2 Tumor protein D54   0.84 0.0422336 
327 Q68FY0 Uqcrc1 Cytochrome b-c1 complex subunit 1, mitochondrial   0.84 0.0172724 





329 P54001 P4ha1 Prolyl 4-hydroxylase subunit alpha-1   0.84 0.0211830 
330 P18665 Mrpl3 39S ribomal protein L3, mitochondrial   0.84 0.0186807 
331 Q641X3 Hexa Beta-hex aminidase subunit alpha   0.84 0.0055643 
332 P04636 Mdh2 Malate dehydrogenase, mitochondrial   0.84 0.0331004 
333 P63086 Mapk1 Mitogen-activated protein kinase 1   0.84 0.0002483 
334 P97629 Lnpep Leucyl-cystinyl aminopeptidase   0.84 0.0001766 
335 Q5U2Z3 Nap1l4 Nucle ome assembly protein 1-like 4   0.84 0.0067304 
336 O35244 Prdx6 Peroxiredoxin-6   0.83 0.0001017 
337 Q62636 Rap1b Ras-related protein Rap-1b   0.83 0.0115236 
338 P13668 Stmn1 Stathmin   0.83 0.0095801 
339 Q5I0P2 Gcsh Glycine cleavage system H protein, mitochondrial   0.83 0.0213464 
340 Q4KLH4 Pspc1 Paraspeckle component 1   0.83 0.0014221 
341 Q63269 Itpr3 In itol 1,4,5-trisph phate receptor type 3   0.83 0.0493230 
342 Q62826 Hnrnpm Heterogeneous nuclear ribonucleoprotein M   0.83 0.0041922 
343 Q9Z2L0 Vdac1 Voltage-dependent anion-selective channel protein 1   0.82 0.0131790 
344 Q4KM73 Cmpk1 UMP-CMP kinase   0.82 0.0126134 
345 Q4KLN7 Arfgap3 ADP-ribylation factor GTPase-activating protein 3   0.82 0.0004936 
346 B0BNM1 Naxe NAD(P)H-hydrate epimerase   0.82 0.0151538 
347 Q66HC5 Nup93 Nuclear pore complex protein Nup93   0.82 0.0010450 
348 P42123 Ldhb L-lactate dehydrogenase B chain   0.82 0.0000820 
349 P08081 Clta Clathrin light chain A   0.82 0.0006031 
350 Q9WUC4 Atox1 Copper transport protein ATOX1   0.82 0.0353984 
351 P97697 Impa1 In itol monoph phatase 1   0.82 0.0126210 
352 Q9JI03 Col5a1 Collagen alpha-1(V) chain   0.82 0.0415892 
353 Q5XI22 Acat2 Acetyl-CoA acetyltransferase, cyt olic   0.82 0.0002279 
354 P06302 Ptma Prothym in alpha   0.82 0.0014951 
355 P11960 Bckdha 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial (Fragment)   0.82 0.0132905 
356 P38659 Pdia4 Protein disulfide-isomerase A4   0.82 0.0144377 
357 P20069 Pmpca Mitochondrial-processing peptidase subunit alpha   0.82 0.0074923 
358 P00507 Got2 Aspartate aminotransferase, mitochondrial   0.82 0.0005887 
359 Q6PDU7 Atp5l ATP synthase subunit g, mitochondrial   0.82 0.0003393 
360 P08461 Dlat Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial   0.82 0.0183297 
361 Q9ESN0 Fam129a Protein Niban   0.81 0.0016023 
362 P70615 Lmnb1 Lamin-B1   0.81 0.0067297 
363 P80254 Ddt D-dopachrome decarboxylase   0.81 0.0324687 
364 Q6QD51 Ccdc80 Coiled-coil domain-containing protein 80   0.81 0.0155696 
365 Q6P7A9 Gaa Lys omal alpha-gluc idase   0.81 0.0009507 
366 Q5I0D1 Glod4 Glyoxalase domain-containing protein 4   0.81 0.0000244 
367 P17046 Lamp2 Lys ome-associated membrane glycoprotein 2   0.81 0.0183831 
368 Q5XHZ0 Trap1 Heat shock protein 75 kDa, mitochondrial   0.81 0.0004147 





370 Q810U0 Ccdc50 Coiled-coil domain-containing protein 50   0.81 0.0329995 
371 Q07936 Anxa2 Annexin A2   0.81 0.0001686 
372 P09456 Prkar1a cAMP-dependent protein kinase type I-alpha regulatory subunit   0.81 0.0091928 
373 Q920D2 Dhfr Dihydrofolate reductase   0.81 0.0468536 
374 Q5XFX0 Tagln2 Transgelin-2   0.81 0.0035694 
375 P20070 Cyb5r3 NADH-cytochrome b5 reductase 3   0.81 0.0014827 
376 P19511 Atp5f1 ATP synthase F(0) complex subunit B1, mitochondrial   0.80 0.0000492 
377 Q99ML5 Pcyox1 Prenylcysteine oxidase   0.80 0.0125499 
378 Q9QXU8 Dync1li1 Cytoplasmic dynein 1 light intermediate chain 1   0.80 0.0005829 
379 Q62733 Tmpo Lamina-associated polypeptide 2, isoform beta   0.80 0.0059960 
380 Q9EPB1 Dpp7 Dipeptidyl peptidase 2   0.80 0.0029135 
381 O88994 Marc2 Mitochondrial amidoxime reducing component 2   0.80 0.0202140 
382 Q8CG09 Abcc1 Multidrug resistance-associated protein 1   0.80 0.0316521 
383 P50137 Tkt Transketolase   0.80 0.0033514 
384 Q64375 P3h4 Synaptonemal complex protein SC65 (Fragment)   0.80 0.0130969 
385 O88767 Park7 Protein deglycase DJ-1   0.80 0.0005405 
386 P63281 Ube2i SUMO-conjugating enzyme UBC9   0.80 0.0002356 
387 Q9JLT0 Myh10 My in-10   0.80 0.0074501 
388 O35303 Dnm1l Dynamin-1-like protein   0.79 0.0007290 
389 Q642C0 Dnajc8 DnaJ homolog subfamily C member 8   0.79 0.0003905 
390 Q07205 Eif5 Eukaryotic translation initiation factor 5   0.79 0.0072797 
391 P49911 Anp32a Acidic leucine-rich nuclear ph phoprotein 32 family member A   0.79 0.0006473 
392 Q6AXT0 Mrpl37 39S ribomal protein L37, mitochondrial   0.79 0.0252430 
393 Q5XIG0 Nudt9 ADP-ribe pyroph phatase, mitochondrial   0.79 0.0349921 
394 P85972 Vcl Vinculin   0.79 0.0417693 
395 P21571 Atp5j ATP synthase-coupling factor 6, mitochondrial   0.79 0.0341873 
396 P80386 Prkab1 5'-AMP-activated protein kinase subunit beta-1   0.79 0.0241881 
397 Q63598 Pls3 Plastin-3   0.79 0.0176144 
398 A2RUW1 Tollip Toll-interacting protein   0.79 0.0155060 
399 E9PT23 Slc38a10 Putative sodium-coupled neutral amino acid transporter 10   0.79 0.0086947 
400 P21775 Acaa1a 3-ketoacyl-CoA thiolase A, peroxisomal   0.79 0.0008882 
401 Q5GFD9 Impact Protein IMPACT   0.79 0.0000745 
402 P34926 Map1a Microtubule-associated protein 1A   0.79 0.0015535 
403 P47860 Pfkp ATP-dependent 6-ph phofructokinase, platelet type   0.79 0.0000319 
404 P35571 Gpd2 Glycerol-3-ph phate dehydrogenase, mitochondrial   0.79 0.0089304 
405 Q63184 Eif2ak2 Interferon-induced, double-stranded RNA-activated protein kinase   0.79 0.0032215 
406 Q5XI78 Ogdh 2-oxoglutarate dehydrogenase, mitochondrial   0.79 0.0003847 
407 Q920L2 Sdha Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial   0.79 0.0010525 
408 Q9Z2F5 Ctbp1 C-terminal-binding protein 1   0.79 0.0221039 
409 Q32KJ6 Galns N-acetylgalact amine-6-sulfatase   0.79 0.0026002 





411 Q704S8 Crat Carnitine O-acetyltransferase   0.78 0.0168116 
412 Q80Z70 Sel1l Protein sel-1 homolog 1   0.78 0.0060134 
413 Q99NA5 Idh3a Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial   0.78 0.0012564 
414 P0C5W1 Map1s Microtubule-associated protein 1S   0.78 0.0154979 
415 P61959 Sumo2 Small ubiquitin-related modifier 2   0.78 0.0000643 
416 Q64057 Aldh7a1 Alpha-aminoadipic semialdehyde dehydrogenase   0.78 0.0008614 
417 Q62940 Nedd4 E3 ubiquitin-protein ligase NEDD4   0.78 0.0002572 
418 F1LP64 Trip12 E3 ubiquitin-protein ligase TRIP12   0.78 0.0055348 
419 P97521 Slc25a20 Mitochondrial carnitine/acylcarnitine carrier protein   0.78 0.0154279 
420 Q9ER34 Aco2 Aconitate hydratase, mitochondrial   0.78 0.0005769 
421 P85125 Cavin1 Polymerase I and transcript release factor   0.77 0.0007397 
422 Q01205 Dlst Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial   0.77 0.0217270 
423 P19836 Pcyt1a Choline-ph phate cytidylyltransferase A   0.77 0.0045096 
424 P47942 Dpysl2 Dihydropyrimidinase-related protein 2   0.77 0.0000575 
425 Q5XIC2 Ecsit Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial   0.77 0.0100090 
426 P32198 Cpt1a Carnitine O-palmitoyltransferase 1, liver isoform   0.77 0.0347431 
427 Q8VHF5 Cs Citrate synthase, mitochondrial   0.77 0.0001331 
428 P05708 Hk1 Hexokinase-1   0.77 0.0000347 
429 P04166 Cyb5b Cytochrome b5 type B   0.77 0.0051621 
430 P15999 Atp5a1 ATP synthase subunit alpha, mitochondrial   0.77 0.0003735 
431 Q62696 Dlg1 Disks large homolog 1   0.77 0.0092286 
432 P05942 S100a4 Protein S100-A4   0.77 0.0003850 
433 Q2TA68 Opa1 Dynamin-like 120 kDa protein, mitochondrial   0.77 0.0205501 
434 P0C1X8 Aak1 AP2-associated protein kinase 1   0.77 0.0480759 
435 Q64361 Lxn Latexin   0.77 0.0261630 
436 P42676 Nln Neurolysin, mitochondrial   0.76 0.0027773 
437 Q06647 Atp5o ATP synthase subunit O, mitochondrial   0.76 0.0053029 
438 P30009 Marcks Myristoylated alanine-rich C-kinase substrate   0.76 0.0052503 
439 Q9Z1E1 Flot1 Flotillin-1   0.76 0.0212713 
440 Q5XIT9 Mccc2 Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial   0.76 0.0000958 
441 Q6AYE2 Sh3glb1 Endophilin-B1   0.76 0.0378772 
442 P97700 Slc25a11 Mitochondrial 2-oxoglutarate/malate carrier protein   0.76 0.0057248 
443 Q6P6R2 Dld Dihydrolipoyl dehydrogenase, mitochondrial   0.76 0.0027338 
444 P32089 Slc25a1 Tricarboxylate transport protein, mitochondrial   0.76 0.0020070 
445 O70351 Hsd17b10 3-hydroxyacyl-CoA dehydrogenase type-2   0.76 0.0042540 
446 P26772 Hspe1 10 kDa heat shock protein, mitochondrial   0.76 0.0369880 
447 P55260 Anxa4 Annexin A4   0.76 0.0055711 
448 Q2EJA0 Yap1 Transcriptional coactivator YAP1   0.75 0.0134712 
449 P04041 Gpx1 Glutathione peroxidase 1   0.75 0.0115888 
450 Q68FP1 Gsn Gelsolin   0.75 0.0000217 





452 Q4QQV3 Fam162a Protein FAM162A   0.75 0.0476892 
453 P00173 Cyb5a Cytochrome b5   0.75 0.0015601 
454 P15865 Hist1h1e Histone H1.4   0.75 0.0143170 
455 Q3B8P0 Parl Presenilins-associated rhomboid-like protein, mitochondrial   0.75 0.0414244 
456 P48037 Anxa6 Annexin A6   0.75 0.0000279 
457 Q10758 Krt8 Keratin, type II cyt keletal 8   0.75 0.0000942 
458 Q4V8H8 Ehd2 EH domain-containing protein 2   0.75 0.0004423 
459 P97571 Capn1 Calpain-1 catalytic subunit   0.74 0.0000103 
460 Q9Z1H9 Cavin3 Protein kinase C delta-binding protein   0.74 0.0044020 
461 P06214 Alad Delta-aminolevulinic acid dehydratase   0.74 0.0303985 
462 Q5U2Q3  N/A Ester hydrolase C11orf54 homolog   0.74 0.0463222 
463 Q68FU3 Etfb Electron transfer flavoprotein subunit beta   0.74 0.0003606 
464 P23785 Grn Granulins   0.74 0.0207259 
465 Q62638 Glg1 Golgi apparatus protein 1   0.74 0.0050421 
466 P30904 Mif Macrophage migration inhibitory factor   0.74 0.0132020 
467 P45953 Acadvl Very long-chain specific acyl-CoA dehydrogenase, mitochondrial   0.74 0.0000231 
468 P38652 Pgm1 Ph phoglucomutase-1   0.74 0.0006844 
469 P21913 Sdhb Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial   0.74 0.0209860 
470 P10688 Plcd1 1-ph phatidylin itol 4,5-bisph phate ph phodiesterase delta-1   0.74 0.0040607 
471 Q8VID1 Dhrs4 Dehydrogenase/reductase SDR family member 4   0.74 0.0295825 
472 P08010 Gstm2 Glutathione S-transferase Mu 2   0.74 0.0001534 
473 P10719 Atp5b ATP synthase subunit beta, mitochondrial   0.74 0.0006633 
474 P52873 Pc Pyruvate carboxylase, mitochondrial   0.73 0.0002753 
475 Q4KM35 Psmb10 Proteasome subunit beta type-10   0.73 0.0404880 
476 P49432 Pdhb Pyruvate dehydrogenase E1 component subunit beta, mitochondrial   0.73 0.0000004 
477 P28042 Ssbp1 Single-stranded DNA-binding protein, mitochondrial   0.73 0.0018510 
478 Q63663 Gbp2 Guanylate-binding protein 1   0.73 0.0071477 
479 Q4V7F2 Creld1 Cysteine-rich with EGF-like domain protein 1   0.73 0.0000831 
480 B0BNF1 Sept8 Septin-8   0.73 0.0156106 
481 P36201 Crip2 Cysteine-rich protein 2   0.73 0.0090930 
482 Q9Z2S9 Flot2 Flotillin-2   0.73 0.0010387 
483 P02454 Col1a1 Collagen alpha-1(I) chain   0.73 0.0019132 
484 Q5I0C3 Mccc1 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial   0.73 0.0358732 
485 Q99068 Lrpap1 Alpha-2-macroglobulin receptor-associated protein   0.73 0.0014664 
486 Q9QZK5 Htra1 Serine protease HTRA1   0.73 0.0181115 
487 Q5PQM0 Tmem168 Transmembrane protein 168   0.72 0.0196592 
488 P63095 Gnas Guanine nucleotide-binding protein G(s) subunit alpha isoforms short   0.72 0.0113979 
489 P63045 Vamp2 Vesicle-associated membrane protein 2   0.72 0.0488765 
490 P15651 Acads Short-chain specific acyl-CoA dehydrogenase, mitochondrial   0.72 0.0064452 
491 P07092 Serpine2 Glia-derived nexin   0.72 0.0399649 





493 Q9JHY2 Sfxn3 Sideroflexin-3   0.72 0.0018098 
494 P14604 Echs1 Enoyl-CoA hydratase, mitochondrial   0.72 0.0030698 
495 P35434 Atp5d ATP synthase subunit delta, mitochondrial   0.72 0.0049924 
496 P97532 Mpst 3-mercaptopyruvate sulfurtransferase   0.72 0.0004222 
497 Q6P747 Hp1bp3 Heterochromatin protein 1-binding protein 3   0.72 0.0000947 
498 Q8CG45 Akr7a2 Aflatoxin B1 aldehyde reductase member 2   0.71 0.0028299 
499 P53534 Pygb Glycogen ph phorylase, brain form (Fragment)   0.71 0.0000647 
500 P47858 Pfkm ATP-dependent 6-ph phofructokinase, muscle type   0.71 0.0001908 
501 P10888 Cox4i1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial   0.71 0.0012368 
502 Q64232 Tecr Very-long-chain enoyl-CoA reductase   0.71 0.0129254 
503 Q6Q0N3 Nt5dc2 5'-nucleotidase domain-containing protein 2   0.71 0.0022816 
504 P13803 Etfa Electron transfer flavoprotein subunit alpha, mitochondrial   0.71 0.0000466 
505 Q75WE7 Vwa5a von Willebrand factor A domain-containing protein 5A   0.71 0.0001544 
506 D4ACN8 Plgrkt Plasminogen receptor (KT)   0.71 0.0009718 
507 P04182 Oat Ornithine aminotransferase, mitochondrial   0.71 0.0047211 
508 P27867 Sord Sorbitol dehydrogenase   0.71 0.0004821 
509 Q4KM98 Mff Mitochondrial fission factor   0.71 0.0435993 
510 P28077 Psmb9 Proteasome subunit beta type-9   0.70 0.0413773 
511 Q4TU93 Mrc2 C-type mann e receptor 2   0.70 0.0008429 
512 O54748 Stk3 Serine/threonine-protein kinase 3   0.70 0.0076585 
513 P60825 Cirbp Cold-inducible RNA-binding protein   0.70 0.0350027 
514 Q63797 Psme1 Proteasome activator complex subunit 1   0.70 0.0002322 
515 Q6AY84 Scrn1 Secernin-1   0.70 0.0018914 
516 Q9JJ22 Erap1 Endoplasmic reticulum aminopeptidase 1   0.70 0.0009802 
517 P41562 Idh1 Isocitrate dehydrogenase [NADP] cytoplasmic   0.70 0.0000098 
518 P15650 Acadl Long-chain specific acyl-CoA dehydrogenase, mitochondrial   0.70 0.0000598 
519 P0C2X9 Aldh4a1 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial   0.70 0.0003332 
520 P11240 Cox5a Cytochrome c oxidase subunit 5A, mitochondrial   0.70 0.0001077 
521 P14882 Pcca Propionyl-CoA carboxylase alpha chain, mitochondrial   0.70 0.0000914 
522 Q60587 Hadhb Trifunctional enzyme subunit beta, mitochondrial   0.70 0.0003499 
523 Q9JIM0 Mre11 Double-strand break repair protein MRE11A   0.70 0.0083976 
524 Q64428 Hadha Trifunctional enzyme subunit alpha, mitochondrial   0.69 0.0000443 
525 Q810F4 Fam3c Protein FAM3C   0.69 0.0013938 
526 Q63321 Plod1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1   0.69 0.0000215 
527 P21396 Maoa Amine oxidase [flavin-containing] A   0.69 0.0000825 
528 P25093 Fah Fumarylacetoacetase   0.69 0.0040200 
529 Q6AXU6 JPT1 Hematological and neurological expressed 1 protein   0.69 0.0014327 
530 Q9Z327 Synpo Synaptopodin   0.69 0.0039664 
531 P56574 Idh2 Isocitrate dehydrogenase [NADP], mitochondrial   0.69 0.0001601 
532 Q7TQ16 Uqcrq Cytochrome b-c1 complex subunit 8   0.69 0.0474050 





534 P11951 Cox6c2 Cytochrome c oxidase subunit 6C-2   0.68 0.0200809 
535 D3ZAF6 Atp5j2 ATP synthase subunit f, mitochondrial   0.68 0.0032847 
536 Q7TPB4 Cd276 CD276 antigen   0.68 0.0001779 
537 P41350 Cav1 Caveolin-1   0.68 0.0016633 
538 Q10739 Mmp14 Matrix metalloproteinase-14   0.68 0.0013451 
539 Q00238 Icam1 Intercellular adhesion molecule 1   0.68 0.0005359 
540 Q9Z0J5 Txnrd2 Thioredoxin reductase 2, mitochondrial   0.68 0.0006278 
541 P12075 Cox5b Cytochrome c oxidase subunit 5B, mitochondrial   0.68 0.0041743 
542 O88775 Emb Embigin   0.68 0.0206963 
543 B0BNA5 Cotl1 Coact in-like protein   0.68 0.0089586 
544 O35854 Bcat2 Branched-chain-amino-acid aminotransferase, mitochondrial   0.68 0.0035203 
545 P15978 RT1-Aw2 Class I histocompatibility antigen, Non-RT1.A alpha-1 chain   0.68 0.0041685 
546 P23965 Eci1 Enoyl-CoA delta isomerase 1, mitochondrial   0.67 0.0000586 
547 P18886 Cpt2 Carnitine O-palmitoyltransferase 2, mitochondrial   0.67 0.0020404 
548 P04906 Gstp1 Glutathione S-transferase P   0.67 0.0132907 
549 P97608 Oplah 5-oxoprolinase   0.67 0.0046135 
550 Q9ER24 Atxn10 Ataxin-10   0.67 0.0153647 
551 P14841 Cst3 Cystatin-C   0.67 0.0215712 
552 P97546 Nptn Neuroplastin   0.67 0.0028680 
553 P97852 Hsd17b4 Peroxisomal multifunctional enzyme type 2   0.67 0.0000660 
554 P06536 Nr3c1 Glucocorticoid receptor   0.67 0.0385047 
555 P18437 Hmgn2 Non-histone chrom omal protein HMG-17   0.66 0.0081645 
556 P50123 Enpep Glutamyl aminopeptidase   0.66 0.0006071 
557 P10860 Glud1 Glutamate dehydrogenase 1, mitochondrial   0.66 0.0002313 
558 P52759 Rida Ribonuclease UK114   0.65 0.0008711 
559 P26453 Bsg Basigin   0.65 0.0012228 
560 Q5XIC0 Eci2 Enoyl-CoA delta isomerase 2, mitochondrial   0.65 0.0000079 
561 Q5XIE6 Hibch 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial   0.65 0.0358018 
562 Q6P7C7 Gpnmb Transmembrane glycoprotein NMB   0.65 0.0001072 
563 P06760 Gusb Beta-glucuronidase   0.65 0.0074165 
564 Q6P0K8 Jup Junction plakoglobin   0.65 0.0005066 
565 P00406 Mtco2 Cytochrome c oxidase subunit 2   0.65 0.0001418 
566 P15684 Anpep Aminopeptidase N   0.64 0.0218193 
567 P28037 Aldh1l1 Cyt olic 10-formyltetrahydrofolate dehydrogenase   0.64 0.0106161 
568 Q920G2 Slc9a3r2 Na(+)/H(+) exchange regulatory cofactor NHE-RF2   0.64 0.0119657 
569 P84817 Fis1 Mitochondrial fission 1 protein   0.64 0.0009579 
570 P21708 Mapk3 Mitogen-activated protein kinase 3   0.64 0.0012310 
571 P70584 Acadsb Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial   0.64 0.0002386 
572 P07150 Anxa1 Annexin A1   0.63 0.0000119 
573 Q4G075 Serpinb1a Leukocyte elastase inhibitor A   0.63 0.0018797 





575 P13596 Ncam1 Neural cell adhesion molecule 1   0.63 0.0015943 
576 Q9QX69 Lancl1 LanC-like protein 1   0.63 0.0007704 
577 P29266 Hibadh 3-hydroxyisobutyrate dehydrogenase, mitochondrial   0.63 0.0000310 
578 Q08850 Stx4 Syntaxin-4   0.63 0.0002746 
579 Q1AAU6 Asap1 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1   0.63 0.0057536 
580 P07154 Ctsl Cathepsin L1   0.63 0.0018394 
581 Q6MG60 Ddah2 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2   0.63 0.0000713 
582 P70550 Rab8b Ras-related protein Rab-8B   0.63 0.0016055 
583 Q9Z252 Lin7b Protein lin-7 homolog B   0.62 0.0109877 
584 P29411 Ak3 GTP:AMP ph photransferase AK3, mitochondrial   0.62 0.0000360 
585 Q9ERB4 Vcan Versican core protein (Fragments)   0.62 0.0116038 
586 Q5XI42 Aldh3b1 Aldehyde dehydrogenase family 3 member B1   0.62 0.0078887 
587 P08011 Mgst1 Micr omal glutathione S-transferase 1   0.62 0.0199485 
588 P18614 Itga1 Integrin alpha-1   0.61 0.0246665 
589 P18297 Spr Sepiapterin reductase   0.61 0.0009427 
590 Q9QWN8 Sptbn2 Spectrin beta chain, non-erythrocytic 2   0.61 0.0019092 
591 P12007 Ivd Isovaleryl-CoA dehydrogenase, mitochondrial   0.61 0.0000446 
592 Q4G017 Nisch Nischarin   0.61 0.0407536 
593 P17764 Acat1 Acetyl-CoA acetyltransferase, mitochondrial   0.61 0.0009736 
594 Q5BJK8 Golim4 Golgi integral membrane protein 4   0.60 0.0000660 
595 Q9WVK7 Hadh Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial   0.60 0.0000067 
596 Q8K5A9 Nradd Death domain-containing membrane protein NRADD   0.60 0.0004733 
597 P04904 Gsta3 Glutathione S-transferase alpha-3   0.59 0.0012798 
598 Q9EPH2 Marcksl1 MARCKS-related protein   0.59 0.0038476 
599 P11915 Scp2 Non-specific lipid-transfer protein   0.59 0.0002519 
600 P07633 Pccb Propionyl-CoA carboxylase beta chain, mitochondrial   0.58 0.0000289 
601 P11505 Atp2b1 Plasma membrane calcium-transporting ATPase 1   0.58 0.0000227 
602 P16086 Sptan1 Spectrin alpha chain, non-erythrocytic 1   0.58 0.0000094 
603 D4A1J4 Bdh2 3-hydroxybutyrate dehydrogenase type 2   0.58 0.0094715 
604 P30839 Aldh3a2 Fatty aldehyde dehydrogenase   0.58 0.0004343 
605 P16391  N/A RT1 class I histocompatibility antigen, AA alpha chain   0.58 0.0048209 
606 Q9JJ19 Slc9a3r1 Na(+)/H(+) exchange regulatory cofactor NHE-RF1   0.57 0.0000786 
607 P12369 Prkar2b cAMP-dependent protein kinase type II-beta regulatory subunit   0.57 0.0045010 
608 Q6JE36 Ndrg1 Protein NDRG1   0.56 0.0058849 
609 Q9WU82 Ctnnb1 Catenin beta-1   0.56 0.0000517 
610 Q62627 Pawr PRKC apopt is WT1 regulator protein   0.55 0.0465606 
611 P13437 Acaa2 3-ketoacyl-CoA thiolase, mitochondrial   0.55 0.0000607 
612 Q02253 Aldh6a1 Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial   0.55 0.0000017 
613 Q5U4F3 Fam107b Protein FAM107B   0.55 0.0026386 
614 P11884 Aldh2 Aldehyde dehydrogenase, mitochondrial   0.54 0.0000111 





616 Q5U2T3 Spats2l SPATS2-like protein   0.52 0.0001881 
617 Q5RKH6 Os9 Protein Os-9   0.51 0.0000169 
618 Q62651 Ech1 Delta (3,5)-Delta (2,4)-dienoyl-CoA isomerase, mitochondrial   0.50 0.0014289 
619 Q64591 Decr1 2,4-dienoyl-CoA reductase, mitochondrial   0.49 0.0002485 
620 O08628 Pcolce Procollagen C-endopeptidase enhancer 1   0.49 0.0000142 
621 P04762 Cat Catalase   0.47 0.0000000 
622 Q63028 Add1 Alpha-adducin   0.44 0.0000762 
623 P08430 Ugt1a6 UDP-glucuron yltransferase 1-6   0.43 0.0000274 
624 O35276 Nrp2 Neuropilin-2   0.43 0.0074137 
625 Q8R4C0 Capn5 Calpain-5   0.39 0.0025916 
626 Q62847 Add3 Gamma-adducin   0.37 0.0052223 
627 Q8VIF7 Selenbp1 Selenium-binding protein 1   0.34 0.0000377 





























Supplementary Table. 2. SRM, baicalein and IN1130 all significantly regulated proteins 
involved in the focal adhesion pathway. Shown here are mean fold changes of proteins 
expression versus TGF-β1 group, p<0.05, "-": not significantly regulated by drug(s).  










P18666 Myl12b 0.55 1.00 - 0.57 0.89 - 0.52 
Q9Z1P2 Actn1 0.70 1.00 - 0.83 0.72 - 0.73 
P18266 Gsk3b 0.71 1.00 - 0.65 0.75 - 0.76 
Q9QXQ0 Actn4 0.72 1.00 - 0.81 0.74 - 0.75 
P04937 Fn1 0.75 1.00 - 1.34 0.87 - 0.83 
Q01986 Map2k1 0.76 1.00 - 0.96 1.09 - 0.77 
P08721 Spp1 0.81 1.00 - 1.00 1.55 - 0.81 
P60711 Actb 0.91 1.00 - 0.88 0.74 - 0.92 
Q9HB97 Parva 0.93 1.00 - 0.90 0.78 - 0.95 
P13941 Col3a1 1.16 1.00 - 1.45 0.89 - 1.45 
P02466 Col1a2 1.18 1.00 - 1.32 0.93 - 1.37 
Q9JI03 Col5a1 1.22 1.00 - 1.37 0.81 - 1.36 
P02454 Col1a1 1.37 1.00 - 1.43 1.16 - 1.53 
P41350 Cav1 1.46 1.00 - 1.06 0.92 - 1.40 
P21708 Mapk3 1.57 1.00 - 1.14 1.06 - 1.46 
P18614 Itga1 1.63 1.00 - 1.07 0.96 - 1.69 




































Supplementary Table. 3. SRM and IN1130 significantly regulated proteins involved in 
the amoebiasis pathway pathway. Shown here are mean fold changes of proteins 
expression versus TGF-β1 group, p<0.05. 
Accession Protein Control TGF-β1 
TGF-β1 
80 μg/mL SRM IN1130 
Q9Z1P2 Actn1 0.70 1.00 0.83 0.73 
P42930 Hspb1 0.71 1.00 0.86 0.75 
Q9QXQ0 Actn4 0.72 1.00 0.81 0.75 
P04937 Fn1 0.75 1.00 1.34 0.83 
P13941 Col3a1 1.16 1.00 1.45 1.45 
P02466 Col1a2 1.18 1.00 1.32 1.37 
Q9JI03 Col5a1 1.22 1.00 1.37 1.36 
P02454 Col1a1 1.37 1.00 1.43 1.53 


















































Supplementary Table. 4. Baicalein and IN1130 significantly regulated proteins involved 
13 KEGG pathways. Shown here are mean fold changes of proteins expression versus 
TGF-β1 group, p<0.05, "-": not significantly regulated by drug(s). 
 
Accession Protein Control TGF-β1 
TGF-β1 
40 μM Baicalein 80 μM Baicalein IN1130 
Drug metabolism - cytochrome P450 
P06757 Adh1 1.18 1.00 1.27 0.99 1.06 
P08010 Gstm2 1.36 1.00 1.04 0.92 1.38 
P21396 Maoa 1.45 1.00 1.48 1.63 1.25 
P04906 Gstp1 1.48 1.00 1.50 1.68 1.40 
Q5XI42 Aldh3b1 1.61 1.00 1.30 1.46 1.48 
P08011 Mgst1 1.62 1.00 1.15 1.03 1.62 
P04904 Gsta3 1.68 1.00 1.78 1.85 1.45 
P08430 Ugt1a6 2.30 1.00 1.33 1.72 2.01 
P11883 Aldh3a1 4.50 1.00 1.71 1.76 4.36 
Histidine metabolism 
P21396 Maoa 1.45 1.00 1.48 1.63 1.25 
Q5XI42 Aldh3b1 1.61 1.00 1.30 1.46 1.48 
P30839 Aldh3a2 1.73 1.00 0.85 0.87 1.62 
P11884 Aldh2 1.85 1.00 1.28 1.36 1.62 
P11883 Aldh3a1 4.50 1.00 1.71 1.76 4.36 
Carbon metabolism 
Q5M819 Psph 0.60 1.00 0.90 0.79 0.72 
P27881 Hk2 0.69 1.00 1.32 1.67 0.70 
P05065 Aldoa 0.89 1.00 1.14 1.44 0.88 
P85968 Pgd 0.98 1.00 1.28 1.14 1.00 
P07323 Eno2 1.17 1.00 1.07 1.33 1.13 
P50137 Tkt 1.25 1.00 1.40 1.56 1.18 
P47860 Pfkp 1.27 1.00 1.16 1.31 1.18 
Q920L2 Sdha 1.27 1.00 0.86 0.69 1.18 
Q99NA5 Idh3a 1.28 1.00 1.16 1.35 1.17 
Q01205 Dlst 1.29 1.00 1.16 1.29 1.14 
Q6P6R2 Dld 1.32 1.00 1.12 1.30 1.18 
P52873 Pc 1.36 1.00 1.29 1.33 1.21 
P47858 Pfkm 1.41 1.00 1.13 1.12 1.37 
P14882 Pcca 1.43 1.00 1.22 1.19 1.33 
P56574 Idh2 1.46 1.00 1.18 1.22 1.30 
P10860 Glud1 1.52 1.00 1.21 1.23 1.39 
P17764 Acat1 1.65 1.00 1.17 1.32 1.53 
P07633 Pccb 1.72 1.00 1.20 1.48 1.51 





P04762 Cat 2.11 1.00 1.84 1.69 1.77 
Metabolic pathways 
Q924C3 Enpp1 0.28 1.00 0.36 0.17 0.37 
P54690 Bcat1 0.52 1.00 0.80 0.91 0.61 
P49088 Asns 0.54 1.00 0.89 0.83 0.57 
Q5M819 Psph 0.60 1.00 0.90 0.79 0.72 
Q05982 Nme1 0.61 1.00 0.94 0.57 0.73 
E9PU28 Impdh2 0.62 1.00 0.98 0.93 0.69 
P07314 Ggt1 0.63 1.00 1.47 1.23 0.63 
D3ZUA0 Mthfd2l 0.64 1.00 1.03 1.23 0.65 
P19804 Nme2 0.64 1.00 1.00 0.70 0.73 
P27881 Hk2 0.69 1.00 1.32 1.67 0.70 
Q5PQL5 Ptdss1 0.70 1.00 0.85 0.60 0.75 
P82808 Gfpt1 0.72 1.00 0.98 0.82 0.76 
P07335 Ckb 0.83 1.00 0.79 0.58 0.87 
P05065 Aldoa 0.89 1.00 1.14 1.44 0.88 
P18298 Mat2a 0.91 1.00 1.14 1.42 0.94 
P07943 Akr1b1 0.96 1.00 1.69 1.79 0.95 
P11348 Qdpr 0.97 1.00 0.98 1.27 0.92 
P85968 Pgd 0.98 1.00 1.28 1.14 1.00 
Q66HF1 Ndufs1 0.98 1.00 0.56 0.42 1.10 
O55171 Acot2 0.99 1.00 1.31 1.46 0.72 
Q5RJP0 Akr1b7 1.04 1.00 3.55 4.72 0.94 
P07323 Eno2 1.17 1.00 1.07 1.33 1.13 
P25286 Atp6v0a1 1.17 1.00 1.12 1.46 1.09 
Q6AYQ8 Fahd1 1.18 1.00 1.33 1.24 1.12 
P06757 Adh1 1.18 1.00 1.27 0.99 1.06 
P69060 Cmas 1.18 1.00 1.15 1.26 1.08 
P54001 P4ha1 1.19 1.00 1.21 1.54 1.14 
Q80Z29 Nampt 1.21 1.00 1.29 1.36 1.13 
P19234 Ndufv2 1.21 1.00 0.71 0.53 1.08 
Q9WTT6 Gda 1.22 1.00 0.98 0.88 1.28 
P11960 Bckdha 1.22 1.00 1.04 1.35 1.15 
P45479 Ppt1 1.24 1.00 1.24 1.44 1.18 
Q920D2 Dhfr 1.24 1.00 1.27 1.30 1.34 
P50137 Tkt 1.25 1.00 1.40 1.56 1.18 
P21571 Atp5j 1.27 1.00 1.13 1.26 1.21 
P21775 Acaa1a 1.27 1.00 1.22 1.35 1.16 
P47860 Pfkp 1.27 1.00 1.16 1.31 1.18 
Q920L2 Sdha 1.27 1.00 0.86 0.69 1.18 
Q9Z2Z8 Dhcr7 1.27 1.00 1.17 1.17 1.33 





Q01205 Dlst 1.29 1.00 1.16 1.29 1.14 
P19836 Pcyt1a 1.29 1.00 1.25 1.31 1.20 
Q06647 Atp5o 1.31 1.00 1.09 1.33 1.20 
P48450 Lss 1.31 1.00 1.24 1.08 1.58 
Q6P6R2 Dld 1.32 1.00 1.12 1.30 1.18 
P06214 Alad 1.35 1.00 1.16 2.34 1.45 
P38652 Pgm1 1.35 1.00 1.12 1.12 1.38 
Q8VID1 Dhrs4 1.36 1.00 1.31 1.39 1.39 
P10719 Atp5b 1.36 1.00 1.15 1.31 1.22 
P52873 Pc 1.36 1.00 1.29 1.33 1.21 
Q5I0C3 Mccc1 1.37 1.00 1.12 1.22 1.36 
P19468 Gclc 1.37 1.00 1.33 1.82 1.27 
P35434 Atp5d 1.39 1.00 1.17 1.27 1.33 
P97532 Mpst 1.40 1.00 1.17 1.05 1.31 
P53534 Pygb 1.40 1.00 1.09 1.14 1.36 
P47858 Pfkm 1.41 1.00 1.13 1.12 1.37 
P10888 Cox4i1 1.41 1.00 1.05 1.30 1.33 
P04182 Oat 1.42 1.00 1.07 1.15 1.35 
P0C2X9 Aldh4a1 1.43 1.00 1.08 1.36 1.51 
P11240 Cox5a 1.43 1.00 1.09 1.36 1.35 
P14882 Pcca 1.43 1.00 1.22 1.19 1.33 
P21396 Maoa 1.45 1.00 1.48 1.63 1.25 
P25093 Fah 1.45 1.00 1.03 1.28 1.40 
P56574 Idh2 1.46 1.00 1.18 1.22 1.30 
Q7TQ16 Uqcrq 1.46 1.00 0.95 1.10 1.35 
D3ZAF6 Atp5j2 1.46 1.00 1.21 1.15 1.32 
P12075 Cox5b 1.47 1.00 1.09 1.37 1.37 
O35854 Bcat2 1.47 1.00 1.12 1.18 1.34 
P97852 Hsd17b4 1.49 1.00 1.37 1.43 1.39 
P10860 Glud1 1.52 1.00 1.21 1.23 1.39 
P06760 Gusb 1.54 1.00 0.96 1.28 1.49 
P15684 Anpep 1.55 1.00 1.05 1.29 1.26 
P70584 Acadsb 1.57 1.00 1.15 1.15 1.33 
P29266 Hibadh 1.59 1.00 1.22 1.32 1.44 
Q5XI42 Aldh3b1 1.61 1.00 1.30 1.46 1.48 
P18297 Spr 1.63 1.00 1.28 1.38 1.46 
P12007 Ivd 1.64 1.00 1.12 1.19 1.40 
P17764 Acat1 1.65 1.00 1.17 1.32 1.53 
Q9WVK7 Hadh 1.67 1.00 1.23 1.13 1.51 
P11915 Scp2 1.69 1.00 1.15 0.98 1.59 
P07633 Pccb 1.72 1.00 1.20 1.48 1.51 





P30839 Aldh3a2 1.73 1.00 0.85 0.87 1.62 
P13437 Acaa2 1.83 1.00 1.25 1.17 1.63 
Q02253 Aldh6a1 1.83 1.00 1.22 1.32 1.60 
P11884 Aldh2 1.85 1.00 1.28 1.36 1.62 
P08430 Ugt1a6 2.30 1.00 1.33 1.72 2.01 
P11883 Aldh3a1 4.50 1.00 1.71 1.76 4.36 
Glycolysis / Gluconeogenesis 
P27881 Hk2 0.69 1.00 1.32 1.67 0.70 
P06757 Adh1 1.18 1.00 1.27 0.99 1.06 
Q6P6R2 Dld 1.32 1.00 1.12 1.30 1.18 
P38652 Pgm1 1.35 1.00 1.12 1.12 1.38 
P47858 Pfkm 1.41 1.00 1.13 1.12 1.37 
Q5XI42 Aldh3b1 1.61 1.00 1.30 1.46 1.48 
P17764 Acat1 1.65 1.00 1.17 1.32 1.53 
P07633 Pccb 1.72 1.00 1.20 1.48 1.51 
P30839 Aldh3a2 1.73 1.00 0.85 0.87 1.62 
P11884 Aldh2 1.85 1.00 1.28 1.36 1.62 
P04762 Cat 2.11 1.00 1.84 1.69 1.77 
P11883 Aldh3a1 4.50 1.00 1.71 1.76 4.36 
Tyrosine metabolism 
Q6AYQ8 Fahd1 1.18 1.00 1.33 - 1.12 
P06757 Adh1 1.18 1.00 1.27 - 1.06 
P21396 Maoa 1.45 1.00 1.48 - 1.25 
Q5XI42 Aldh3b1 1.61 1.00 1.30 - 1.48 
P17764 Acat1 1.65 1.00 1.17 - 1.53 
Q9WVK7 Hadh 1.67 1.00 1.23 - 1.51 
P30839 Aldh3a2 1.73 1.00 0.85 - 1.62 
P11884 Aldh2 1.85 1.00 1.28 - 1.62 
P04762 Cat 2.11 1.00 1.84 - 1.77 
P11883 Aldh3a1 4.50 1.00 1.71 - 4.36 
Glutathione metabolism 
P07314 Ggt1 0.63 1.00 1.47 - 0.63 
Q91XR8 Gpx4 0.96 1.00 1.32 - 0.83 
Q91XR8 Gpx4 0.96 1.00 1.32 - 0.83 
P85968 Pgd 0.98 1.00 1.28 - 1.00 
P85968 Pgd 0.98 1.00 1.28 - 1.00 
P08010 Gstm2 1.36 1.00 1.04 - 1.38 
P56574 Idh2 1.46 1.00 1.18 - 1.30 
P04906 Gstp1 1.48 1.00 1.50 - 1.40 
P97608 Oplah 1.48 1.00 1.02 - 1.54 
P08011 Mgst1 1.62 1.00 1.15 - 1.62 





Metabolism of xenobiotics by cytochrome P450 
P06757 Adh1 1.18 1.00 1.27 - 1.06 
P06757 Adh1 1.18 1.00 1.27 - 1.06 
P08010 Gstm2 1.36 1.00 1.04 - 1.38 
Q8CG45 Akr7a2 1.40 1.00 1.09 - 1.35 
P04906 Gstp1 1.48 1.00 1.50 - 1.40 
Q5XI42 Aldh3b1 1.61 1.00 1.30 - 1.48 
P08011 Mgst1 1.62 1.00 1.15 - 1.62 
P04904 Gsta3 1.68 1.00 1.78 - 1.45 
P08430 Ugt1a6 2.30 1.00 1.33 - 2.01 
P11883 Aldh3a1 4.50 1.00 1.71 - 4.36 
Chemical carcinogenesis 
Q9R063 Prdx5 0.75 1.00 1.16 - 0.75 
P07895 Sod2 1.06 1.00 1.28 - 1.04 
P06757 Adh1 1.18 1.00 1.27 - 1.06 
Q704S8 Crat 1.28 1.00 1.13 - 1.32 
P56574 Idh2 1.46 1.00 1.18 - 1.30 
P04906 Gstp1 1.48 1.00 1.50 - 1.40 
Q5XI42 Aldh3b1 1.61 1.00 1.30 - 1.48 
P04904 Gsta3 1.68 1.00 1.78 - 1.45 
P11915 Scp2 1.69 1.00 1.15 - 1.59 
Q62651 Ech1 2.02 1.00 1.01 - 1.73 
P11883 Aldh3a1 4.50 1.00 1.71 - 4.36 
Peroxisome 
P07895 Sod2 1.06 1.00 1.28 - 1.04 
P06757 Adh1 1.18 1.00 1.27 - 1.06 
Q8VID1 Dhrs4 1.36 1.00 1.31 - 1.39 
P08010 Gstm2 1.36 1.00 1.04 - 1.38 
P97852 Hsd17b4 1.49 1.00 1.37 - 1.39 
P08011 Mgst1 1.62 1.00 1.15 - 1.62 
P04762 Cat 2.11 1.00 1.84 - 1.77 
P08430 Ugt1a6 2.30 1.00 1.33 - 2.01 
Biosynthesis of antibiotics 
P54690 Bcat1 0.52 1.00 - 0.91 0.61 
Q5M819 Psph 0.60 1.00 - 0.79 0.72 
Q05982 Nme1 0.61 1.00 - 0.57 0.73 
P19804 Nme2 0.64 1.00 - 0.70 0.73 
P27881 Hk2 0.69 1.00 - 1.67 0.70 
P82808 Gfpt1 0.72 1.00 - 0.82 0.76 
P05065 Aldoa 0.89 1.00 - 1.44 0.88 
P07323 Eno2 1.17 1.00 - 1.33 1.13 





P50137 Tkt 1.25 1.00 - 1.56 1.18 
P21775 Acaa1a 1.27 1.00 - 1.35 1.16 
P47860 Pfkp 1.27 1.00 - 1.31 1.18 
Q920L2 Sdha 1.27 1.00 - 0.69 1.18 
Q99NA5 Idh3a 1.28 1.00 - 1.35 1.17 
Q01205 Dlst 1.29 1.00 - 1.29 1.14 
P48450 Lss 1.31 1.00 - 1.08 1.58 
Q6P6R2 Dld 1.32 1.00 - 1.30 1.18 
P38652 Pgm1 1.35 1.00 - 1.12 1.38 
P47858 Pfkm 1.41 1.00 - 1.12 1.37 
P04182 Oat 1.42 1.00 - 1.15 1.35 
P14882 Pcca 1.43 1.00 - 1.19 1.33 
P56574 Idh2 1.46 1.00 - 1.22 1.30 
O35854 Bcat2 1.47 1.00 - 1.18 1.34 
P29411 Ak3 1.61 1.00 - 1.26 1.37 
P17764 Acat1 1.65 1.00 - 1.32 1.53 
Q9WVK7 Hadh 1.67 1.00 - 1.13 1.51 
P07633 Pccb 1.72 1.00 - 1.48 1.51 
P30839 Aldh3a2 1.73 1.00 - 0.87 1.62 
P13437 Acaa2 1.83 1.00 - 1.17 1.63 
P11884 Aldh2 1.85 1.00 - 1.36 1.62 
P04762 Cat 2.11 1.00 - 1.69 1.77 
Valine, leucine and isoleucine degradation 
P54690 Bcat1 0.52 1.00 - 0.91 0.61 
P11960 Bckdha 1.22 1.00 - 1.35 1.15 
P21775 Acaa1a 1.27 1.00 - 1.35 1.16 
Q6P6R2 Dld 1.32 1.00 - 1.30 1.18 
Q5I0C3 Mccc1 1.37 1.00 - 1.22 1.36 
P14882 Pcca 1.43 1.00 - 1.19 1.33 
O35854 Bcat2 1.47 1.00 - 1.18 1.34 
P70584 Acadsb 1.57 1.00 - 1.15 1.33 
P29266 Hibadh 1.59 1.00 - 1.32 1.44 
P12007 Ivd 1.64 1.00 - 1.19 1.40 
P17764 Acat1 1.65 1.00 - 1.32 1.53 
Q9WVK7 Hadh 1.67 1.00 - 1.13 1.51 
P07633 Pccb 1.72 1.00 - 1.48 1.51 
P30839 Aldh3a2 1.73 1.00 - 0.87 1.62 
P13437 Acaa2 1.83 1.00 - 1.17 1.63 
Q02253 Aldh6a1 1.83 1.00 - 1.32 1.60 
P11884 Aldh2 1.85 1.00 - 1.36 1.62 
Glyoxylate and dicarboxylate metabolism 





P14882 Pcca 1.43 1.00 - 1.19 1.33 
P17764 Acat1 1.65 1.00 - 1.32 1.53 
P07633 Pccb 1.72 1.00 - 1.48 1.51 














































































Supplementary Table. 5. SRM significantly regulated proteins involved 5 KEGG 
pathways. Shown here are mean fold changes of proteins expression versus TGF-β1 group, 
p<0.05. 
 
Accession Protein Control TGF-β1 TGF-β1 + 80 μg/mL SRM 
ECM-receptor interaction 
P04937 Fn1 0.75 1.00 1.34 
P13941 Col3a1 1.16 1.00 1.45 
P02466 Col1a2 1.18 1.00 1.32 
Q9JI03 Col5a1 1.22 1.00 1.37 
P02454 Col1a1 1.37 1.00 1.43 
Platelet activation 
P18666 Myl12b 0.55 1.00 0.57 
P13941 Col3a1 1.16 1.00 1.45 
P02466 Col1a2 1.18 1.00 1.32 
Q9JI03 Col5a1 1.22 1.00 1.37 
P02454 Col1a1 1.37 1.00 1.43 
Protein digestion and absorption 
P13941 Col3a1 1.16 1.00 1.45 
P02466 Col1a2 1.18 1.00 1.32 
Q9JI03 Col5a1 1.22 1.00 1.37 
P02454 Col1a1 1.37 1.00 1.43 
PI3K-Akt signalling pathway 
P18266 Gsk3b 0.71 1.00 0.65 
P04937 Fn1 0.75 1.00 1.34 
P13941 Col3a1 1.16 1.00 1.45 
P02466 Col1a2 1.18 1.00 1.32 
Q9JI03 Col5a1 1.22 1.00 1.37 
P02454 Col1a1 1.37 1.00 1.43 
Tight junction 
P18666 Myl12b 0.55 1.00 0.57 
O35889 Afdn 0.71 1.00 0.80 
Q9QXQ0 Actn4 0.72 1.00 0.81 

























Supplementary Table. 6. Baicalein significantly regulated proteins involved 18 KEGG 
pathways. Shown here are mean fold changes of proteins expression versus TGF-β1 group, 
p<0.05, "-": not significantly regulated by 40 μΜ or 80 μΜ baicalein.  
 
Accession Protein Control TGF-β1 
TGF-β1 
40 μM Baicalein 80 μM Baicalein 
Galactose metabolism 
P27881 Hk2 0.69 1.00 1.32 1.67 
P07943 Akr1b1 0.96 1.00 1.69 1.79 
Q5RJP0 Akr1b7 1.04 1.00 3.55 4.72 
P47860 Pfkp 1.27 1.00 1.16 1.31 
Fructose and mannose metabolism 
P27881 Hk2 0.69 1.00 1.32 1.67 
P07943 Akr1b1 0.96 1.00 1.69 1.79 
Q5RJP0 Akr1b7 1.04 1.00 3.55 4.72 
P47860 Pfkp 1.27 1.00 1.16 1.31 
P05065 Aldoa 0.89 1.00 1.14 1.44 
Cardiac muscle contraction 
P04692 Tpm1 0.76 1.00 0.52 0.30 
P09495 Tpm4 0.87 1.00 0.70 0.58 
P68035 Actc1 0.84 1.00 0.79 0.64 
P58775 Tpm2 0.63 1.00 0.47 0.30 
P17209 Myl4 0.67 1.00 0.43 1.11 
P11240 Cox5a 1.43 1.00 1.09 1.36 
P12075 Cox5b 1.47 1.00 1.09 1.37 
P10888 Cox4i1 1.41 1.00 1.05 1.30 
Dilated cardiomyopathy 
P58775 Tpm2 0.63 1.00 0.47 - 
P04692 Tpm1 0.76 1.00 0.52 - 
P68035 Actc1 0.84 1.00 0.79 - 
P09495 Tpm4 0.87 1.00 0.70 - 
P60711 Actb 0.91 1.00 0.74 - 
P63095 Gnas 1.38 1.00 1.42 - 
Hypertrophic cardiomyopathy (HCM) 
P58775 Tpm2 0.63 1.00 0.47 - 
P04692 Tpm1 0.76 1.00 0.52 - 
P68035 Actc1 0.84 1.00 0.79 - 
P09495 Tpm4 0.87 1.00 0.70 - 
P60711 Actb 0.91 1.00 0.74 - 





P58775 Tpm2 0.63 1.00 0.47 - 
P17209 Myl4 0.67 1.00 0.43 - 
P04692 Tpm1 0.76 1.00 0.52 - 
P68035 Actc1 0.84 1.00 0.79 - 
P09495 Tpm4 0.87 1.00 0.70 - 
P63095 Gnas 1.38 1.00 1.42 - 
Phenylalanine metabolism 
P21396 Maoa 1.45 1.00 1.48 - 
Q5XI42 Aldh3b1 1.61 1.00 1.30 - 
P11883 Aldh3a1 4.50 1.00 1.71 - 
Adherens junction 
Q9Z1P2 Actn1 0.70 1.00 0.72 - 
O35889 Afdn 0.71 1.00 0.80 - 
Q9QXQ0 Actn4 0.72 1.00 0.74 - 
P60711 Actb 0.91 1.00 0.74 - 
Alzheimer's disease 
P0DP29 Calm1 0.48 1.00 - 0.45 
P18266 Gsk3b 0.71 1.00 - 0.75 
Q9EPV5 Apaf1 0.91 1.00 - 1.36 
Q66HF1 Ndufs1 0.98 1.00 - 0.42 
Q63269 Itpr3 1.21 1.00 - 1.38 
P19234 Ndufv2 1.21 1.00 - 0.53 
P21571 Atp5j 1.27 1.00 - 1.26 
Q920L2 Sdha 1.27 1.00 - 0.69 
Q06647 Atp5o 1.31 1.00 - 1.33 
P10719 Atp5b 1.36 1.00 - 1.31 
P10888 Cox4i1 1.41 1.00 - 1.30 
P11240 Cox5a 1.43 1.00 - 1.36 
P12075 Cox5b 1.47 1.00 - 1.37 
Parkinson's disease 
Q9JJM9 Sept5 0.84 1.00 - 0.74 
Q9EPV5 Apaf1 0.91 1.00 - 1.36 
Q66HF1 Ndufs1 0.98 1.00 - 0.42 
P19234 Ndufv2 1.21 1.00 - 0.53 
P21571 Atp5j 1.27 1.00 - 1.26 
Q920L2 Sdha 1.27 1.00 - 0.69 
Q06647 Atp5o 1.31 1.00 - 1.33 
P10719 Atp5b 1.36 1.00 - 1.31 
P10888 Cox4i1 1.41 1.00 - 1.30 
P11240 Cox5a 1.43 1.00 - 1.36 





Biosynthesis of amino acids 
Q5M819 Psph 0.60 1.00 - 0.79 
P05065 Aldoa 0.89 1.00 - 1.44 
P18298 Mat2a 0.91 1.00 - 1.42 
P07323 Eno2 1.17 1.00 - 1.33 
P50137 Tkt 1.25 1.00 - 1.56 
P47860 Pfkp 1.27 1.00 - 1.31 
Q99NA5 Idh3a 1.28 1.00 - 1.35 
P52873 Pc 1.36 1.00 - 1.33 
Citrate cycle (TCA cycle) 
Q920L2 Sdha 1.27 1.00 - 0.69 
Q99NA5 Idh3a 1.28 1.00 - 1.35 
Q01205 Dlst 1.29 1.00 - 1.29 
Q6P6R2 Dld 1.32 1.00 - 1.30 
P52873 Pc 1.36 1.00 - 1.33 
Oxidative phosphorylation 
Q66HF1 Ndufs1 0.98 1.00 - 0.42 
P25286 Atp6v0a1 1.17 1.00 - 1.46 
P19234 Ndufv2 1.21 1.00 - 0.53 
P21571 Atp5j 1.27 1.00 - 1.26 
Q920L2 Sdha 1.27 1.00 - 0.69 
Q06647 Atp5o 1.31 1.00 - 1.33 
P10719 Atp5b 1.36 1.00 - 1.31 
P10888 Cox4i1 1.41 1.00 - 1.30 
P11240 Cox5a 1.43 1.00 - 1.36 
P12075 Cox5b 1.47 1.00 - 1.37 
Pentose and glucuronate interconversions 
P07943 Akr1b1 0.96 1.00 - 1.79 
Q5RJP0 Akr1b7 1.04 1.00 - 4.72 
P06760 Gusb 1.54 1.00 - 1.28 
P11884 Aldh2 1.85 1.00 - 1.36 
P08430 Ugt1a6 2.30 1.00 - 1.72 
Porphyrin and chlorophyll metabolism 
P06762 Hmox1 0.70 1.00 - 2.65 
P46844 Blvra 0.92 1.00 - 1.23 
P06214 Alad 1.35 1.00 - 2.34 
P06760 Gusb 1.54 1.00 - 1.28 
P08430 Ugt1a6 2.30 1.00 - 1.72 
Huntington's disease 
Q9EPV5 Apaf1 0.91 1.00 - 1.36 
Q66HF1 Ndufs1 0.98 1.00 - 0.42 





P19234 Ndufv2 1.21 1.00 - 0.53 
P21571 Atp5j 1.27 1.00 - 1.26 
Q920L2 Sdha 1.27 1.00 - 0.69 
Q06647 Atp5o 1.31 1.00 - 1.33 
P10719 Atp5b 1.36 1.00 - 1.31 
P10888 Cox4i1 1.41 1.00 - 1.30 
P11240 Cox5a 1.43 1.00 - 1.36 
P12075 Cox5b 1.47 1.00 - 1.37 
Arginine and proline metabolism 
P07335 Ckb 0.83 1.00 - 0.58 
P54001 P4ha1 1.19 1.00 - 1.54 
P0C2X9 Aldh4a1 1.43 1.00 - 1.36 
P21396 Maoa 1.45 1.00 - 1.63 
P11884 Aldh2 1.85 1.00 - 1.36 
Folate biosynthesis 
P11348 Qdpr 0.97 1.00 - 1.27 
Q920D2 Dhfr 1.24 1.00 - 1.30 




































Supplementary Table. 7. IN1130 significantly regulated proteins involved 9 KEGG 
pathways. Shown here are mean fold changes of proteins expression versus TGF-β1 group, 
p<0.05. 
 
Accession Protein Control TGF-β1 TGF-β1 +1N1130 
Fatty acid degradation 
P32198 Cpt1a 1.30 1.00 1.29 
P18886 Cpt2 1.48 1.00 1.40 
P70584 Acadsb 1.57 1.00 1.33 
P17764 Acat1 1.65 1.00 1.53 
Q9WVK7 Hadh 1.67 1.00 1.51 
P30839 Aldh3a2 1.73 1.00 1.62 
P13437 Acaa2 1.83 1.00 1.63 
P11884 Aldh2 1.85 1.00 1.62 
Fatty acid metabolism 
P32198 Cpt1a 1.30 1.00 1.29 
Q64232 Tecr 1.41 1.00 1.37 
P18886 Cpt2 1.48 1.00 1.40 
P70584 Acadsb 1.57 1.00 1.33 
P17764 Acat1 1.65 1.00 1.53 
Q9WVK7 Hadh 1.67 1.00 1.51 
P13437 Acaa2 1.83 1.00 1.63 
beta-Alanine metabolism 
Q5XI42 Aldh3b1 1.61 1.00 1.48 
P30839 Aldh3a2 1.73 1.00 1.62 
Q02253 Aldh6a1 1.83 1.00 1.60 
P11884 Aldh2 1.85 1.00 1.62 
P11883 Aldh3a1 4.50 1.00 4.36 
Colorectal cancer 
P14056 Araf 0.68 1.00 0.79 
P18266 Gsk3b 0.71 1.00 0.76 
Q63690 Bax 0.72 1.00 0.77 
Q01986 Map2k1 0.76 1.00 0.77 
P21708 Mapk3 1.57 1.00 1.46 
Q9WU82 Ctnnb1 1.77 1.00 1.69 
Propanoate metabolism 
P14882 Pcca 1.43 1.00 1.33 
P17764 Acat1 1.65 1.00 1.53 
P07633 Pccb 1.72 1.00 1.51 
Q02253 Aldh6a1 1.83 1.00 1.60 





O55171 Acot2 0.99 1.00 0.72 
Q64232 Tecr 1.41 1.00 1.37 
Q9WVK7 Hadh 1.67 1.00 1.51 
P13437 Acaa2 1.83 1.00 1.63 
Endometrial cancer 
P14056 Araf 0.68 1.00 0.79 
P18266 Gsk3b 0.71 1.00 0.76 
Q01986 Map2k1 0.76 1.00 0.77 
P21708 Mapk3 1.57 1.00 1.46 
Q9WU82 Ctnnb1 1.77 1.00 1.69 
Lysine degradation 
Q63321 Plod1 1.45 1.00 1.35 
P17764 Acat1 1.65 1.00 1.53 
Q9WVK7 Hadh 1.67 1.00 1.51 
P30839 Aldh3a2 1.73 1.00 1.62 
P11884 Aldh2 1.85 1.00 1.62 
Prion diseases 
Q63690 Bax 0.72 1.00 0.77 
Q01986 Map2k1 0.76 1.00 0.77 
P21708 Mapk3 1.57 1.00 1.46 




Supplementary Table. 8. Validation of the molecular weights of synthetic baicalein 
derivatives by HRMS. 







S2 C17H12O6 No signal 313.0712[M+H]+ - ESI±/APCI+ 
S3 C19H14O7 No signal 355.0817[M+H]+ - ESI±/APCI+ 
6-Acetoxy-5,7-dimethoxyflavone (S5) C19H16O6 341.1018 [M+H]+ 341.1025 [M+H]+ -2.0522 ESI+ 
5,6,7-Trimethoxyflavone S6 C18H16O5 313.1066 [M+H]+ 313.1076 [M+H]+ -3.1938 ESI+ 
6,7-Diacetoxy-5-methoxyflavone (S7) C20H16O7 369.0966 [M+H]+ 369.0974 [M+H]+ -2.1674 ESI+ 
5-Hydroxy-6,7-dimethoxyflavone (S8) C17H14O5 299.0911 [M+H]+ 299.0919 [M+H]+ -2.6748 ESI+ 







(S10) C24H18O6 403.1172 [M+H]
+ 403.1181 [M+H]+ -2.4807 APCI+ 
6,7-(Diphenylmethylenedioxy)-5-methoxyflavone 
(S13) C29H20O5 449.1379 [M+H]
+ 449.1389 [M+H]+ -2.2265 ESI+ 
5,6-Diacetoxy-7-(benzyloxy) flavone (S14) C26H20O7 445.1273 [M+H]+ 445.1287 [M+H]+ -3.1452 APCI+ 
6-(Benzyloxy)-5,7-dihydroxyflavone (S15) C22H16O5 361.1066 [M+H]+ 361.1076 [M+H]+ -2.7693 ESI+ 
5-Hydroxy-6,7-dipropyloxyflavone (S18) C21H22O5 355.1537 [M+H]+ 355.1545 [M+H]+ -2.2525 ESI+ 
5-Methoxy-6,7-(methylenedioxy) flavone (S20) C17H12O5 297.0753 [M+H]+ 297.0763 [M+H]+ -3.3661 ESI+ 
5,7-Dimethoxy-6-propyloxy-flavone (S22) C20H20O5 341.1378 [M+H]+ 341.1389 [M+H]+ -3.2245 ESI+ 
5-Methoxy-6,7-dipropyloxyflavone (S23) C22H24O5 369.1689 [M+H]+ 369.1702 [M+H]+ -3.5214 ESI+ 
6,7-Diacetoxy-8-bromo-5-hydroxyflavone (S24) C19H13BrO7 432.9907 [M+H]+ 432.9923 [M+H]+ -3.6952 APCI+ 
8-Bromo-5,6,7-trihydroxyflavone (S25) C15H9BrO5 346.9566 [M-H]- 346.9555[M-H]- 3.1704 ESI- 
6-Ethoxy-5,7-dihydroxyflavone (S32) C17H14O5 299.0907 [M+H]+ 299.0919 [M+H]+ -4.0121 ESI+ 
6,7-Diethoxy-5-hydroxyflavone (S33) C19H18O5 327.1226 [M+H]+ 327.1232 [M+H]+ -1.8342 ESI+ 
5-Hydroxy-6,7-(dioctyloxy) flavone (S34) C31H42O5 495.3090 [M+H]+ 495.3110 [M+H]+ -4.0379 APCI+ 
6-Ethoxy-5-hydroxy-7-methoxyflavone (S38) C18H16O5 313.1063 [M+H]+ 313.1076 [M+H]+ -4.1519 ESI+ 
5-Hydroxy-6,7-(dipentyloxy) flavone (S40) C25H30O5 411.2166 [M+H]+ 411.2171 [M+H]+ -1.2159 ESI+ 
5-Methoxy-6,7-(dipentyloxy) flavone (S41) C26H32O5 425.2319 [M+H]+ 425.2328 [M+H]+ -2.1165 ESI+ 
6,7-(Dihexyloxy)-5-hydroxyflavone (S42) C27H34O5 439.2478 [M+H]+ 439.2484 [M+H]+ -1.3660 ESI+ 
6,7-(Dihexyloxy)-5-methoxyflavone (S43) C28H36O5 453.2631 [M+H]+ 453.2641 [M+H]+ -2.2062 ESI+ 
6,7-Dibutoxy-5-hydroxyflavone (S45) C23H26O5 383.1847 [M+H]+ 383.1858 [M+H]+ -2.8707 ESI+ 
6,7-Dibutoxy-5-methoxyflavone (S46) C24H28O5 397.2001 [M+H]+ 397.2015 [M+H]+ -3.5247 ESI+ 
